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Pa r ox y s m a l  N o c t u r N a l  H e m o g lo b i N u r i a
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare disease characterized by acquired 
somatic mutations of the phosphatidylinositol glycan complementation class A (PIG-A) gene 
in hematopoietic stem cells (HSC) 1-3. The PIG-A gene codes for the N-acetylglucosaminyl 
phosphatidylinositol transferase enzyme, which is essential in the synthesis of the glycosyl 
phosphatidyl inositol (GPI) anchor. Impaired synthesis of the GPI anchor results in partial or 
complete absence of all proteins tethered to the cell membrane by a GPI anchor. Therefore, 
PIG-A gene mutations in HSC result in a clone of GPI-deficient daughter cells. The PIG-A gene is 
located on the X chromosome, explaining why a single acquired mutation is sufficient to cause 
the clinical phenotype, as in female patients, one of the X chromosomes is always inactivated. 
The most prominent clinical features of the classical presentation of PNH are hemolytic 
anemia, hemoglobinuria and an increased risk of thrombosis. Hemolysis occurs intravascularly 
and, if severe, results in hemoglobinuria, particularly in the morning. This was elegantly 
demonstrated by Strübing in 1880, who noted that the plasma was colored red and erythrocytes 
were absent from the urine during a hemolytic attack 4. Intravascular hemolysis results in 
fatigue, anemia, and associated symptoms such as abdominal pain, dysphagia and erectile 
dysfunction. Strübings observations were extended by Hijmans van den Bergh in 1911, who 
was the first to demonstrate that hemolysis was due to a defect in the PNH erythrocyte itself. 
He observed that PNH patient red cells lysed in both patient and healthy control serum upon 
acidification by the addition of carbon dioxide 4. This mechanism may explain why in typical 
PNH patients hemolysis aggravates at night, as CO
2
 retention may acidify the serum. Ham was 
the first to conclude in 1939 that the complement system is responsible for hemolysis in PNH 4. 
In the 1980’s several groups discovered that hemolysis in PNH is caused by deficient expression 
of GPI-anchored CD59 (membrane inhibitor of reactive lysis, MIRL) and, to a lesser extent, CD55 
(decay-accelerating factor, DAF) on affected erythrocytes, resulting in increased sensitivity for 
complement-mediated lysis of PNH erythrocytes 4. Besides hemolysis, another major feature 
of PNH is a highly increased risk of thrombosis. The pathophysiology of thrombosis in PNH has 
not been fully elucidated but is probably multifactorial.  This topic will be introduced separately 
in Chapter 5. Finally, a variable degree of underlying bone marrow failure often complicates 
the clinical picture. Bone marrow failure increases susceptibility to infections, and may require 
immunosuppressive therapy depending on the degree of severity. 
The prevalence of PNH is estimated at 1-2 per 100.000 and the incidence at 1 per 1.000.000 
per year 5. The diagnosis of PNH is often delayed and prevalence may be underestimated. For 
unknown reasons, geographical differences exist in the most prominent disease features. The 
disease affects men and women equally. It often presents in young adults with a median age 
between 30-42 years, though cases in children and the elderly occur as well 6-10.
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c l i N i c a l  m a N i F e s tat i o N s  i N  P N H  Pat i e N t s
c o m p l e m e n t - m e d i a t e d  i n t r a v a s c u l a r  h e m o l y s i s  a n d  a s s o c i a t e d 
s y m p t o m s 
The cardinal manifestation of PNH is Coombs-negative intravascular hemolysis due to the 
deficiency of the complement inhibitors CD55 and CD59 on the surface of erythrocytes. The 
complement system is part of the innate immune system and is composed of a series of plasma 
proteins that sequentially activate each other (Figure 1). It is activated via three different pathways, 
the classic, the alternative and the lectin pathway. The classic pathway is activated mainly by 
immune complexes, whereas the lectin pathway is activated by bacterial surfaces. The alternative 
pathway is activated by continuous and spontaneous hydrolysis of C3, or so-called “tick-over”. 
All three pathways converge by the generation of a C3 convertase, a protease that cleaves C3 in 
C3a and C3b. The C3 convertase is then converted into a C5 convertase by addition of C3b, which 
subsequently cleaves C5 into C5a and C5b. C5b is the substrate for the formation of the membrane 
attack complex (MAC), consisting of C5b, C6, C7, C8 and C9 (C5b-9). The MAC is a pore-forming 
complex of molecules that can insert into the membrane of micro-organisms, resulting in 
cytotoxic lysis. Other important functions of the complement system are the generation of the 
anaphylatoxins C3a and C5a, opsonization of bacteria by C3b, and immune complex clearance. 
Figure 1: structure of the gPi anchor. The GPI anchor is composed of a single phosphatidyl-inositol residue 
inserted into the outer leaflet of the cell membrane, a glucosamine molecule, three mannose sugars, and a 
phospho-ethanolamine residue which links the protein to the GPI-anchor. Abbreviations: P: phosphatidyl; M: 
mannose; GlcN: glucosamine; E: ethanolamine. 
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The complement system has evolved several mechanisms to discriminate between self and 
non-self. One of these mechanisms is the expression of complement inhibitors on self cells. 
These include GPI-anchored CD55, which inhibits the formation of the C3 convertases of the 
classical pathway, whereas GPI-anchored CD59 inhibits MAC formation. Deficiency of CD55 
and CD59 on the erythrocyte membrane results in complement-mediated hemolysis in PNH. 
Patients with congenital deficiency of CD55 do not have hemolysis 11,12. Therefore, CD59 is likely 
the major determinant of susceptibility for complement-mediated lysis.
The degree of hemolysis is generally correlated with the size of the PNH granulocyte 
clone. However, this does not account for the PNH erythrocyte clone size which is negatively 
affected by the degree of hemolysis. A continuous low-level C3 tick-over via the alternative 
pathway results in spontaneous low-level MAC generation, and therefore, a basal level of 
hemolysis is always present in patients with PNH. The typical picture of a PNH patient with 
macroscopic hemoglobinuria only in the morning is therefore rare. Factors that enhance 
complement activation may aggravate hemolysis, resulting in attacks of hemolysis, or so called 
paroxysms. These factors include infections, but also certain drugs may induce hemolysis 13. 
Haptoglobin, which scavenges free hemoglobin, is easily saturated, resulting in undetectable 
levels. Excess free hemoglobin is excreted by the kidneys resulting in tubular hemosiderin 
deposition and hemoglobinuria. The severity of anemia is influenced by the level of hemolysis 
and importantly, the capacity of the bone marrow to compensate for hemolysis. Often, iron 
deficiency is present. 
Other symptoms related to hemolysis include dysphagia, abdominal pain, dyspnea, and 
erectile dysfunction, which particularly occur during paroxysms 13. Its etiology likely involves 
decreased availability of nitric oxide (NO), which is scavenged by free hemoglobin 14. NO 
normally maintains smooth muscle relaxation and vasodilatation. Thus, low NO availability may 
therefore result in esophageal spasms and erectile dysfunction. These phenomena may also be 
responsible for abdominal pain frequently experienced during paroxysms; however whether 
(microvascular) thrombosis of abdominal blood vessels also contributes is unknown. NO 
depletion is held responsible, at least partially, for the high frequency of elevated pulmonary 
artery pressure and reduced right ventricular function in PNH patients, which was reported in 
41% and 80% of patients in the study of Hill et al. including 29 patients with hemolytic PNH 15.  
Renal dysfunction is common in PNH. The incidence of renal failure is unknown, but was 
reported as the cause of death in 8-18% of patients 7. Hillmen et al. reported some degree of 
renal dysfunction in 65% of 195 patients who participated in the various eculizumab trials 16. 
The majority of these patients (68%) had stage 1-2 chronic kidney disease, i.e. a glomerular 
filtration rate higher than 60 ml/min./1.73m2. Acute renal failure occurred in 14 patients (7%) 
of which 5 required dialysis. The mechanism of renal failure in PNH patients has not been fully 
clarified. Kidney biopsies and magnetic resonance imaging (MRI) findings showed interstitial 
inflammation and fibrosis, and tubular hemosiderin deposition respectively. In cases of acute 
renal failure, acute tubular necrosis was demonstrated, but no renal vascular thrombosis 17-24. 
Together with the absence of renal vein or artery thrombosis in the series of Hillmen et al. 16, 
this finding indicates that the contribution of macrovascular thrombosis in the pathogenesis of 
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renal failure in PNH is probably limited. Decreased availability of NO may further contribute to 
the development of renal failure by limiting blood flow in the afferent arterioles of the kidney. 
P a n c y t o p e n i a  a n d  o v e r l a p  w i t h  o t h e r  b o n e  m a r r o w  f a i l u r e 
s y n d r o m e s
The clinical spectrum of patients with PNH is highly variable. It ranges from classic PNH with 
large PNH clone sizes and clinically evident hemolysis, to patients with relatively small clone 
sizes without any relevant hemolysis (i.e. subclinical PNH). The latter group usually presents with 
underlying bone marrow diseases such as aplastic anemia (AA) or myelodysplastic syndromes 
(MDS) and has more prominent pancytopenia. In fact, a PNH clone is a frequent finding at 
diagnosis of AA (20-55 % of patients) 25 and in some cases of MDS (estimated prevalence of 
10-20%) 26-32. In MDS, PNH clones were most prevalent in patients with the refractory anemia 
(RA) subtype, and were found both in patients with hyper- and hypocellular bone marrows. 
Whereas in AA and PNH, GPI-deficient clones were shown to arise from multipotent HSC, in 
MDS these probably arise from more committed hematopoietic progenitor cells 33. Regardless 
of the presence of a specific underlying bone marrow disease, in 20-30% of PNH patients bi- or 
pancytopenia is found, including those with classic PNH 6,8,9. 
The international PNH interest group (IPIG) has proposed a working classification for PNH, 
distinguishing classic PNH, PNH in the setting of another specified bone marrow disorder and 
subclinical PNH (Table 1) 13. The latter category is defined as patients without clinical or laboratory 
evidence of hemolysis. The heterogeneous clinical picture of PNH is difficult to capture in 
a stringent classification. Classic PNH patients frequently have mild cytopenias other than 
anemia, suggesting the presence of some degree of bone marrow failure in this category as well. 
Abnormalities in bone marrow morphology, though insufficient to diagnose MDS, are frequent 
in PNH as shown by Araten et al. 34. In addition, this study identified cytogenetic abnormalities 
in 24% of 46 patients, including patients with the clinical picture of classic PNH. Maciejewski et 
al. showed abnormal cytogenetics in 11% of 136 patients (68% AA/PNH, 16% MDS and 15% classic 
PNH) 35. These data illustrate the considerable overlap between the different PNH subcategories. 
Classifying patients is further complicated by the fact that the clinical picture often changes 
during the course of disease, as PNH clone size may change, and marrow failure may ameliorate 
or progress. Sugimori et al. showed that in patients with a PNH clone of <10% at diagnosis, the 
PNH clone size increased in 17% and disappeared in 24% of the patients 32. Araten et al. reported an 
table 1: international PNH interest group (iPig) classification for PNH 13
iPig category Hemolysis associated bone marrow disorder
Classic PNH Yes No (cellular bone marrow with normal or near-normal 
morphology, no cytogenetic abnormalities)
PNH in the setting of another 
specified bone marrow disorder
Yes Yes
Subclinical PNH (PNH-sc) No Yes
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increase in PNH clone size in 33% of 36 patients within 6 years after diagnosis, with no difference in 
clinical parameters in patients with and without expansion of the PNH clone 36. 
d i ag N o s i s  o F  P N H
The method of choice to diagnose PNH is flow cytometry on peripheral blood. Using fluorescently 
labeled antibodies against GPI-anchored proteins in combination with lineage specific markers, 
a population of GPI-deficient cells can be detected in various hematopoietic cell types. It is 
recommended to use antibodies to at least two different GPI-anchored proteins to exclude the rare 
possibility of a congenital deficiency of a single GPI-anchored protein 13. Depending on cell type, 
a combination of different GPI-anchored markers or fluorescently labeled aerolysin (FLAER) is 
recommended 37. FLAER is a fluorochrome conjugated inactivated variant of the bacterially derived 
channel-forming protein aerolysin, which binds specifically to GPI anchors 38,39. For granulocytes, 
a combination of at least two markers including FLAER, CD24, CD66b and CD16 is recommended, 
whereas for monocytes, these markers include FLAER, CD14, CD48, CD55 and CD157. 
PNH clone size is typically defined as the percentage of GPI-deficient PNH granulocytes. 
Using high-sensitivity assays, a population of 0,01% GPI-deficient cells can reliably be detected 
in granulocytes 40. In contrast to PNH erythrocyte clone size, PNH granulocyte clone size is not 
influenced by hemolysis and concomitant blood transfusions. Nevertheless, the determination 
of PNH erythrocyte clone size is useful, because it provides a better discrimination between 
type I (i.e. normal cells), type II (cells with partial deficiency of GPI-anchored proteins) and type 
III cells (cells with complete deficiency of GPI-anchored proteins) 37,40. 
t H e  g P i  a N c H o r  a N d  c o N s e q u e N c e s  o F  g P i 
d e F i c i e N c y  i N  l e u ko c y t e s 
The GPI anchor is composed of a single phosphatidyl-inositol residue inserted into the outer 
leaflet of the cell membrane, a glucosamine molecule, three mannose sugars, and a phosphor-
ethanolamine residue which links the protein 41 (Figure 2). GPI anchors are widely distributed 
among different organisms and are particularly abundant in protozoa. In mammals, they 
occur in virtually all cell types anchoring a wide variety of proteins to the cell membrane. The 
function of GPI anchors is not fully known, but it is hypothesized that they influence membrane 
composition and allow proteins to move freely along the cell membrane. Mouse models 
have shown that GPI anchor deficiency during embryonic development is lethal. As PNH is a 
consequence of acquired mutations in HSC, GPI anchor deficiency is only present in blood cells. 
Deficiency of GPI-anchored proteins in leukocytes may influence immunity. Infections are 
common complications in PNH. Latour et al. reported at least one severe microbiologically proven 
infection requiring treatment in 41% of all PNH patients with a similar incidence in classic PNH and 
PNH with AA 9. Infections are the cause of death in 17% of patients 8. So far, no specific types of 
infections were identified in PNH patients. Although the occurrence of infections is at least partially 
attributed to the presence of neutropenia, the observation that patients with infections tend to have 
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larger PNH clone sizes suggests that GPI anchor deficiency in immune cells itself may also play a 
role 7. Table 2 provides an overview of GPI-anchored proteins with a function in the immune system. 
Many GPI-anchored proteins have important functions in T cells. It has been shown that the 
in vitro and in vivo capability of GPI-deficient murine T cells to respond to T cell receptor (TCR) 
stimulation is normal 42 or even increased 43. In contrast, studies in human GPI-deficient T cell 
lines and PNH patient lymphocytes demonstrated defective TCR-mediated signaling 44-46, and 
a more naive phenotype of PNH lymphocytes 46. Although these data clearly show that T cell 
function might be affected in PNH patients, the fact that the proportion of GPI-negative T cells 
is usually very low, even in patients with large PNH granulocyte clone sizes 47, suggests that the 
clinical relevance of these defects is probably low. GPI-deficient NK cells may have an impaired 
response to chemotaxis 48. In B lymphocytes, the consequences of GPI-anchor deficiency have 
not been investigated.
Several studies have analyzed the function of myeloid cells in PNH. PNH neutrophils do not 
appear to have a reduced life span, suggesting that they are not affected by complement-mediated 
lysis 49. Their ability to ingest bacteria was shown to be increased by Cacciapuoti et al., possibly due 
to increased binding of C3 when CD55 is absent. However, their capacity to synthesize reactive 
Figure 2: overview of the complement system and blocking of terminal complement by eculizumab. 
Activation of the complement system can occur by three different pathways, the classic, the alternative and the 
lectin pathway. All three pathways converge by the generation of a C3 convertase, which catalyzes the conversion 
of C3 in C3a and C3b. The C3 convertase is then converted to a C5 convertase which cleaves C5 into C5a and C5b. 
C5b, together with C6, C7, C8 and C9 (C5b-9) forms the membrane attack complex (MAC). Eculizumab blocks the 
complement level at the level of C5, thereby preventing the formation of C5a and the MAC. 
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oxygen species (ROS) upon ingestion appears to be reduced 50, possibly because GPI-anchored 
Fcγ RIIIb (CD16) is absent on PNH neutrophils 51. Finally, PNH neutropils migrate slower than 
their normal counterparts 52. This may be a result of deficiency of several GPI-anchored proteins 
involved in leukocyte adherence and transendothelial migration, such as CD157 (Bone marrow 
stromal cell antigen-1, BST-1) 53, GPI-80 54, and urokinase plasminogen activator receptor (uPAR) 55. 
In conclusion, these studies demonstrate several functional defects in GPI-deficient neutrophils; 
however they do not translate clinically into susceptibility for infections associated with a 
functional granulocytic defect. In murine GPI-deficient myeloid cells (dendritic cells (DCs) and 
macrophages), Fcγ receptor expression, and binding and endocytosis of IgG immune complexes 
was shown to be normal. However, tumor necrosis factor-α (TNF-α) release, DC maturation, and 
antigen presentation by GPI-deficient macrophages was highly impaired 56.  Ruggiero et al. have 
shown that GPI-deficient monocytes are unable to undergo in vitro differentiation into dendritic 
cells (DC), and as a consequence, these have impaired functional capacity 57. 
t r e atm e N t  o F  P N H 
s u p p o r t i v e  c a r e
Until the complement inhibitor eculizumab became available, supportive care was the only 
treatment available. Supportive care continues to be an essential component of treatment 
in all PNH patients. It consists of erythrocyte transfusions, thrombosis prophylaxis, folate 
supplementation to meet the higher requirements of increased erythropoiesis, and iron 
supplementation or sometimes iron chelation therapy in patients with frequent transfusions 13. 
Thrombosis prophylaxis with coumarins is recommended for patients with a PNH granulocyte 
clone size > 50% and no contra-indications; however, it does not offer guaranteed 
protection 9,99. Washing of erythrocytes to reduce the amount of donor plasma containing 
complement and prevent consequent hemolysis has proved unnecessary 100. To prevent 
parvovirus B19 infection, parvovirus-naïve patients are given parvovirus-free blood products. 
Iron supplementation may aggravate hemolysis in some patients 13. The mechanism is unknown, 
but possibilities include an increase in the number of GPI-deficient erythrocytes, or complement 
activation 101. In case of prominent bone marrow failure, platelet transfusions may be needed. 
e c u l i z u m a b
Eculizumab is a humanized monoclonal antibody to complement factor C5 in which the 
heavy chain constant region of the original murine antibody was replaced with components 
of both human IgG2 and IgG4, in order to diminish binding to Fcγ receptors and activation 
of the classical complement pathway 102. Binding of eculizumab to C5 prevents cleavage of C5 
in pro-inflammatory mediators C5a and C5b, which blocks subsequent terminal complement 
activation. Thus, it prevents the formation of the MAC, consisting of complement factors 
C5b-C9, on the surface of erythrocytes, and thereby effectively reduces hemolysis (Figure 1). 
Eculizumab does not affect the early complement factors, leaving other complement functions 
like opsonization and immune complex clearance intact. 
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The promising results of an initial pilot study in 11 patients in 2004 103 were confirmed in 
a randomized, multicenter placebo-controlled phase III study (TRIUMPH), which included 87 
transfusion-dependent patients 104. During this 6-month study, the median number of units 
transfused in the eculizumab group (0) was significantly lower than in the placebo group 
(10) (p<0.001). LDH levels almost immediately decreased to normal or near-normal levels. 
Hemoglobin levels in absence of transfusions stabilized in 49% of eculizumab treated patients 
compared to none in the placebo group (p<0.001). Patients treated with eculizumab experienced 
significantly less fatigue (p<0.001) compared to the placebo group and their quality of life 
improved 105. Moreover, eculizumab resolved hemolysis-associated symptoms such as abdominal 
pain, dysphagia, erectile dysfunction, dyspnea, and improved renal function 106-109. A subsequent 
multi-center open label phase III study (SHEPHERD) confirmed the efficacy of eculizumab also in 
patients with lower or no transfusion requirements and/or lower platelet counts 110. In contrast 
to the previous study, eculizumab not only significantly reduced transfusion requirements but 
also increased hemoglobin levels, although hemoglobin levels still remained below normal. 
Finally, retrospective analysis has shown that eculizumab significantly reduced the frequency of 
thrombosis with 85%, compared to the same patient group before treatment (n=195; 7,37 versus 
1,07 tromboembolic events per 100 patient years, p < 0,001)111. Long-term safety studies showed 
that eculizumab is safe and remains effective during prolonged use 107,112,113.
Indications for eculizumab, as defined in the concept guideline of the Dutch Society of 
Hematology, include hemolytic anemia (which may or may not result in transfusion dependency) 
and/or severe, burdening symptoms associated with hemolysis such as fatigue or abdominal 
pain. In addition, patients with a history of thrombosis or currently experiencing a thrombotic 
event are also candidates for eculizumab treatment because of the reduction in thrombotic 
risk and the observation that eculizumab may abrogate ongoing thrombosis 111,114. Finally, it is 
recommended to commence eculizumab treatment during pregnancy (2nd trimester). 
Eculizumab is intravenously administered at a dosage of 600 mg weekly for 4 weeks, and 
900 mg at 14 (12-16) day intervals from week 5 onwards. During eculizumab treatment, both 
the number and proportion of GPI-deficient erythrocytes increases in most patients because 
of their prolonged survival 104,110. Theoretically, this may pose a risk of massive hemolysis of GPI-
deficient erythrocytes upon discontinuation of eculizumab. Due to defective MAC formation, 
another important risk of eculizumab treatment is the increased susceptibility for infections 
with encapsulated bacteria, such as meningococci and gonococci, similarly as reported in 
inherited C5 deficiency 115. For this reason, patients receive a polyvalent meningococcal vaccine 
and are instructed to promptly initiate preemptive high dose antibiotic treatment directed to 
encapsulated micro-organisms in case of fever. Finally, a drawback of eculizumab is the necessity 
to administer treatment lifelong at high costs (currently estimated at 360.000 € per year). 
e x t r a v a s c u l a r  h e m o l y s i s  d u r i n g  e c u l i z u m a b  t r e a t m e n t 
During eculizumab treatment, some patients do not achieve transfusion independency. 
Although hemoglobin levels stabilize, they often do not normalize. In addition, laboratory 
parameters of hemolysis such as LDH and bilirubin usually remain slightly elevated and 
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haptoglobin remains undetectable 104,116. These observations suggest that, despite terminal 
complement blockade, a low level of hemolysis is ongoing in these patients. Risitano and Hill 
et al. showed that in eculizumab treated patients, a proportion of GPI-deficient erythrocytes 
binds complement factor C3 117,118. This proportion correlated significantly with reticulocyte 
count and hematological response to eculizumab. Lack of CD55 which regulates the activity 
of C3 convertase of the alternative pathway might explain this phenomenon. As a result, 
C3 coated PNH erythrocytes may be opsonized by macrophages expressing complement 
receptors in liver and spleen. In vivo erythrocyte survival studies performed by Risitano et 
al. showing reduced erythrocyte life span with increased uptake in spleen and liver, indeed 
confirmed extravascular hemolysis in eculizumab-treated PNH patients 117. Whether a low level 
of extravascular hemolysis is also present in untreated patients but remains undetected due to 
rapid destruction of such cells by MAC is unknown. 
Treatment options for extravascular hemolysis are limited. Both splenectomy and prednisone 
have been proposed as possible treatment but raise concerns of additional susceptibility for 
infections and serious side effects 117,119,120. Novel complement inhibitors that may block both intra- 
and extravascular hemolysis are currently under preclinical and clinical investigation 121-127.
i m m u n o s u p p r e s s i v e  t r e a t m e n t  ( i s t )  a n d  c o r t i c o s t e r o i d s
IST, including antithymocyte globulin (ATG) and/or cyclosporin aiming to treat underlying bone 
marrow failure as in AA can be applied according to the state of art (reviewed in 128). IST does 
not ameliorate hemolysis though. In fact, some studies describe an expansion of a PNH clone 
after initiating immune suppression in AA 129,130, whereas others do not 29,32,36,131. Even if PNH clone 
expansion does occur after immune suppression, this probably reflects the course of disease 
rather than a consequence of treatment. Corticosteroids and the androgen danazol have 
been used previously to treat both chronic hemolysis and acute exacerbations with a possible 
response in some patients; however no placebo controlled data are available to support these 
observations 13,132. The availability of eculizumab has rendered these practices obsolete. 
s t e m  c e l l  t r a n s p l a n t a t i o n  ( s c t )
Allogeneic SCT remains the only curative therapy for PNH. In classic PNH, the aim of SCT is 
to eradicate the PNH clone. In contrast, in AA-PNH overlap syndromes, SCT primarily aims to 
reverse immune-mediated marrow failure by replacing the immune system. Nonrandomized 
studies have reported sustained remissions with both myeloablative and nonmyeloablative/
reduced-intensity conditioning regimens, however patient numbers are low and SCTs were 
performed over long time periods making results difficult to interpret 133. 
Saso et al. described the outcome of 57 consecutive allogeneic SCTs for PNH between 1978 
and 1995 134. Median two-year survival was 56% for HLA-identical transplants, whereas only one 
of 7 patients who received an HLA-matched unrelated donor transplant survived. In the series 
of Santarone et al. (1988-2006), including 26 PNH patients of whom 22 had classic PNH, 10-year 
disease-free survival was 57% 135. Peffault de Latour et al. conducted a retrospective comparison 
of 211 PNH patients transplanted between 1978 and 2005, and 402 non-transplanted PNH 
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patients 136. Five-year overall survival in transplanted patients was 68%. In a matched comparison 
of transplanted and non-transplanted patients with a history of thromboembolism, SCT was 
associated with a worse outcome (hazard ratio 10.0; 95% confidence interval, 1.3-78.1; p=0.007). 
None of these studies included patients on eculizumab. Eculizumab has strongly decreased 
the incidence of thrombosis 111. However, eculizumab is not a curative treatment ant its costs 
outweigh those of SCT. SCT on the other hand may cure PNH but has considerable transplant-
related morbidity and mortality. Weighing all these aspects, severe hemolysis or life-threatening 
thrombosis in PNH should no longer be an indication for SCT if eculizumab is available. However, 
in patients with predominant bone marrow failure SCT remains an important treatment modality. 
P r o g N o s i s  o F  P N H
Before the introduction of eculizumab, prognosis for PNH patients was poor. Median survival was 
estimated at 22 years in a large French retrospective study 9. Thrombosis negatively influenced 
survival in both patients with classic PNH and AA-PNH overlap syndrome 9. In classic PNH, the 
development of bi- or pancytopenia 9, MDS or acute myeloid leukemia (AML) 8, advanced age 8,9 
and a diagnosis before 1986 9 worsened survival. In the French series, the most frequent cause 
of death was central nervous system thrombosis or hemorrhage (23%), followed by infectious 
diseases (23%), the Budd-Chiari syndrome (21%) and malignant diseases (9%) 9. Socié et al. 
reported 2 and 9 patients who developed acute leukemia and MDS respectively among 220 
PNH patients over a period of 46 years, resulting in estimated cumulative 2-year incidences of 
1.2 and 4% 8. In the series of Hillmen et al. including 80 patients over a period of 30 years, none 
were reported 6. 
A retrospective study of Kelly et al. in 79 patients who were treated with eculizumab for a 
median duration of 39 months showed that overall survival was similar to an age- and sex-
matched healthy population. A control group of untreated PNH patients with similar disease 
characteristics had a significantly worse survival. Five-year survival rates on eculizumab were 
96% (95% confidence interval 88-99%) compared to 67% (41-85%) in the group not treated with 
eculizumab (p 0.01). A similar 3-year survival rate of 97,6% was reported in a study including 195 
patients treated with eculizumab 113. Although these results are promising, follow-up is still short 
and the number of patients is relatively low. The increased risk to develop AA or AML in PNH 
patients 6,8,9 probably remains present in eculizumab-treated patients. 
Pat H o g e N e s i s  o F  P N H  a N d  t H e  m e c H a N i s m  o F  c lo N a l 
e x Pa N s i o N 
The pathogenesis of PNH requires at least two steps: the occurrence of a mutation in the PIG-A 
gene of a HSC, and second, the acquisition of a selective growth advantage for the mutated HSC 
compared to normal HSC, resulting in benign clonal expansion. Additionally, a role for autoimmune 
mediated bone marrow failure has been proposed. The mechanism of clonal expansion in PNH is 
still unknown. In the following section, various hypotheses will be discussed in detail (Figure 3). 
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r o l e  o f  a u t o i m m u n e  m e d i a t e d  b o n e  m a r r o w  f a i l u r e
The frequent association between PNH and AA has led to the hypothesis that autoimmune mediated 
marrow failure also plays a role in PNH, similar as in AA. These diseases have a close relationship as 
40% of AA patients have predominantly subclinical PNH clones at diagnosis and overt PNH often 
develops during the course of AA 25. The fact that 20-30% of all PNH patients not only have anemia, 
but bi- or pancytopenia suggests that marrow failure is common in PNH as well 6,8,9. 
Marrow failure in both AA and PNH is thought to be immune-mediated. For instance, 
immunosuppressive therapy may ameliorate the marrow failure component of PNH, and the 
presence of a PNH clone in patients with AA or MDS predicts the response to immunosuppressive 
therapy 27,137. Furthermore, oligoclonal CD4 and CD8 T cell populations with potential autoreactivity 
were found in patients with PNH, AA and MDS, as evidenced by a skewed repertoire of the 
complementarity-determining-region-3 (CDR3) of the T cell receptor (TCR) variable β (Vβ) chain 
138-145. Some of these studies have shown that T cell clones expressing specific TCR Vβ chains 
and/or CDR3 regions indeed lyse autologous CD34+ cells 140,143, or that the in vivo decline of such 
clones in individual patients correlates with hematological responses 138-141,143. 
Additionally, associations of specific HLA alleles with both classic PNH and PNH-AA suggest 
that an autoimmune mechanism may play a role. The association with HLA-DRB1*1501 (HLA-DR2) 
was reported most consistently in American, Japanese and Italian patients 146-148. Other associations 
include HLA-A2*01, HLA-B*1402, HLA-Cw*0802, and HLA-DRB1*0102 148. In the Italian study, the 
strongest association was found with a haplotype including the HLA-A33, HLA-B*1402, HLA-
Cw*0802 and DRB1*0102 and DQB1*0501 alleles 148. The association with a haplotype rather than a 
specific HLA allele may indicate an association with a non-HLA gene linked to this haplotype. 
Finally, the presence of auto-antibodies in PNH patients may indicate a role for 
autoimmunity in PNH 149-152. However, such antibodies could also result from complement-
mediated cell damage rather than the cause of immune-mediated marrow failure. For example, 
the specific association of antibodies against the intracellular protein kinesin family member 
20B with elevated LDH levels in PNH patients suggests the latter 151. 
t h e  P i g -a  m u t a t i o n  a l o n e  i s  n o t  s u f f i c i e n t  f o r  e x p a n s i o n  
o f  a  P N H  c l o n e
By analysis of specific PIG-A mutations it was demonstrated that hematopoiesis in PNH patients 
is mono- or oligoclonal. Multiple PNH clones may coexist in parallel in one PNH patient, and 
different PNH clones can be found in a single PNH patient during the course of disease 153,154. 
In many PNH patients, hematopoiesis is supported predominantly by PNH cells, indicating 
that a massive clonal expansion of one or few PIG-A mutated HSC must have taken place. The 
mechanism of clonal expansion is however still unknown.
It was hypothesized that the PIG-A mutation itself may confer the hematopoietic stem cell 
with a growth advantage. However, several lines of evidence suggest that this is not the case. 
First, the PIG-A mutation was also found in a very small percentage of hematopoietic cells in 
healthy individuals 155. Given the rarity of PNH, these PIG-A mutated hematopoietic cells hardly 
ever give rise to PNH. It must be noted though that in this study, GPI deficiency was only assessed 
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in mature erythrocytes and granulocytes. Thus, the possibility that in healthy individuals the 
PIG-A mutation arises in more differentiated precursor cells cannot be excluded. Other studies 
showed that T cells in healthy donors also harbor PIG-A mutations 156. These mutations are often 
different from those found in myeloid cells 157, confirming the hypothesis that PIG-A mutations 
in healthy donors occur in more differentiated hematopoietic progenitor cells. 
Murine models contradict the hypothesis that the PIG-A mutation itself is responsible for 
clonal expansion in PNH. When PIG-A deficient hematopoiesis was created by conditional knock-
out, the number of GPI-deficient blood cells remained stable over time, or even decreased 158-160. 
Figure 3: schematic overview of the various hypotheses explaining clonal expansion of gPi-deficient 
hematopoietic stem cells in PNH. The pathogenesis of PNH requires at least two steps: the occurrence of a mutation 
in the PIG-A gene of a hematopoietic stem cell (step 1), and second, the acquisition of a selective growth advantage for 
the mutated, i.e. GPI-deficient HSC compared to the normal HSC resulting in clonal expansion (step 2, left panel). Several 
different, not mutually exclusive, hypotheses for step 2 have been proposed. First, the GPI-deficient HSC may acquire a 
second mutation which may result in a proliferative advantage or a decreased sensitivity to apoptosis (upper right panel). 
Second, in a setting of immune-mediated attack to the bone marrow, the GPI-deficient HSC may be better capable to 
withstand this attack (middle right panel). Lastly, differences in homing and mobility of GPI-deficient cells in the bone 
marrow may result in their predominance over their normal counterparts in peripheral blood (lower right panel). 
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Lastly, in the majority of PNH patients no further expansion of the PNH clone occurs after diagnosis, 
or in some cases the clone even regresses. This indicates that the tendency to overgrow normal 
cells is not an intrinsic property of the PNH clone itself 32,36. Taken together, these observations 
suggest the PIG-A mutation on its own is insufficient for the selective expansion of a PNH clone, 
and other factors must be present. Several, not mutually exclusive hypotheses (Figure 3) have 
been put forward which will be discussed in detail in the following section. 
a d d i t i o n a l  m u t a t i o n s  r e s u l t i n g  i n  a n  i n t r i n s i c  g r o w t h 
a d v a n t a g e  o f  t h e  P N H  c l o n e ?
Few studies have investigated the possibility that GPI-deficient cells have acquired an 
additional mutation resulting in an intrinsic growth advantage of the PNH clone. Chen et al. 
indeed showed that the proliferation rate in GPI-deficient CD34+ cells was higher than in their 
GPI+ counterparts, but similar to CD34+ cells of healthy individuals 161. This suggested that a true 
intrinsic growth advantage is less likely. The increased risk of AML in PNH patients estimated 
at 1% suggests that secondary mutations do occur 162. Such mutations may explain clonal 
expansion in a subpopulation of patients. 
Patients with a secondary mutation were described by Inoue et al. 163. They reported two patients 
with a translocation of chromosome 12 resulting in overexpression of the High Mobility Group 
AT-hook 2 (HMGA2) gene. The HMGA2 gene is frequently overexpressed in benign mesenchymal 
tumors and also in some hematological and solid malignancies. Induced overexpression of 
HMGA2 in murine HSC resulted in dominance of such HSC over their normal counterparts in 
serial bone marrow transplantations 164. However, besides these two Japanese patients, no other 
patients with this particular translocation were described. Furthermore, HMG2A mRNA levels in 
granulocytes of PNH patients were similar to healthy controls 165. Thus, HMG2A overexpression in 
HSC may result in clonal expansion but probably only in a subpopulation of PNH patients.
The recent study by Shen et al., who performed whole genome exome sequencing (WES) on paired 
CD59+ and CD59- cell populations in 12 PNH patients, showed that additional mutations in the GPI-
deficient population may be much more frequent than initially thought 166. They identified additional 
somatic mutations in genes known to be involved in myeloid neoplasms such as MDS, including TET2, 
SUZ12, U2AF1 and JAK2 in the majority of patients. Interestingly, this study demonstrated that these 
mutations can either arise before or after the occurrence of the PIG-A mutation. 
r e s i s t a n c e  t o  a p o p t o s i s  r e s u l t i n g  i n  a n  i n t r i n s i c  g r o w t h 
a d v a n t a g e  o f  t h e  P N H  c l o n e ?
Although PNH HSC do not seem to grow faster than their normal counterparts in healthy donors, 
an alternative explanation for clonal expansion could be a decreased sensitivity to apoptosis. 
Studies on this topic are conflicting. Szpurka et al. found an accumulation of anti-apoptotic 
proteins in lipid rafts of GPI-deficient variants of leukemic cell lines, specifically in response to 
pro-inflammatory cytokines such as TNF-α 167. Brodsky and Ware et al. found a higher resistance 
to in vitro apoptosis induction compared to normal controls in cell line models and granulocytes 
of PNH patients 168,169. This was also true for GPI-deficient CD34+ cells when compared to GPI+ 
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CD34+ cells derived from the same PNH patient 168. The study of Ware et al. failed to demonstrate a 
correlation with the percentage of GPI-deficient granulocytes 169, suggesting that lower apoptosis 
rates were not specifically linked to either the GPI+ or the GPI-deficient population. 
The study of Chen et al. confirmed that apoptosis rates in directly ex vivo isolated CD34+ 
GPI-deficient cells were lower than in their GPI+ counterparts but similar to CD34+ cells from 
healthy controls. This would indicate that a higher rate of apoptosis in the GPI+ cells rather than 
a lower susceptibility for apoptosis in the GPI- cells causes the difference between GPI+ and GPI-
deficient cells 161. Such a higher apoptosis rate in GPI+ CD34+ cells might result from pre-existing 
damage in vivo, which is consistent with higher levels of Fas receptor demonstrated on these 
cells 170. Further evidence for this hypothesis was provided by the study of Chen, who showed 
upregulation of several genes involved in apoptosis and immune responses in GPI+ CD34+ cells 
compared to GPI-deficient CD34+ cells 171. 
Taken together, these studies suggest that in the bone marrow of PNH patients CD34+ GPI+ 
cells are subjected to apoptosis induction to which CD34+ GPI- cells may be less susceptible or 
resistant.  Autoimmune mediated marrow failure may cause this apoptosis induction. 
a l t e r n a t i v e  h y p o t h e s e s  f o r  t h e  m e c h a n i s m  o f  c l o n a l  e x p a n s i o n 
i n  P N H
An alternative explanation for clonal expansion in PNH which has received little attention in literature 
is a potential difference in homing and mobility of normal and GPI-deficient HSC. More motile 
PNH HSC may displace normal HSC from their bone marrow niches due to defective adhesion and 
enhanced migration. This theory, which has drawn little attention in the field of PNH,  is supported 
by the observation that in PNH, circulating GPI-deficient CD34+ cells  predominate in peripheral 
blood 172, and that granulocyte-colony-stimulating factor (G-CSF) treatment preferentially mobilizes 
GPI-deficient CD34+CD38- hematopoietic progenitor cells 173. The role of certain GPI-anchored 
proteins in HSC homing is compatible with this theory 174, which still requires additional study. 
Another hypothesis was proposed by Dingli et al., who presented an interesting 
mathematical simulation supporting a ‘neutral evolution model’, in which expansion of a PNH 
clone can occur even without a survival advantage. Remarkably, their model accurately predicts 
the known incidence of PNH, especially in a setting of decreased stem cell numbers as is the 
case in immune mediated marrow failure 175. 
i m m u n o l o g i c a l  e s c a p e  o f  g P i - d e f i c i e n t  c e l l s  a s  a  c a u s e  o f  c l o n a l 
ex p a n s i o n
Most research has focused on the hypothesis that clonal expansion of GPI-deficient cells in 
PNH occurs as a result of autoimmune-mediated bone marrow damage. GPI-deficient HSC 
may survive immune attack, whereas their GPI+ counterparts do not. As a consequence, lower 
susceptibility of PIG-A mutated HSC to immune attack may lead to a selective growth advantage 
and thus, clonal expansion.
Why PIG-A mutated cells would be better capable of withstanding immune-mediated bone 
marrow attack is still unclear. A possible explanation is the missing GPI anchor or a GPI-anchored 
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protein serving as an auto antigen. As a consequence, a differential immune response towards 
normal and GPI-deficient cells may take place. Second, lack of the GPI anchor may result in altered 
processing and presentation of GPI-anchored proteins by GPI-deficient antigen presenting cells 
(APCs). A third possibility is that deficient costimulation by GPI-anchored proteins results in an 
inefficient immune response to PIG-A mutated HSC. Support for the first possibility that PIG-A 
mutated cells can expand as a consequence of immune-mediated attack to a GPI-anchored 
antigen came from studies in B-cell Non-Hodgkin lymphoma patients. In such patients, PIG-A 
mutated T cell clones emerged during treatment with Campath-1H, an antibody to GPI-anchored 
CD52 present on both T and B cells 176. The hypothesis of differential susceptibility to immune-
mediated damage was extensively studied but no definitive consensus has been reached yet. 
Most of these studies have challenged this hypothesis in in vitro models using allogeneic effector 
cells, which limits their relevance. Candidate effector cells mediating differential susceptibility 
include both T cells, NK cells and T cells with innate features such as Natural Killer cell receptor 
(NKR) expression, which will be subsequently discussed in the following sections. 
ro l e  o f  t  c e l l - m e d i a t e d  a u t o i m m u n i ty  i n  i m m u n o l o g i c a l  e s c a p e 
o f  g P i - d e f i c i e n t  c e l l s
As mentioned previously, several studies have demonstrated skewing of the T cell repertoire 
in CD4 and CD8 T cells in PNH and AA-PNH 138-145. Only two of these studies were able to 
demonstrate that skewed T cell clones were indeed capable of lysis of autologous CD34+ 
cells in a limited number of patients. However, none of these studies assessed the differential 
susceptibility of GPI+ and GPI-deficient CD34+ cells 140,143. 
Studies in cell line models on the role of T cells as effectors have yielded conflicting results. 
Karadimitris et al. have studied the in vitro sensitivity of paired normal and GPI-deficient Epstein-
Barr virus (EBV) transformed cell lines derived from PNH patients to autologous EBV-specific 
cytotoxic T cells (CTLs) but did not find any difference 177.  Murakami et al. demonstrated in a 
murine model that GPI-deficient hematopoietic fetal liver cells become dominant over their GPI+ 
counterparts through negative selection by allogeneic CD4+ T cells 178. The same study showed in 
an in vitro murine cell line model that both allogeneic and antigen-specific CD4+ T cells responded 
less efficiently to GPI-deficient target cells. In vivo evidence arguing against a decreased 
susceptibility of GPI-deficient cells for immune-mediated lysis is derived from the setting of 
allogeneic SCT, in which GPI-deficient cells quickly recover after conditioning but completely 
disappear after engraftment. This implies that their presumed relative resistance to immune 
attack does not apply to the relatively powerful immune response induced by allogeneic effector 
cells 179. In contrast, Mochizuki et al. have described an AA patient who received an allogeneic SCT 
and developed a donor-derived small PNH clone during late graft failure, supporting the concept 
of decreased susceptibility of GPI-deficient HSC for immune-mediated bone marrow attack 180.
The possibility that the GPI anchor itself may serve as a T cell auto-antigen was investigated 
by Gargiulo et al 181. They hypothesized the involvement of invariant natural killer T cells (iNKT) 
in PNH pathogenesis. iNKT cells are a special population of T cells recognizing glycolipids in 
the context of CD1d, a non-classical MHC molecule 182. GPI can be presented by CD1d 183 and is 
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capable of activating iNKT, as evidenced by CD1d-restricted T cell responses to GPI-anchored 
antigens derived from parasites in mice 184. In humans, the majority of these T cells carry a TCR 
Vα24Jα18 chain, preferentially coupled to a Vβ11 chain 182. These T cells have a variety of different 
immunoregulatory and immunostimulatory functions 185. Although CD1d expression has not yet 
been evaluated in PNH patient bone marrow, expression was demonstrated on human cord 
blood CD34+ cells 186 and mouse HSC and progenitor cells 187. 
TCR Vα24 Vβ11 iNKT cells were reduced in the bone marrow of AA patients 188, arguing against 
a potential role as autoimmune effectors. However, Gargiulo et al. demonstrated a significantly 
higher frequency and responsiveness of CD1d-restricted CD8+ T cells reactive to human GPI in 
predominantly hemolytic PNH patients, compared to healthy controls 181. Analysis of the TCRα and β 
chain repertoire within GPI-specific CD1d-restricted T cells revealed a novel invariant TCR Vα21Jα31-1 
chain different from classical iNKT cells. This TCR Vα21Jα31-1 chain was overrepresented in the T 
cell repertoire of the majority of PNH patients but not in healthy controls 181. Taken together, these 
results suggest that this CD1d-restricted T cell population may represent autoimmune effector cells 
PNH, although their reactivity towards PNH HSC remains to be proven. 
r o l e  o f  N k  c e l l s  a n d  N k  c e l l  r e c e p t o r  e x p r e s s i n g  N k  c e l l s  
i n  P N H
A potential role for T cells expressing Natural Killer cell receptors (NKR) in the pathogenesis 
of PNH was first suggested by Poggi et al., who observed a slightly increased frequency of T 
cells expressing NKRs, i.e. killer-cell immunoglobulin-like (KIRs) and C-type lectin receptors, in 
PNH patients versus healthy controls 189. In AA, overexpression of KIR mRNA was found in bone 
marrow CD8+ T cells 190. In PNH, NKR-expressing T cells expressed predominantly the activating 
isoforms of these receptors 189. Importantly, cloned NKR-expressing T cells isolated from PNH 
patients mediated less efficient killing of a GPI-deficient K562 cell line compared to GPI+ K562 
cells. These data suggested that T cells expressing activating NKR may promote the expansion 
of a PNH clone by selective lysis of GPI+ cells. Whether these T cells overlap with the CD1d-
restricted invariant NKT cell population described by Gargiulo et al. is unknown 181. 
Evidence supporting a role for NK cells in mediating immune escape of GPI-deficient cells 
came from a study showing that healthy donor peripheral blood NK cells killed GPI-deficient 
variants of various hematopoietic cell lines less efficiently than their GPI+ counterparts 191. 
Interestingly, the UL16 binding proteins (ULBPs), which bind to the activating NKR NKG2D and 
are expressed upon cellular stress, attach to the cell membrane using a GPI anchor. Hanaoka 
et al. subsequently showed that blocking ULBPs or NKG2D abolished the difference in NK cell 
mediated killing of GPI+ versus GPI-deficient target cells 192. In addition, ULBP was detected on 
GPI-deficient granulocytes and CD34+ cells of some, although not all PNH patients, whereas 
it was absent in healthy donors 192,193. Anti-NKG2D treatment improved hematopoietic colony 
formation in vitro, providing further evidence for the involvement of NKG2D expressing 
lymphocytes in bone marrow failure in PNH 193. 
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r o l e  o F  N k  c e l l  r e c e P to r s  i N  H e a lt H  a N d  ot H e r 
a u to  i m m u N e  d i s e a s e s
a n  i n t r o d u c t i o n  o n  N a t u r a l  k i l l e r  c e l l  r e c e p t o r s
Natural Killer (NK) cell activation and function is tightly regulated by the balance between 
activating and inhibitory NK cell receptors (NKR), determining whether or not its target cell, 
e.g. an infected or malignant cell, is killed. NKR are not exclusively expressed on NK cells but 
can be present on a subset of T cells as well. In contrast to NK cells, NKR function on T cells is 
not fully elucidated. In healthy donors NKR expressing T cells are infrequent (typically < 5 % of 
CD8+ T cells). They consist predominantly of CD8+ memory T cells and are thought to play a role 
in conditions of chronic immune activation 194. Elevated numbers are found in the elderly and 
patients with autoimmune diseases 195. NKR on T cells mediate costimulation and can in some 
circumstances exert TCR independent effector functions 196-199. 
Three broad categories of NKRs can be distinguished within the large variety of known NKR. 
These include Killer-cell Immunoglobulin-like Receptors (KIR, CD158 isoforms), C type lectin 
receptors of the NKG2 family, and natural cytotoxicity receptors (NCRs) (Table 3). Inhibitory KIR 
isoforms recognize Major Histocompatibility Class I (MHC-I) molecules, and thereby enable NK 
cell tolerance towards self MHC. Alternatively, activating KIR isoforms bind with lower affinity 
to MHC-I molecules and to yet unidentified molecules 200. 
NKG2 receptors are heterodimers of CD94 and activating (NKG2C) or inhibitory (NKG2A) 
molecules, triggered by the non-classical MHC-I molecule HLA-E. HLA-E binds a restricted 
subset of peptides derived from signal peptides of classical MHC class I molecules, thereby 
providing NK cells with another mechanism of tolerance towards self. Activating NKG2D binds 
the stress-inducible MHC-I-chain-related molecules (MICs) and human cytomegalovirus 
UL16-binding proteins (ULBPs). Lastly, the NCRs NKp30, NKp44, NKp46 and NKp80, give rise 
to another important group of activating receptors 200,201. The NCRs bind a variety of known 
and unknown ligands, including viral haemagglutinins and other viral proteins, heparin, heparin 
sulfates, B7-H6 for NKp30, and activation-induced C type lectin (AICL) for NKp80 202,203. 
t  c e l l s  w i t H  N k  c e l l  r e c e P to r s  i N  H e a lt H  
a N d  a u to i m m u N e  d i s e a s e s
k i r 
KIR expression by T cells in healthy adults was shown in 5% of CD8+ T cells and 0.2% of CD4+ T 
cells, with frequencies increasing upon ageing 207,208. Sustained KIR upregulation was shown in 
CMV specific CD8+ T cells after resolve of acute infection, suggesting a role of these receptors in 
viral control 209. In both CD4+ and CD8+ T cells, KIR+ T cells consist predominantly of oligoclonal, 
terminally differentiated effector memory T cells 207,208,210. Both CD8+ and CD4+ KIR+ T cells have a 
different KIR repertoire from NK cells, and in CD8+ T cells, usually a single KIR is dominant 208,210. 
KIR acquisition occurs most likely after termination of TCR rearrangement, as T cells with identical 
TCR rearrangements can express highly variable KIR patterns 211-213. In CD8+ T cells, KIR expression 
occurs as a consequence of progressive promoter demethylation occurring with ageing 214. 
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Inhibitory KIR isoforms are capable of inhibiting T cell effector functions, such as cytokine 
production, proliferation and cytotoxicity 194,195,215-217. In contrast, activating KIR are capable of 
costimulating T cell responses 218, and in certain circumstances also exert antigen-independent 
effector functions 196, particularly if expressed in association with the signaling molecule DAP12 197. 
The potential role of KIR-expressing T cells in autoimmune disease has been studied most 
extensively in rheumatoid arthritis (RA). Yen et al. described an association of the KIR2DS2 gene 
with a subgroup of RA patients with vasculitis 219. CD4+ T cells lacking CD28, which are found 
at increased frequency in RA, particularly in the subgroup of patients with vasculitis, partially 
express activating KIRs and also NKG2D, whereas CD4+CD28- T cells from healthy donors do 
not 220,221. In RA patients, such CD4+CD28- T cells generally lack inhibitory NKR. Furthermore, 
they are capable of costimulating T cell proliferation, but not cytotoxicity 219,220. 
Another disease in which an increased frequency of KIR-expressing T cells was reported 
is systemic lupus erythematosus (SLE) 222. Specific triggering of KIR2DL4 on SLE patient T cells 
resulted in increased interferon-gamma (IFN-γ) release 222. In psoriatic arthritis, genetic 
association studies showed that several activating KIR genes increase disease susceptibility, 
particularly when the HLA ligands for the corresponding inhibitory receptors are lacking 223-225. An 
increased frequency of KIR and CD94/NKG2A expressing CD8+ T cells was found both in peripheral 
blood and psoriasis lesions 226, and such T cells were capable of inducing psoriasis plaques in 
murine models 227. Finally, a pathogenetic role for KIRs was proposed in several other autoimmune 
diseases, such as systemic sclerosis 228,229, type I diabetes mellitus 230,231, and Sjögren’s syndrome 232. 
N kg 2  r e c e p t o r s
NKG2D, a major activating NKR, is broadly expressed on the majority of γδ and CD8+ T cells, and 
a minority of CD4+ T cells. It uses DAP10 as an intracellular adapter signaling molecule 194. NKG2D 
was shown to function as a costimulatory receptor in CMV specific CD8+ T cells 233-235, whereas 
upon ex vivo activation, it can also induce MHC unrestricted cytotoxicity 236.  The heterodimer 
of the activating NKR NKG2C and CD94 has a similar expression pattern as NKG2D, and uses 
DAP12 as an intracellular adapter 237. Also NKG2C is upregulated in CMV specific CD8+ T cells 
after resolve of acute infection, suggesting a role in viral control 209. Unlike NKG2D, triggering 
of CD94/NKG2C elicits T cell effector functions such as proliferation, cytokine production 
and cytotoxicity, independent of TCR triggering 198,237. Inhibitory CD94/NKG2A is expressed on 
CD8+ T cells activated by TCR triggering or cytokine stimulation, and can downmodulate TCR-
mediated cytotoxicity and cytokine production 238. CD94/NKG2A expression is upregulated 
during chronic viral infections such as CMV and human immunodeficiency virus 239,240. 
As well as the KIRs, the NKG2 receptors have been implicated in several autoimmune diseases. 
In RA, polymorphisms in the genes for NKG2A, NKG2C and NKG2D modify disease risk 241. In RA 
but not in healthy donors, the CD4+CD28- T cell population not only expresses activating KIRs but 
also NKG2D 220,221. Importantly, the synoviocytes in RA, the target of immune-mediated damage, 
were shown to express the NKG2D ligand MIC 221. In celiac disease, gut intraepithelial CTLs express 
NKG2C, in addition to other activating NKR such as NKG2D, NKp44 and NKp46 198,242. Upon NKG2C 
triggering, such T cells are capable of cytokine production and proliferation, independent of TCR 
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triggering and costimulated by NKG2D 198. Consistent with a role for NKG2C and NKG2D in vivo, 
gut epithelial cells from celiac patients expressed the corresponding ligands HLA-E and MIC 198,242. 
Similarly, in Crohn’s disease, an inflammatory bowel disease, an increased frequency of intra-
epithelial CD4+ NKG2D+ T cells was demonstrated, with the epithelium itself expressing the NKG2D 
ligand MICA 243,244. In contrast, in SLE, the CD4+ NKG2D+ population is inversely correlated with 
disease activity, suggesting a rather regulatory phenotype 245. Finally, in type I diabetes murine 
studies have shown NKG2D expressing T cells mediating pancreatic islet damage 246. 
a i m s  a N d  s c o P e  o F  t H i s  t H e s i s
Despite considerable progress in the treatment of PNH with the advent of eculizumab, major 
questions remain to be solved. Although eculizumab effectively reduces hemolysis, associated 
symptoms and thrombotic risk, and thereby greatly improves patients’ quality of life, it is a 
maintenance treatment which does not cure PNH. It is still unknown what triggers the bone 
marrow failure component of PNH, and what mechanism is causing clonal expansion in PNH. 
Understanding these mechanisms is an essential first step in designing a rational curative therapy 
for PNH in order to prevent clonal expansion and the development of bone marrow failure. Part 
1 of this thesis focuses on the role of autoimmunity and bone marrow failure in PNH. 
In Chapter 2, we have investigated the presence of T cells with NKR in PNH, and their 
potential involvement in clonal expansion of GPI-deficient HSC by selective immune attack to 
normal and not GPI-deficient HSC. Several NKR-expressing T cell populations were found at 
increased frequency in PNH patients compared to healthy donors. NKR+ CTL lines isolated from 
PNH patient peripheral blood and bone marrow displayed high cytotoxicity towards CD34+ 
hematopoietic progenitor cell lines and K562 cells, and were in some circumstances capable of 
differential lysis of GPI+ and GPI- hematopoietic cell lines.
In Chapter 3, we have studied bone marrow histology in a large series of patients with a 
PNH clone in different presentations in order to provide the first comprehensive overview of the 
spectrum of BM histology in such patients. We show that in both patients with AA-PNH overlap 
syndrome as well as classic PNH patients clearly demonstrate histological evidence of bone marrow 
failure, indicating that autoimmunity may play a role in both patient categories. In Chapter 4, we 
have answered the question whether the increased NKR expressing T cell populations were specific 
for PNH or a more general phenomenon in auto immune or auto-inflammatory diseases. Therefore, 
we have extensively characterized NKR expression patterns in T and NK cells in rheumatoid arthritis 
(RA) and psoriatic arthritis (PsA). We show here that although in PNH, RA and PsA, T cell populations 
with expression of NKR are present at increased frequency, the pattern of NKR expression is different. 
Another major unresolved topic in the field of PNH is the mechanism of thrombosis. 
Understanding this mechanism and improving the possibilities to estimate and predict thrombotic 
risk is of major importance to reduce the incidence of thrombosis and its burdening symptoms, 
particularly in those patients who are not treated with eculizumab. Part 2 of this thesis focuses on 
thrombosis in PNH in association with eculizumab treatment, and some potential complications in 
the management of patients treated with eculizumab. In Chapter 5 the current knowledge on the 
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epidemiology, mechanisms and treatment of thrombosis in PNH is reviewed. In Chapter 6, we have 
we have studied coagulation and fibrinolysis in a large population of PNH patients by measuring 
procoagulant microparticles, prothrombin fragment 1+2, and D dimer levels as parameters of 
coagulation and fibrinolysis respectively. These parameters were correlated with clinical parameters 
such as LDH, PNH clone size and history of thrombosis in order to try and identify markers that may 
aid in estimating thrombosis risk. In addition, we have evaluated the effect of eculizumab on these 
parameters in order to try and gain more insight in the mechanism via which eculizumab reduces 
thrombotic risk. In Chapter 7, we aimed to determine the role of neutrophil extracellular traps 
(NET) formation in the pathogenesis of thrombosis in PNH. NETs are extracellular meshworks of 
DNA fibers comprising histones and neutrophil proteases which are extruded from neutrophils 
and other myeloid cells upon activation. They are highly procoagulant as they form a platform for 
platelet adhesion, activation and aggregation. We have determined elastase-α1-antitrypsin (EA) 
complex and circulating nucleosomes levels as markers of neutrophil activation and NET formation 
respectively in PNH patients before and during eculizumab treatment and demonstrated increased 
nucleosomes levels in PNH patients with a history of thrombosis, suggesting ongoing low-grade 
NET formation which is possibly inhibited by eculizumab. 
When introducing a novel treatment into clinical practice, especially in a rare disease as 
PNH, it is essential that potential complications of this treatment are investigated and reported. 
Chapter 8 reports on a PNH patient who developed thrombosis shortly after withdrawal of 
eculizumab treatment, which may suggest a causal relationship. With the availability of eculizumab, 
effective complement inhibition is possibly during complement-enhancing events such as surgery. 
However, knowledge on adequate dosing during surgery is lacking. Chapter 9 discusses the 
management of potential complications of a PNH patient on eculizumab treatment undergoing 
elective cardiothoracic surgery requiring cardiopulmonary bypass. Finally, Chapter 10 summarizes 
the findings described in this thesis and discusses the future prospects in PNH research. 
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a b s t r ac t: 
objective: To investigate the presence of T cells with NK cell receptors (NKR) in paroxysmal 
nocturnal hemoglobinuria (PNH), and their potential involvement in clonal expansion of 
glycosylphosphatidylinositol (GPI) deficient hematopoietic stem cells (HSC) by selective 
immune attack to normal and not GPI-deficient HSC. 
Patients and methods: By flow cytometry, the frequency and number of T cells expressing NKR 
was evaluated in 39 PNH patients and compared to healthy controls. Elevated T cell subsets in 
PNH were assessed for differential cytotoxic lysis of GPI+ and GPI-deficient CD34+ hematopoietic 
progenitor cell lines. 
results: In PNH patients, the frequency (p<0.001) and absolute number of T cells expressing 
the NKR CD56 (p=0.01) were significantly increased. Furthermore, a higher percentage of T cells 
expressed the activating NKRs NKG2D (p<0.01), NKG2C (p<0.01), and KIR2DS4 (p=0.01). Further 
characterization showed that these populations predominantly consist of CD8+ effector memory 
CD45RA+ T cells (T
EMRA
). NKR+ cytotoxic T lymphocyte (CTL) lines isolated from PNH patient 
peripheral blood and bone marrow displayed high cytotoxicity towards CD34+ hematopoietic 
progenitor cell lines and K562 cells, suggesting MHC class I independent cytotoxicity. These 
CTL lines are capable of differential lysis of GPI+ and GPI-deficient hematopoietic cell lines, 
however not in all cases. This suggests that multiple factors, such as the highly activated status 
of in vitro cultured CTLs, influence whether GPI dependent lysis occurs. 
conclusion: The increased frequency of CD8+ effector-memory T cells with activating NKRs 
and cytotoxicity towards hematopoietic cell lines suggests involvement in bone marrow failure 
and clonal expansion in PNH.  
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i N t r o d u c t i o N
PNH is a bone marrow disease characterized by intravascular hemolysis, an increased risk 
of thrombosis and a variable degree of pancytopenia. The disease results from an acquired 
mutation in the X-linked PIG-A gene in the hematopoietic stem cell (HSC), leading to a clone 
of hematopoietic cells with deficient expression of GPI-anchored proteins (GPI-AP). Deficiency 
of GPI-anchored complement inhibitors CD59 and CD55 on erythrocytes results in chronic 
intravascular hemolysis upon complement activation. 
The clinical evolution of PNH arises through clonal expansion of PIG-A deficient HSC. 
Interestingly, the PIG-A mutation may also be found in a very small percentage of hematopoietic 
cells in healthy individuals, usually in more mature hematopoietic progenitors 1;2. However, in 
this situation PIG-A-mutated hematopoietic cells do not expand and do not give rise to PNH. 
Furthermore, in murine PIG-A gene knockout models the PIG-A deficient clone does not 
expand either 3;4. Apparently, the PIG-A mutation alone cannot explain the selective expansion 
of a PNH clone and other mechanisms are involved. 
Several observations support a role for immune-mediated bone marrow failure in PNH. For 
example, a PNH clone is not specific for PNH but also occurs frequently in other immune-mediated 
bone marrow failure diseases such as aplastic anemia (AA) and myelodysplastic syndromes 
(MDS) 5-8. Immunosuppressive therapy may ameliorate the marrow failure component of PNH 
and the presence of a PNH clone in patients with AA or MDS is of predictive value for the response 
to immunosuppressive therapy 8;9. Furthermore, several groups have described the presence of 
potentially oligoclonal T cell expansions in patients with PNH, AA and MDS 10-15. Taken together, 
these data indicate a role for autoimmune mediated bone marrow failure in the presence of a PNH 
clone. In this setting, the expansion of a PNH clone could be explained by selective survival of GPI-
deficient HSC, whereas normal HSC are lysed by autoreactive immune effector cells. 
It has been demonstrated that T cells expressing activating isoforms of natural killer (NK) 
cell receptors (NKR) such as Killer cell Immunoglobulin-like receptors (KIRs or CD158 isoforms) 
and C-type lectin receptors (CLRs) may be implicated in PNH related bone marrow failure 16. 
KIRs bind to HLA class I molecules and exist in activating and inhibitory isoforms. CLRs consist 
of a heterodimer of CD94 coupled to a NKG2 molecule which can either be activating (NKG2C) 
or inhibitory (NKG2A), both binding to HLA-E. NKG2D is expressed as a homodimer and binds 
to stress inducible MHC class I chain-related molecules (MICs) or human cytomegalovirus UL16 
binding proteins (ULBPs). Normally, T cells expressing KIRs or CLRs are present in low numbers 
(typically <5 % of CD8+ T cells) and consist predominantly of CD8+ memory T cells 17. Upon ageing 
or conditions of chronic immune activation, such as viral infections and autoimmune diseases, 
they are found at increased frequency, for example in rheumatoid arthritis, celiac disease and 
cytomegalovirus (CMV) infection 18-20. In certain circumstances T cells expressing activating 
NKR are capable of T cell receptor (TCR) independent effector functions, such as cytokine 
production, cytotoxicity and proliferation 19;21-23. 
In PNH patients, T cells expressing NKR were found at a slightly increased frequency 16. 
Furthermore, T cell clones expressing activating NKR could be isolated at a high frequency from 
PNH patient peripheral blood. More importantly, these T cell clones mediated less efficient 
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killing of a GPI-deficient K562 cell line compared to GPI-positive K562 cells. These data suggested 
that T cells expressing activating NKR may promote the expansion of a PNH clone by selectively 
lysing GPI+ cells. Other studies have described NKG2D ligand expression in bone marrow and 
in peripheral blood granulocytes of PNH patients. Moreover, anti-NKG2D treatment improved 
hematopoietic colony formation in vitro, providing further evidence for the involvement of 
NKG2D expressing lymphocytes in bone marrow failure in PNH 24;25. 
In this study, we have found significantly increased frequencies of T cells expressing the 
activating receptors KIR2DS4, NKG2C and NKG2D in PNH patients. Fitting their presumed role 
as autoimmune effectors in bone marrow failure in PNH, we show here that these T cells consist 
of cytotoxic effector memory T cells co-expressing several (activating) NKR. Furthermore, they 
display high cytolytic potential towards hematopoietic cell lines which in some cases is GPI 
dependent, suggesting involvement in bone marrow failure and clonal expansion in PNH. 
m at e r i a l  &  m e t H o d s
P N H  p a t i e n t s
Blood and bone marrow samples from 39 PNH patients were collected after obtaining informed 
consent according to RUNMC institutional procedures. This study was performed in accordance 
with the Declaration of Helsinki and approved by the RUNMC ethical committee. Blood samples 
from healthy controls (n = 25) were used from donor apheresis products or buffy coats (Sanquin 
Blood bank, Nijmegen, the Netherlands). In Table 1 the clinical characteristics of PNH patients 
and healthy controls are shown. 
F l o w  c y t o m e t r y
Peripheral blood (PBMC) or bone marrow mononuclear cells (BMMC) were isolated from whole 
blood by Ficoll Hypaque gradient separation. Determination of NKR expression on CD8+ and 
table 1: clinical and hematological features of PNH patients 
PNH patients (n = 39) Healthy donors (n = 25)
Median age (years) 39 (range 21 - 88) 49 (range 20 – 68)
Male/female 21/18 (54/46%) 10/15 (60/40%)
Median PNH granulocyte clone size (%) 83% (range 6 - 100%) NA
History of AA 16 (41%) NA
Current treatment:
Supportive
Cyclosporin A
Eculizumab
24 (62%)
2 (5%)
13 (33%)
NA
Median duration of disease (years) 7 (range 1 - 39) NA
Prior immunosuppression 25 (64%) NA
NA = not applicable
48
T c
ells w
iTh
 a
c
Tiv
a
Tin
g
 n
K
 c
ell rec
epTo
r
s in
 pn
h
2
CD56+ T cells was performed using 5-color flow cytometry using anti-CD8-FITC, anti-CD3-
ECD, anti-CD4-PECy5, CD56-PECy7 on a FC500 flow cytometer (Beckman Coulter, Fullerton, 
CA, USA). The following phycoerythrin (PE) conjugated NKR antibodies were used: anti-
CD158b1/b2,j (clone GL183, recognizes KIR2DL2, KIR2DL3 and KIR2DS2), anti-CD158a,h (clone 
EB6B, recognizes KIR2DL1 and KIR2DS1), anti-CD158e1/e2 (clone Z27.3.7, recognizes KIR2DL1 and 
KIR3DS1), anti-CD158i (clone FES172, recognizes KIR2DS4), anti-NKG2A (clone Z199), anti-CD94 
(clone HP-3B1) (all Beckman Coulter), anti-NKG2C (R&D systems, Minneapolis, MN, USA), anti-
NKG2D (clone 1d11, BD Biosciences, Franklin Lakes, NJ, USA).
To determine NKR co-expression patterns on specific NKR+ T cell subsets 10 color flow 
cytometry was performed using a 10-color, 3-laser Navios flow cytometer (Beckman Coulter). 
PBMCs were stained with the following antibodies: CD3-FITC, CD8-ECD, CD158i-PECy5.5, 
CD158b1/b2,j-PECy7, CD45-Krome Orange, NKG2D-APC, CD158a,h-APC Alexa 700, CD56-APC 
Alexa 750, NKG2A-Pacific Blue (all kindly provided by Beckman Coulter, Marseille, France), and 
NKG2C-PE (R&D Systems). Further characterization was performed by using anti-TCRαβ-PE-
Cy5, anti-TCRγδ-FITC, anti-CD48-FITC, anti-CD45RA-ECD (all Beckman Coulter), anti-CCR7-
fluorescein (R&D systems), anti-CD16 (BD Biosciences) and anti-TCR Vα24Jα18-PE antibodies 
(eBiosciences, San Diego, CA, USA). Expression of NKR ligands on cell lines was determined 
using anti-CD244-PECy5 (Beckman Coulter), anti-CD155 fluorescein conjugated (R&D systems) 
and anti-CD112-PE (BD Pharmingen). 
g e n e r a t i o n  o f  t  c e l l  l i n e s  e x p r e s s i n g  N k r s
CD8+ T cells were sorted from BMMC or PBMC of two patients by fluorescence activated cell 
sorting (FACS). Clinical characteristics of these patients are shown in table 2. Sorted CD8+ T cells 
were polyclonally stimulated using MACSibeads coated with anti-CD2, anti-CD3 and anti-CD28 
(T cell activation & expansion kit, Miltenyi Biotec), 20 U/ml IL-2 (Chiron, Emeryville, CA) and 
5 ng/ml IL-15 (Immunotools, Friesoythe, Germany) for 7-10 days. Thereafter, CD8+ KIR2DS4+ T 
cells were FACS sorted at 1 cell/well, 10 cells/well and 100 cells/well using an Epics Elite Flow 
Cytometer (Beckman Coulter). Sorted cells were cultured in round-bottom 96-wells plates in 
200 μl Iscove’s modified Dulbecco medium (IMDM; Invitrogen, Carlsbad, CA) plus 10% human 
serum (Sanguin Blood Bank, Nijmegen, the Netherlands), containing 1 x 105/ml irradiated 
table 2: clinical and hematological features of patients investigated
Patient
age 
(y) m/ F
time since 
diagnosis 
(y)
Peripheral blood values
PNH 
clone* 
current 
treatment
Hb  
(g/l)
Platelets  
(x 109/l)
wbc 
(x 109/l)
aNc  
(x 109/l)
reticulocytes 
(‰)
1 45 F 2 92 50 3.5 2.1 46 70% Supportive†
2 39 F 22 115 130 1.9 0.48 53 95% Eculizumab‡
Hb = hemoglobin; WBC = white blood cells; ANC = absolute neutrophil count. *PNH clone size is indicated as 
the percentage of granulocytes with deficient expression of GPI-anchored proteins. † Previously treated with 
cyclosporine A. ‡ Previously treated with Antithymocyte globulin (ATG) and prednisolone. 
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allogeneic PBMCs of 2 different donors, 1 x 105/ml irradiated 721.221 cells transduced with 
HLA-Cw4*04:01 as a ligand for KIR2DS4, 100 U/ml IL-2 (Chiron, Emeryville, CA) and 1 μg/ml 
phytohaemagluttinin-M (PHA-M; Boehringer Mannheim, Germany). Thereafter, T cell cultures 
were weekly restimulated with irradiated allogeneic PBMCs, 721.221*HLA-Cw4*04:01 cells, IL-2, 
PHA-M and IL-15 (5 ng/ml, Immunotools, Friesoythe, Germany). 
c y t o t ox i c i t y  a s s a y s
Cytolytic activity of NKR+ cytotoxic T lymphocyte (CTL) lines was determined by standard 
chromium release assays. Briefly, 106 target cells were labeled with 100 μCi 51Cr (Perkin Elmer, 
Groningen, the Netherlands) for 1.5 h.  Subsequently, 103 target cells were mixed with CTLs in 
triplicate at various effector to target (E:T) ratios in 96 well V-bottom plates in a final volume 
of 150 μl IMDM with 10% fetal calf serum (FCS; Integro, Zaandam, The Netherlands). Co-
cultures were incubated for 4 hours at 37°C. Thereafter, 100 μl supernatant of each sample was 
collected and radioactivity was determined by a gamma counter. Percentage of specific lysis 
was calculated using the following formula: % specific cytotoxicity = (experimental release – 
spontaneous release)/(maximum release – spontaneous release) x 100. Spontaneous release 
was typically less than 25% of maximum release. 
K562 cells and its mutagenized GPI-deficient variant 26 (kindly provided by Dr. A. Poggi, 
Laboratory for Experimental Oncology, National Institute for Cancer Research, Geneva, Italy) 
were used as target cells. In other experiments, CD34+ GPI-deficient TF-1 cells containing a 
tetracyclin inducible PIG-A gene (kindly provided by Dr. R. Brodsky, Division of Hematology, 
Johns Hopkins University School of Medicine, Baltimore, USA) were used 27. TF-1 cells were 
cultured with tetracyclin 2 μg/ml for > 2 days, resulting in expression of GPI-AP in > 95% of cells, or 
without tetracycline for GPI-deficient cells (typically > 95%). KG1a with low and normal expression 
of GPI-AP were generated by incubating KG1a cells with the GPI anchor specific enzyme 
phospholipase C (PI-PLC, Sigma-Aldrich) or medium. Briefly, KG1a cells were incubated for 1 hr 
at 37°C in IMDM/10% FCS plus 10% buffer containing 0.05 % BSA, 10 mM Tris, 144 mM NaCl at pH 
7.4, with or without PI-PLC at a final concentration of 1 U/ml and subsequently used as target cells 
in 51Cr release assays. Reduced expression of GPI-AP lasted for at least 6 hours (data not shown).
s t a t i s t i c s
Mann-Whitney U test was used for comparison of T cell and NK cell subset frequencies and 
absolute numbers. Statistical significance was accepted for p values below 0.05. Two way ANOVA 
was used to test for significant differences in specific lysis of GPI+ and GPI-deficient target cells 
at different effector to target (E:T) ratios. Linear regression analysis was used to determine 
correlations between percentages of lymphocyte subsets and clinical characteristics. 
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r e s u lt s
e l e v a t e d  f r e q u e n c i e s  o f  t  c e l l s  e x p r e s s i n g  N k  c e l l  r e c e p t o r s 
c d 5 6,  k i r 2 d s 4,  c d 1 5 8 b 1 / b 2 , j ,  N kg 2 c ,  N kg 2 d  i n  p e r i p h e r a l 
b l o o d  o f  P N H  p a t i e n t s
In order to evaluate the role of autoimmunity in the pathogenesis of PNH and the mechanism 
of expansion of a PNH clone, we have performed immunophenotyping of lymphocyte subsets 
in peripheral blood samples of PNH patients, focusing specifically on T cells expressing 
NKR. In Figure 1A, a representative example of a PNH patient with several NKR expressing T 
cell populations is shown. In our cohort of 39 patients, we observed significantly increased 
percentages (p < 0.001) and absolute numbers (p 0.01) of T cells expressing the general marker 
CD56 as compared to healthy volunteers (Figure 1B). 
Next, we investigated the expression of various NK cell markers including KIRs and CLRs on 
peripheral blood T cells of PNH patients. Interestingly, a significantly higher percentage of T cells 
expressing the activating NK cell receptors KIR2DS4 (CD158i) (p = 0.01), NKG2D (p < 0.01) and NKG2C 
(p < 0.01) was found in PNH patients compared to healthy controls (Figure 1C). Moreover, frequencies 
of T cells expressing CD158b1/b2,j (representing KIR2DL2, KIR2DL3 and KIR2DS2) (p = 0.04) were also 
elevated (Figure 1D), and a trend was observed towards a significantly increased frequency of T cells 
expressing CD158a/h (KIR2DS1/KIR2DL1, p = 0.07) (Figure 1C and D). For the CD158b1/b2,j and CD158a,h 
receptors it is not possible to determine by flow cytometry whether these represent activating or 
inhibitory receptors since these molecules only differ in their intracellular part. Also, a trend towards 
an increased frequency of T cells expressing the inhibitory NKG2A molecule (p = 0.05) was observed 
(Figure 1D). The frequency of CD94 expressing T cells was significantly elevated (p = 0.04) (Figure 1D), 
correlating with the frequency of NKG2A and NKG2C expressing T cells (data not shown). 
In summary, we show that in patients with PNH, the frequency of T cells expressing specific, 
mainly activating, NKRs is increased compared to healthy controls. Correlations between the 
frequency of KIR and NKG2 expressing T cells with clinical characteristics of PNH patients 
such as age, granulocyte clone size, history of aplastic anemia, eculizumab treatment, and 
duration of disease were not found (data not shown). Only for CD158b1/b2,j but not for other 
NKR expressing T cells a significantly higher frequency was found in patients with serological 
evidence of past CMV infection (p = 0.02, Mann Whitney U test, Supplementary figure 1). 
c d 5 6 +,  k i r 2 d s 4 +,  N kg 2 c + a n d  N kg 2 d + t  c e l l s  i n  P N H  p a t i e n t s 
m a i n l y  c o n s i s t  o f  c d 8 +  e f f e c t o r  m e m o r y  t  c e l l s  a n d  v a r i a b l y 
c o - e x p r e s s  s e v e r a l  a c t i v a t i n g  N k r s
The CD56+, KIR2DS4+, NKG2C+ and NKG2D+ T cell populations in PNH patients were further 
characterized by flow cytometry to determine TCR type, differentiation status, function (helper 
or cytotoxic), and co-expression of NKR. CD56+ T cells in PNH patients (Figure 2A) consist of a 
highly variable percentage of both TCRαβ T cells (median 62%, range 43-99%) and TCRγδ T cells 
(median 21%, range 5-61%). Furthermore, the number of TCR Vα24Jα18 positive T cells, which 
contain the classical CD1d restricted Natural Killer T (NKT) cells recognizing glycolipid antigens, 
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is low within the CD56+ T cell population (median 1,3%, range 0.2-2%). In addition, CD56+ T cells 
are predominantly CD8 positive (median 60%, range 17-88%), classically corresponding to 
cytotoxic function. In the majority of patients, a small percentage of CD56+ T cells (median 
2.3%, range 0,5-23.7%) expresses CD16 at low levels. 
Next, we determined the differentiation status of CD56+, KIR2DS4+, NKG2C+, and NKG2D+ 
T cells, defined by the expression of CCR7 and CD45RA 28. CD56+ T cells predominantly consist 
of T effector memory (T
EM
, CD45RA-, CCR7-) (median 18%, range 3-33%) and T effector memory 
CD45RA+ T cells (T
EMRA
, CD45RA+, CCR7-) (median 78%, range 69-93%) in both PNH patients 
(Figure 2A) and controls (data not shown). No naïve (CD45RA++, CCR7+) (median 0.6%, range 
0-3%) or central memory T cells (T
CM
, CD45RA-, CCR7+) (median 0.4%, range 0-1%) are present 
within this population. Phenotypical characterization of KIR2DS4+, NKG2C+ and NKG2D+ T cells 
is comparable to CD56+ T cells and again shows that these predominantly consist of CD8+ T
EMRA 
cells and T
EM 
cells with a highly variable percentage of TCRγδ T cells, and a low frequency of 
naïve and T
CM 
cells. Generally, expression of CD16 is low in most patients (Figure 2A).  
Figure 1: t cells expressing Nkrs cd56, cd158b1/b2,j and cd94, and activating receptors kir2ds4, Nkg2c 
and Nkg2d are present at increased frequency in patients with PNH. Figure 1A: Expression of NKRs within T 
cell population of a representative PNH patient. PBMCs were stained with anti-CD3 in combination with specific 
NKR antibodies. Results are depicted as flow cytometry dot plots gated on CD3+ T cells with sideward scatter 
on the X axis and log fluorescence intensity of specific markers on the Y axis. The percentage of positive cells 
was determined by comparison to appropriate isotype controls and are shown in the respective plots. Figure 
1B: Percentage (right panel) and absolute numbers of CD56 expressing T cells (left panel) in PNH patients versus 
healthy controls. Figure 1C: Percentage of KIR (CD158 variants) expressing T cells in PNH patients (○) versus 
healthy controls (●): CD158a/h is KIR2DS1 and KIR2DL1, CD158b1/b2,j is KIR2DL2, KIR2DL3 and KIR2DS2, CD158e1/
e2 is KIR3DL1 and KIR3DS. Figure 1D: Percentage of CLR expressing T cells in PNH patients (○) versus healthy 
controls (●). N.S. Not significant. Bars represent median values. 
PNH Control
0
5
10
15
20
p < 0.001
%
of
T
ce
lls
ex
pr
es
si
ng
CD
56
PNH Control
0.00
0.05
0.10
0.15
0.20
0.25
p = 0.01
No
of
CD
56
+
T
ce
lls
(x
10
9 /l
)
0
5
10
15
p  < 0.01p  = 0.05p  = 0.04 p < 0.01
15
25
35
45
55
65
75
       CD94                   NKG2A                 NKG2C                 NKG2D
%
of
T
ce
lls
0.0
2.5
5.0
7.5
10.0
   KIR2DS4             CD158ah          CD158b1b2j        CD158e1e2
NSp  = 0.07p  = 0.01 p = 0.04
%
of
T
ce
lls
A B 
C
0.2% 0.9% 12.7% 0.3%
NKG2A        NKG2D             CD94NKG2C
CD158ah         CD158e1e2 KIR2DS4 CD158b1b2j         
0% 2.5% 0.4% 3.3% 
CD56         
3.6% 
D 
52
T c
ells w
iTh
 a
c
Tiv
a
Tin
g
 n
K
 c
ell rec
epTo
r
s in
 pn
h
2
Whether NKR-expressing T cells are activated is determined by the balance between activating 
and inhibitory signals. Therefore, we examined the co-expression patterns of various NKR on 
KIR2DS4+, NKG2C+ and NKG2D+ T cells by 10-color flow cytometry. The majority of KIR2DS4+ T cells 
co-express either only NKG2D (median 24%, range 2 – 74%), or a combination of activating NKG2D 
and NKG2C, and CD158b1/b2,j (median 16%, range 1 – 55%) (Figure 2B). Similarly, NKG2C+ T cells also 
co-express NKG2D (median 21%, range 3-71%), or a combination of CD158b1/b2,j, and activating 
NKG2C and NKG2D (median 20%, range 1–60%) (Figure 2C). Analysis of NKG2D+ T cells, which 
represents a much larger subset compared to the KIR2DS4+ and NKG2C+ T cell subsets, revealed that 
these T cells generally do not express other NKR (median 77%, range 53-84%) (Figure 2D). 
Collectively, these data demonstrate that PNH patient peripheral blood contains elevated 
numbers of T cells expressing CD56 and specific activating NKRs such as KIR2DS4, NKG2C and 
NKG2D displaying a cytotoxic T
EM
 or T
EMRA 
and activation prone
 
phenotype. These findings fit their 
putative role as effectors in autoreactivity to hematopoietic progenitor cells in PNH patients.
kir2ds4 + Nkg2d + cy totoxic t cell liNe s (ctl) liNe s 
eFFicieNtly lyse HematoPoietic ProgeNitor cell liNe s
To determine the presumed role of T cells with activating NKRs in bone marrow failure in PNH 
patients and the expansion of a PNH clone, their ability for differential killing of GPI-positive 
and GPI-negative hematopoietic progenitor cells was assessed. Therefore, CD8+ CTL lines 
expressing the activating NKRs KIR2DS4 and NKG2D were generated by sorting KIR2DS4+ CD8+ 
T cells from peripheral blood or bone marrow of two patients. The resulting CTL lines were 
functionally analyzed in 51Cr release assays for cytotoxicity towards normal and GPI-deficient 
variants of leukemia cell lines K562, TF-1 and KG1a. All CTL lines expressed CD55, indicating that 
they did not originate from the PNH clone (data not shown). 
Two CD8+ CTL lines, designated OC5 and OB8, were isolated from the bone marrow of PNH 
patient 1. Both CTL lines highly express the activating NKR NKG2D and KIR2DS4 (Figure 3A and 
4A). As determined by TCR-Vβ family analysis, > 90% of CD8+ T cells express a single TCR-Vβ 
chain, i.e. Vβ 5.1 for CTL OC5 and Vβ7 for CTL OB8, indicating clonal origin. CTL OC5 is highly 
cytotoxic towards TF-1 even at low E:T ratios in three independent experiments (Figure 3B), but 
not towards K562 or KG1a (data not shown). In one out of three experiments significantly higher 
cytotoxic lysis of GPI+ TF-1 cells was demonstrated (p = 0.03, two-way ANOVA) (Figure 3B, left 
panel), whereas in the other two experiments no significant differences were observed (Figure 
3B, middle and right panel). Consistent with different clonal origin, the cytotoxicity pattern 
of CTL OB8 differs from CTL OC5, being highly cytotoxic towards KG1a (Figure 5C), but not 
TF-1 or K562 (data not shown). PI-PLC treatment of KG1a cells efficiently reduces expression of 
GPI-AP CD55 and CD59, and to a lower extent also CD58, which exists in both a GPI-anchored 
and a transmembrane form (Figure 4B). Significantly lower cytotoxic activity towards PI-PLC 
treated KG1a (p < 0.0001 and p = 0.0003, two-way ANOVA) was observed in two out of three 
independent experiments (Figure 4C, left and middle panel). In a third experiment, no 
differences in cytotoxicity were observed (Figure 4C, right panel). 
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Figure 2: cd56+, kir2ds4+, Nkg2c+ and Nkg2d+ t cell populations predominantly consist of cd8+ effector-
memory t cells,  are heterogeneously composed of αβ and γδ t cells and variably co-express other Nkr. 
Figure 2A: Frequencies of naïve T cells (CD45RA+, CCR7+), T
CM 
(CD45RA-, CCR7+),
 
T
EM 
(CD45RA-, CCR7-), T
EMRA 
(CD45RA+, CCR7-) cells, and TCRαβ,  γδ, Vα24Jα18, CD8, and CD16 expressing T cells were determined within the 
CD56+,  KIR2DS4+ , NKG2C+ and NKG2D+ T cell populations in 6 PNH patients. Bars represent median values. Figure 
2B-D: NKR coexpression by KIR2DS4+ (Figure 2B, NKG2C+ (Figure 2C) and NKG2D+ (Figure 2D) T cells. PBMCs were 
stained with anti-CD3 in combination with various anti-NKR antibodies. Plots were gated on KIR2DS4+, NKG2C+ 
and NKG2D+ T cell populations as indicated. Each column represents the frequency of a single T cell population 
which co-expresses the NKR indicated with + in the tree diagram below the graph. Lines represent median 
frequency of a specific T cell subset, boxes indicate 25th and 75th percentiles, and outer whiskers indicate the 
most extreme data points of 7 different PNH patients. 
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Figure 3: gPi+ and gPi- cell line tF-1 is lysed by a Nkg2d+ kir2ds4+ ctl line isolated from PNH patient bone marrow. 
Figure 3A: Phenotype of CTL OC5. CTL OC5 was stained with antibodies to CD3, CD8 and one of the following markers: 
CD158a,h, CD158b1/b2,j, CD158e1/e2, NKG2A, NKG2C and NKG2D and TCR Vβ5.1. Percentage of positive cells based on 
appropriate isotype controls within CD3+ CD8+ T cells is shown. Figure 3B: Cytolytic activity of CTL OC5 against TF-1 was 
determined in a 4-hour 51Cr release assay at the indicated effector to target (E:T) ratios in 3 independent experiments. 
Results are expressed as the mean % of specific 51Cr release of triplicate samples plus and minus SD. 
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Another NKR-expressing CD8+ CTL line, designated L6, was isolated from peripheral blood of PNH 
patient 2. Besides KIR2DS4, this TCRαβ positive CTL line expresses the activating receptors NKG2C 
and NKG2D, and CD158a,h and CD158b1/b2,j (Figure 5A). This CTL line is highly cytotoxic towards TF-1 
cells (Figure 5B) and MHC-deficient K562 cells (Figure 5C). For K562, no differences in susceptibility for 
cytotoxic lysis were observed. However, GPI-negative TF-1 cells were less efficiently lysed by CTL L6 as 
shown in two independent experiments (p < 0.0001 and p = 0.005, two-way ANOVA). 
In summary, our results demonstrate that in certain but not in all circumstances GPI-
deficient hematopoietic progenitor cells are less susceptible to NKR+ CTL-mediated lysis. 
High expression levels of activating receptors on ex vivo expanded CTLs may mask subtle 
differences in cytotoxicity towards GPI+ and GPI- target cells that are however relevant in vivo. 
In particular, high dose IL-2 or IL-15 was reported to induce upregulation or acquisition of NKR 
expression during in vitro culture and in some cases even TCR-independent killing capacity 29-31. 
Therefore, we compared expression levels of the activating receptors NKp44, NKp46, NKp30, 
NKp80, CD48 and DNAX accessory molecule-1 (DNAM-1) levels on in vitro cultured CTL lines to 
peripheral blood CD8+ KIR2DS4+ T cells (Supplementary Figure 2). NKp44, NKp46, NKp30 and 
NKp80 were not expressed on either CD8+ KIR2DS4+ T cells or CTL lines (data not shown). In 
contrast, CTL lines expressed higher levels of CD48 than peripheral blood CD8+ KIR2DS4+ T cells. 
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Figure 4: gPi+ and gPi- cell line kg1a is lysed by a Nkg2d+ kir2ds4+ ctl line isolated from PNH patient bone 
marrow. Figure 4A: Phenotype of CTL OB8. CTL OB8 was stained with antibodies to CD3, CD8 and one of the 
following markers: CD158a,h, CD158b1/b2,j, CD158e1/e2, NKG2A, NKG2C and NKG2D and TCR Vβ7. Percentage of 
positive cells based on appropriate isotype controls within CD3+ CD8+ T cells is shown. Figure 4B: Expression levels of 
GPI-anchored proteins CD55, CD59, and CD58 on KG1a cells treated with or without PI-PLC for 1 hour, as determined 
by flow cytometry. Delta mean fluorescence intensity (ΔMFI) of specific markers compared to appropriate isotype 
controls are shown of one representative experiment. Figure 4C: Cytolytic activity of CTL OB8 against KG1a was 
determined in a 4-hour 51Cr release assay at the indicated effector to target (E:T) ratios in 3 independent experiments. 
Results are expressed as the mean % of specific 51Cr release of triplicate samples plus and minus SD. 
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K562, TF-1 and KG1a target cells all express DNAM-1 ligands CD155 and CD112. The CD48 ligand 
CD244 is highly expressed on KG1a cells and at low levels on TF-1 and K562 cells (Supplementary 
Figure 3). Thus, the interaction between CD48 on CTLs and CD244 on target cells may be one 
of the factors contributing to higher in vitro cytotoxic activity and of influence whether GPI 
dependent lysis occurs. 
d i s c u s s i o N
The mechanism of expansion of a PNH clone is an unsolved question in the pathogenesis of PNH. 
Autoimmune mediated bone marrow failure in which GPI-deficient hematopoietic progenitor 
cells preferentially survive may account for the expansion of a PNH clone. In this study, we show 
that T cells expressing the general NK cell marker CD56 are highly elevated in patients with 
PNH as compared to healthy controls. Furthermore, in PNH patients the frequency of T cells 
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Figure 5: gPi+ and gPi- cell lines tF-1 and k562 are lysed by a Nkg2d+ kir2ds4+ ctl line isolated from PNH 
patient peripheral blood. Figure 5A: Phenotype of CTL L6. CTL L6 was stained with antibodies to CD3, CD8 and 
one of the following markers: CD158a,h, CD158b1/b2,j, CD158e1/e2, NKG2A, NKG2C and NKG2D and TCR αβ. 
Percentage of positive cells based on appropriate isotype controls within CD3+ CD8+ T cells is shown. Figure 5B 
and 5C: Cytolytic activity of CTL L6 against TF-1 (Figure 5B) and K562 (Figure 5C) was determined in a 4-hour 51Cr 
release assay at the indicated effector to target (E:T) ratios in 2 independent experiments. Results are expressed 
as the mean % of specific 51Cr release of triplicate samples plus and minus SD. 
E E E E E E E E
C
:T
10
:1
:T
6:1
:T
3:1
:T
1:1
0
10
20
30
40
50
60
70
K562 GPI+
K562 GPI-
%
sp
ec
ifi
c
ly
si
s
p = 0.44
:T
10
:1
:T
6:1
:T
3:1
:T
1:1
0
10
20
30
40
50
60
70
K562 GPI+
K562 GPI-
p = 0.86
%
sp
ec
ifi
c
ly
si
s
E
       0%                           2,4%                            95%                             98%
NKG2A NKG2C NKG2D TCRáß
CD158ah CD158b1b2j CD158e1e2 CD158i
             95%                         98%                           0%                         98%
      0                           43                        100                         96
A
B
:T
10
:1
E:T
6:1
E:T
3:1
E:T
1:1
0
10
20
30
40
50
60
70
80
90 TF-1 GPI+
TF-1 GPI-
p < 0.0001
%
sp
ec
ifi
c
ly
si
s
E:T
10
:1
E:T
6:1
E:T
3:1
E:T
1:1
0
10
20
30
40 TF-1 GPI+
TF-1 GPI-
p = 0.005
%
sp
ec
ifi
c
ly
si
s
expressing the activating NKR KIR2DS4, NKG2C and NKG2D is significantly increased. Fitting their 
presumed role in mediating autoimmune attack, these T cell populations predominantly consist 
of highly differentiated CD8+ T
EM
 and T
EMRA
 cells, co-expressing one or several activating NKR. 
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Increased frequencies of peripheral blood CD56+ T cells are found upon ageing 32 and 
in autoimmune disease such as rheumatoid arthritis 33, Behçet’s disease 34 and sarcoidosis 35. 
Previously, large-granular lymphocyte (LGL)-like clonal T cell expansions with expression of CD56 
were also described in cases of PNH 14. CD56+ T cells are usually oligoclonal 32, potent producers 
of IFN-γ, perforin and granzyme-B 36 and as in our study, express effector memory T cell markers. 
Triggering CD56 can costimulate T cells but may also induce TCR independent T cell activation 
32. Both their increased frequency in other autoimmune diseases and their effector memory 
phenotype with high cytotoxic potential supports a role for CD56+ T cells in autoimmunity in PNH. 
As our study indicates, the CD56+ T cell population is not composed of classical, CD1d 
restricted Natural Killer T (NKT) cells expressing the invariant Vα24Jα18 TCR. However, this 
population may contain non-classical NKT cells, which have a more diverse TCR repertoire 37. 
NKT cells recognize glycolipid antigens presented in the context of the non-classical MHC 
molecule CD1d. GPI has been proposed as a natural ligand for CD1d 38, and recently it has been 
described that GPI-anchored proteins are able to provide costimulation to CD1d-restricted T 
cells 39. Therefore, NKT cells may exert differential killing of GPI-deficient and normal HSC in 
PNH. However, further research is necessary to determine whether or not NKR expressing T 
cells in PNH patients contain non-classical NKT cells. 
Involvement of NKR and their ligands in the pathogenesis of PNH was suggested by several 
authors 16;24;25. Poggi et al. investigated the presence of T cells expressing NKR in PNH patients, 
but did not find significant differences in either frequencies or absolute numbers compared to 
healthy controls. In comparison to the study of Poggi et al., we included three times as many 
patients and more specifically investigated the presence of individual KIRs and NKG2 receptors 
instead of using a pan KIR2D marker for KIRs and CD94 for NKG2 receptors. Thus, we were 
able to demonstrate a significantly increased frequency of T cells expressing mostly activating 
NKRs including CD158b1/b2,j, CD158i, NKG2C and NKG2D in peripheral blood of PNH patients. 
Interestingly, NKG2D ligand expression has been observed in bone marrow and peripheral 
blood granulocytes of PNH patients 24. Improvement of in vitro hematopoietic colony formation 
in the presence of an anti-NKG2D antibody further supports involvement of NKG2D-expressing 
lymphocytes in bone marrow failure in PNH.
To investigate the putative role of NKR+ CD8+ T
EM 
cells in bone marrow damage in PNH 
patients, we performed cytotoxicity studies with KIR2DS4+ NKG2D+ CTL lines isolated from PNH 
bone marrow or peripheral blood. Interestingly, potent cytolytic activity towards hematopoietic 
progenitor cell lines was observed in different model cell lines, KG1a and TF-1. For several CTL 
lines, of which one example was shown, cytotoxic activity towards the MHC class I negative 
K562 cell line was also observed, indicating that these CTL lines possess TCR independent killing 
capacity which may instead be mediated via activating NKR. For other KIR2DS4+ NKG2D+ CTLs no 
cytolytic activity towards K562 was observed, suggesting that these mediate a TCR-dependent 
antigen response in the bone marrow of this patient for which NKR may provide costimulation. 
Cytotoxic activity towards hematopoietic progenitor cell lines by activating NKR expressing 
T cell lines suggests involvement in bone marrow failure in PNH. However, to explain clonal 
expansion in PNH, these T cells should exhibit higher cytolytic activity towards GPI+ HSC. We 
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indeed observed a higher cytolytic activity towards GPI+ variants of CD34+ hematopoietic cell 
lines in some but not all experiments, suggesting that multiple factors determine whether GPI 
dependent differences in cytotoxic lysis occur. Several groups have tried to demonstrate such 
differences, and as yet, no definitive consensus has been achieved. Karadimitris et al. studied 
the in vitro sensitivity of normal and GPI- Epstein-Barr virus (EBV) transformed B cell lines to 
autologous EBV-specific CTLs and did not observe differences 40. In addition, Dingli et al. 
presented an interesting mathematical simulation supporting a ‘neutral evolution model’, in 
which clonal expansion can occur even without a survival advantage. Their model accurately 
predicts the known incidence of PNH, especially in a setting of decreased stem cells numbers 
as is the case in immune-mediated marrow failure 41. 
In contrast, others did observe differences in susceptibility for CTL or NK cell mediated 
cytotoxic lysis in vitro and in vivo, supporting the theory of autoimmune mediated selection 
resulting in clonal expansion. Hanaoka et al. found decreased susceptibility of GPI-deficient 
K562 cells for cytotoxicity mediated by an NK cell line 25. Furthermore, Poggi et al. demonstrated 
less efficient killing of GPI-deficient K562 than GPI+ K562 by NKR-expressing T cells isolated 
from PNH patients. In vivo evidence supporting the immune selection theory was provided by 
Murakami et al. who nicely demonstrated in a murine transplant model that GPI-deficient cells 
preferentially survived alloreactive CD4+ T cell attack 42. Finally, Savage et al. showed that GPI-
deficient CD34+ cells isolated from PNH patients were less susceptible to apoptosis induction 
upon coculture with autologous T cells prestimulated with TF-1 cells 27. 
Although we did not always find clear differences, this does not necessarily exclude a role 
for differential susceptibility for cytotoxic lysis of HSC in vivo. First, leukemic cell lines used in our 
functional studies might be better capable of stimulating T cell responses than normal HSC for 
example by using the activating receptor ligands CD112, CD155 and CD244. More importantly, in 
our experiments we have used ex vivo expanded CTLs. These may become highly cytolytic during 
in vitro culture, for example by acquiring additional activating receptors. Of the receptors tested 
we found only CD48 expression to be increased upon in vitro CTL culture. Still, differences in 
stimulatory capacity of cell lines and HSC, and a higher cytolytic capacity of in vitro cultured CTLs 
may mask subtle differences in cytotoxicity that are however highly relevant in vivo. 
In conclusion, we found increased frequencies and absolute numbers of T cells expressing 
the NKR CD56 in PNH patient peripheral blood compared to healthy controls. Furthermore, 
we observed elevated frequencies of CD8+ T
EMRA
 cells expressing activating NKR such as 
KIR2DS4, NKG2C and NKG2D with the capability of targeting hematopoietic progenitor cell 
lines. Our results suggest that these T cells are the autoimmune effectors directed towards 
PNH CD34+ hematopoietic progenitor cells, and may have emerged as a consequence of an 
ongoing chronic immune response in PNH bone marrow. However, further studies are required 
to gain more insight into the response of these T cells to immunosuppressive treatment and 
subsequent recovery of marrow failure.
Financial disclosures: SB, MW, FP, AM and HD: none. PM received research support and is a 
member of advisory boards of Alexion pharmaceuticals. Alexion had no role in study design, 
data collection and analysis, decision to publish, or preparation of the manuscript. 
60
T c
ells w
iTh
 a
c
Tiv
a
Tin
g
 n
K
 c
ell rec
epTo
r
s in
 pn
h
2
acknowledgements: This study was funded by an unrestricted educational grant of Alexion 
pharmaceuticals (Cheshire, USA). The authors would like to thank the Dutch PNH patient 
association “AA&PNH contactgroep” for their financial contribution and participation in this 
study. Lastly, we would like to thank Alessandro Poggi (National Institute for Cancer Research, 
Genoa, Italy) for providing GPI+ and GPI- K562 cell lines, antibodies and helpful advice, Robert 
Brodsky (Johns Hopkins Medicine Hospital, Baltimore, USA) for providing the TF-1 cell line, and 
Rob Woestenenk and Jeroen van Velzen for technical assistance. 
r e F e r e N c e  l i s t
1 Hu R, Mukhina GL, Piantadosi S, Barber JP, Jones 
RJ, Brodsky RA. PIG-A mutations in normal 
hematopoiesis. Blood 2005;105:3848-54.
2 Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. 
Clonal populations of hematopoietic cells with 
paroxysmal nocturnal hemoglobinuria genotype 
and phenotype are present in normal individuals. 
Proc Natl Acad Sci U S A 1999;96:5209-14.
3 Murakami Y, Kinoshita T, Maeda Y, Nakano T, 
Kosaka H, Takeda J. Different roles of glyco-
sylphosphatidylinositol in various hematopoietic 
cells as revealed by a mouse model of paroxysmal 
nocturnal hemoglobinuria. Blood 1999;94:2963-70.
4 Tremml G, Dominguez C, Rosti V, et al. Increased 
sensitivity to complement and a decreased 
red blood cell life span in mice mosaic for a 
nonfunctional Piga gene. Blood 1999;94:2945-54.
5 Dunn DE, Tanawattanacharoen P, Boccuni P, et 
al. Paroxysmal nocturnal hemoglobinuria cells 
in patients with bone marrow failure syndromes. 
Ann Intern Med 1999;131:401-8.
6 Iwanaga M, Furukawa K, Amenomori T, et al. 
Paroxysmal nocturnal haemoglobinuria clones 
in patients with myelodysplastic syndromes. Br J 
Haematol 1998;102:465-74.
7 Schrezenmeier H, Hertenstein B, Wagner B, 
Raghavachar A, Heimpel H. A pathogenetic 
link between aplastic anemia and paroxysmal 
nocturnal hemoglobinuria is suggested by a 
high frequency of aplastic anemia patients with 
a deficiency of phosphatidylinositol glycan 
anchored proteins. Exp Hematol 1995;23:81-7.
8 Wang H, Chuhjo T, Yasue S, Omine M, Nakao 
S. Clinical significance of a minor population 
of paroxysmal nocturnal hemoglobinuria-type 
cells in bone marrow failure syndrome. Blood 
2002;100:3897-902.
9 Sugimori C, Chuhjo T, Feng X, et al. Minor 
population of CD55- CD59- blood cells predicts 
prognosis and response to immunosuppressive 
therapy in patients with aplastic anemia. Blood 
2006;107:1308-14.
10 Karadimitris A, Manavalan JS, Thaler HT, et al. 
Abnormal T-cell repertoire is consistent with 
immune process underlying the pathogenesis 
of paroxysmal nocturnal hemoglobinuria. Blood 
2000;96:2613-20.
11 Risitano AM, Kook H, Zeng W, Chen G, Young 
NS, Maciejewski JP. Oligoclonal and polyclonal 
CD4 and CD8 lymphocytes in aplastic anemia and 
paroxysmal nocturnal hemoglobinuria measured 
by V beta CDR3 spectratyping and flow cytometry. 
Blood 2002;100:178-83.
12 Risitano AM, Maciejewski JP, Green S, Plasilova 
M, Zeng W, Young NS. In-vivo dominant immune 
responses in aplastic anaemia: molecular tracking 
of putatively pathogenetic T-cell clones by TCR 
beta-CDR3 sequencing. Lancet 2004;364:355-64.
13 Wlodarski MW, Gondek LP, Nearman ZP, et 
al. Molecular strategies for detection and 
quantitation of clonal cytotoxic T-cell responses 
in aplastic anemia and myelodysplastic syndrome. 
Blood 2006;108:2632-41.
14 Risitano AM, Maciejewski JP, Muranski P, et al. Large 
granular lymphocyte (LGL)-like clonal expansions 
in paroxysmal nocturnal hemoglobinuria (PNH) 
patients. Leukemia 2005;19:217-22.
15 Gargiulo L, Lastraioli S, Cerruti G, et al. Highly 
homologous T-cell receptor beta sequences 
support a common target for autoreactive T 
cells in most patients with paroxysmal nocturnal 
hemoglobinuria. Blood 2007;109:5036-42.
16 Poggi A, Negrini S, Zocchi MR, et al. Patients with 
paroxysmal nocturnal hemoglobinuria have a high 
frequency of peripheral-blood T cells expressing 
activating isoforms of inhibiting superfamily 
receptors. Blood 2005;106:2399-408.
17 McMahon CW, Raulet DH. Expression and 
function of NK cell receptors in CD8+ T cells. Curr 
Opin Immunol 2001;13:465-70.
61
T c
ells w
iTh
 a
c
Tiv
a
Tin
g
 n
K
 c
ell rec
epTo
r
s in
 pn
h
2
18 Namekawa T, Snyder MR, Yen JH, et al. Killer cell 
activating receptors function as costimulatory 
molecules on CD4+CD28null T cells clonally 
expanded in rheumatoid arthritis. J Immunol 
2000;165:1138-45.
19 Meresse B, Curran SA, Ciszewski C, et al. 
Reprogramming of CTLs into natural killer-like 
cells in celiac disease. J Exp Med 2006;203:1343-55.
20 van Stijn A, Rowshani AT, Yong SL, et al. Human 
cytomegalovirus infection induces a rapid 
and sustained change in the expression of 
NK cell receptors on CD8+ T cells. J Immunol 
2008;180:4550-60.
21 Mandelboim O, Kent S, Davis DM, et al. Natural 
killer activating receptors trigger interferon 
gamma secretion from T cells and natural killer 
cells. Proc Natl Acad Sci U S A 1998;95:3798-803.
22 Snyder MR, Nakajima T, Leibson PJ, Weyand CM, 
Goronzy JJ. Stimulatory killer Ig-like receptors 
modulate T cell activation through DAP12-
dependent and DAP12-independent mechanisms. 
J Immunol 2004;173:3725-31.
23 Chen X, Bai F, Sokol L, et al. A critical role for DAP10 
and DAP12 in CD8+ T cell-mediated tissue damage 
in large granular lymphocyte leukemia. Blood 
2009;113:3226-34.
24 Hanaoka N, Nakakuma H, Horikawa K, et al. NKG2D-
mediated immunity underlying paroxysmal nocturnal 
haemoglobinuria and related bone marrow failure 
syndromes. Br J Haematol 2009;146:538-45.
25 Hanaoka N, Kawaguchi T, Horikawa K, Nagakura 
S, Mitsuya H, Nakakuma H. Immunoselection by 
natural killer cells of PIGA mutant cells missing 
stress-inducible ULBP. Blood 2006;107:1184-91.
26 Hirose S, Mohney RP, Mutka SC, et al. Derivation 
and characterization of glycoinositol-
phospholipid anchor-defective human K562 cell 
clones. J Biol Chem 1992;267:5272-8.
27 Savage WJ, Barber JP, Mukhina GL, et al. 
Glycosylphosphatidylinositol-anchored protein 
deficiency confers resistance to apoptosis in PNH. 
Exp Hematol 2009;37:42-51.
28 Appay V, van Lier RA, Sallusto F, Roederer M. 
Phenotype and function of human T lymphocyte 
subsets: consensus and issues. Cytometry A 
2008;73:975-83.
29 von Lilienfeld-Toal M, Nattermann J, Feldmann 
G, et al. Activated gammadelta T cells express the 
natural cytotoxicity receptor natural killer p 44 
and show cytotoxic activity against myeloma cells. 
Clin Exp Immunol 2006;144:528-33.
30 Sugita J, Tanaka J, Yasumoto A, et al. Differential 
effects of interleukin-12 and interleukin-15 on 
expansion of NK cell receptor-expressing CD8+ T 
cells. Ann Hematol 2010;89:115-20.
31 Meresse B, Chen Z, Ciszewski C, et al. Coordinated 
induction by IL15 of a TCR-independent NKG2D 
signaling pathway converts CTL into lymphokine-
activated killer cells in celiac disease. Immunity 
2004;21:357-66.
32 Lemster BH, Michel JJ, Montag DT, et al. Induction 
of CD56 and TCR-independent activation of T cells 
with aging. J Immunol 2008;180:1979-90.
33 Michel JJ, Turesson C, Lemster B, et al. CD56-
expressing T cells that have features of senescence 
are expanded in rheumatoid arthritis. Arthritis 
Rheum 2007;56:43-57.
34 Ahn JK, Chung H, Lee DS, Yu YS, Yu HG. 
CD8brightCD56+ T cells are cytotoxic effectors 
in patients with active Behcet’s uveitis. J Immunol 
2005;175:6133-42.
35 Katchar K, Soderstrom K, Wahlstrom J, Eklund 
A, Grunewald J. Characterisation of natural killer 
cells and CD56+ T-cells in sarcoidosis patients. Eur 
Respir J 2005;26:77-85.
36 Ohkawa T, Seki S, Dobashi H, et al. Systematic 
characterization of human CD8+ T cells with 
natural killer cell markers in comparison with 
natural killer cells and normal CD8+ T cells. 
Immunology 2001;103:281-90.
37 Godfrey DI, Kronenberg M. Going both ways: 
immune regulation via CD1d-dependent NKT 
cells. J Clin Invest 2004;114:1379-88.
38 Joyce S, Woods AS, Yewdell JW, Bennink JR, De Silva 
AD, Boesteanu A, et al. Natural ligand of mouse 
CD1d1: cellular glycosylphosphatidylinositol. 
Science 1998;279:1541-4.
39 Mannik LA, Chin-Yee I, Sharif S, Van KL, Delovitch 
TL, Haeryfar SM. Engagement of glycosyl-
phosphatidylinositol-anchored proteins results in 
enhanced mouse and human invariant natural killer T 
cell responses. Immunology 2011;132:361-75.
40 Karadimitris A, Notaro R, Koehne G, Roberts IA, 
Luzzatto L. PNH cells are as sensitive to T-cell-
mediated lysis as their normal counterparts: 
implications for the pathogenesis of paroxysmal 
nocturnal haemoglobinuria. Br J Haematol 
2000;111:1158-63.
41 Dingli D, Luzzatto L, Pacheco JM. Neutral evolution 
in paroxysmal nocturnal hemoglobinuria. Proc 
Natl Acad Sci U S A 2008;105:18496-500.
42 Murakami Y, Kosaka H, Maeda Y, et al. 
Inefficient response of T lymphocytes to 
glycosylphosphatidylinositol anchor-negative 
cells: implications for paroxysmal nocturnal 
hemoglobinuria. Blood 2002;100:4116-22.
62
T c
ells w
iTh
 a
c
Tiv
a
Tin
g
 n
K
 c
ell rec
epTo
r
s in
 pn
h
2
supplementary Figure 1. Correlations between frequency of NKR expressing T cells and history of CMV infection. 
Each plot shows the frequency of a specific NKR expressing T cell subset within 34 PNH patients with (CMV+, n 
= 19) and without serological evidence of past CMV infection (CMV-, n = 15)). Only for CD158b1/b2,j but not for 
other NKR expressing T cells a significantly higher frequency was found in patients with serological evidence of 
past CMV infection (p = 0.02, Mann Whitney U test). Bars represent median values.
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+ + +CD3  CD8  CD158i  
PBMCs patient 2
+ + +CD3  CD8  CD158i
PBMCs patient 1
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supplementary Figure 2. Expression levels of receptors CD244, CD48 and DNAM-1 were determined by flow cytometry 
on CD3+ CD8+ KIR2DS4+ T cells within the CTL lines OC5, OB8 and L6, or on CD3+ CD8+ KIR2DS4+ T cells in PBMC samples 
from patient 1 and 2 (Table II). The fluorescence intensity of the indicated receptors is depicted by black lines, and the 
background staining of appropriate isotype controls is shown by a grey line in each histograms. Numbers indicate delta 
mean fluorescence intensity (ΔMFI) of specific staining minus background of isotype control. 
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supplementary Figure 3. Expression levels of receptors CD112, CD155 and CD244 were determined by flow 
cytometry on K562 GPI+, K562 GPI-, KG1a, TF-1 GPI+ and TF-1 GPI- cells. The fluorescence intensity of the indicated 
receptors is depicted by black lines, and the background staining of appropriate isotype controls is shown by a 
grey line in each histograms. Numbers indicate ΔMFI of specific staining minus background of isotype control. 
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a b s t r ac t 
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a disease with variable presentation, including 
classical PNH (cPNH) and PNH with aplastic anemia (AA-PNH). Here, we describe bone marrow 
(BM) histology related to clinical findings in 67 patients with a PNH clone. 
Patients were divided in AA-PNH (n=39) and cPNH (n=28) based on clinical criteria, and 
compared to 17 AA patients without PNH clone. Median PNH clone size was higher in cPNH (75%) 
than in AA-PNH (10%) (p<0.0001). BM cellularity was normal or increased in 65% of cPNH, while 
decreased in AA-PNH and AA (95% and 100%) (p<0.0001). Myelopoiesis and megakaryopoiesis were 
decreased in 85% and 100% of AA-PNH and 100% of AA patients, but also in 86% and 46% of cPNH 
patients, even when peripheral blood values were normal. The percentage of CD59 deficient late 
stage myeloid cells determined immunohistochemically correlated to PNH granulocyte clone size.
Lymphoid nodules and increased mast cell numbers were present in all groups but more 
frequently in AA-PNH (38% and 73%) than in cPNH (20% and 43%). BM iron was decreased 
in 88% of cPNH, while increased in AA-PNH (64%) and AA (100%) (p<0.0001). Hemolysis was 
present in all cPNH but also in AA-PNH patients (67%).
In conclusion, cPNH patients had more cellular BM and more prominent erythropoiesis 
than AA-PNH patients. Nonetheless, cPNH patients also show AA features such as myeloid and 
megakaryocyte hypoplasia and inflammatory infiltrates, although more subtle than in AA-PNH. 
No significant differences were found between BM of AA patients with and without PNH clone. 
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i N t r o d u c t i o N
PNH is a very rare disease characterized by an acquired mutation of the PIG-A gene in the 
hematopoietic stem cell (HSC). The PIG-A gene product is essential in the synthesis of GPI-
anchors, which tether several proteins to the cell membrane. Therefore, this mutation results in 
a clone of blood cells with deficiency of GPI-anchored proteins at the cell membrane. Deficiency 
of the GPI-anchored complement inhibitors CD59 and CD55 on PNH erythrocytes renders these 
susceptible to complement-mediated lysis, resulting in hemolysis, the most prominent clinical 
features of classical PNH (cPNH) 1.  
The clinical spectrum of PNH is highly variable, ranging from cPNH patients with large 
clone sizes associated with severe hemolysis and a higher risk of thrombosis, to patients with 
relatively small clone sizes who usually do not have clinically relevant hemolysis but present with 
prominent pancytopenia. These latter patients often have underlying bone marrow diseases 
such as aplastic anemia (AA) or myelodysplastic syndromes (MDS). In fact, a PNH clone is a 
frequent finding in AA (20-55 % of patients) 2 and in some cases of MDS (estimated prevalence 
of 10%) 3-6. The close relationship between these diseases is further underlined by the fact that 
PNH frequently evolves from AA or rarely vice versa during the course of disease 7. 
Immune-mediated BM failure is proposed as a common pathogenetic mechanism explaining 
the pancytopenia encountered in AA and MDS with a PNH clone, but also frequently in cPNH. 
Although usually more overt in AA and MDS, bi- or pancytopenia is found in 20-30% of all PNH 
patients 7-9. The observation that AA patients with a small PNH clone appear to respond better 
to immunosuppressive therapy than those without supports a role for immune-mediated BM 
failure in PNH 4,10. In addition, oligoclonal T cell populations with potential autoreactivity towards 
the HSC were detected in patients with AA, PNH and MDS 11-16. The expansion of a PNH clone, 
which is observed in some AA patients in the course of disease, may be attributed to selective 
immune-mediated damage to normal HSC and not GPI-deficient HSC 17,18. A higher degree of 
apoptosis in normal HSC compared to GPI-deficient HSC further supports this hypothesis 19-21. 
The current working classification for PNH as proposed by the International PNH interest 
group (IPIG) distinguishes cPNH, PNH in the setting of another specified BM disorder 
diagnosed at any time and subclinical PNH 1. Patients with clinical PNH may be treated with the 
complement inhibitor eculizumab which effectively blocks intravascular hemolysis 22-24; if the 
underlying bone marrow disease prevails, immunosuppressive drugs may be considered. The 
IPIG classification however does not adequately represent the heterogeneous clinical picture 
of PNH. For example, cPNH patients may also have (mild) cytopenias. In addition, the clinical 
picture often changes in the course of disease, as patients with AA can progress to clinical PNH 
and sometimes vice versa. These factors complicate diagnosis and treatment decisions.
The IPIG recommends a full BM examination at diagnosis of PNH for classification, and 
exclusion of other BM failure syndromes. However, a comprehensive overview of the spectrum 
of BM histology in patients with a PNH clone in different presentations is still unavailable. In this 
study, we aim to provide such an overview in a large series of patients. To this end, we divided 
patients with a PNH clone in two groups based on clinical picture and peripheral blood counts: 
one group with peripheral blood counts fulfilling criteria of aplastic anemia (AA-PNH) and the 
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other having clinical or laboratory evidence of hemolysis and peripheral blood counts not 
fulfilling those criteria (cPNH). Histology was correlated with clinical features such as hemolysis 
and PNH clone size. To investigate differences between AA patients with a PNH clone and those 
without, a group of AA patients without PNH clone was included. Finally, we have assessed 
the utility of CD59 as a marker to assess GPI deficiency in the various lineages and stages of 
hematopoietic differentiation in BM biopsies by CD59 immunohistochemical stainings. 
m e t H o d s
P a t i e n t  c h a r a c t e r i s t i c s
We reviewed 67 diagnostic bone marrow biopsies (BMB) of all patients with a PNH clone who 
presented at the Radboud University Nijmegen Medical Centre (RUNMC) (n = 58) or the Hospices 
Civils de Lyon (n = 8) between 1991 and 2010. BMB of patients with a PNH clone and evidence of 
MDS were excluded. The study was approved by the RUNMC medical ethical committee. 
To evaluate differences in bone BM histology in the different presentations of PNH, 
patients were divided in two groups based on peripheral blood counts. The first group (n = 39) 
was composed of patients with a PNH clone and peripheral blood counts fulfilling the criteria 
for aplastic anemia as defined by the International Agranulocytosis and Aplastic Anemia Study 
Group 25, i.e. at least 2 out of the following: untransfused hemoglobin <100 g/l, platelet count 
<50 x 109/l and/or neutrophil count < 1.5 x 109/l in the absence of other causes. In the second 
group (n = 28), patients with clinical evidence of intravascular hemolysis and peripheral blood 
counts not fulfilling the criteria of AA were included. Henceforward, in this article, these two 
patient groups will be referred to as AA-PNH and cPNH respectively. BMB of AA-PNH and cPNH 
patients were compared to an age-matched control group consisting of AA patients (n= 17), 
who never developed a PNH clone. Non-severe AA (NSAA), severe AA (SAA) and very severe 
AA (VSAA) were defined according to previously published guidelines 26.
PNH clone size was determined by flow cytometric measurement of the percentage of 
granulocytes in the peripheral blood with deficiency of at least two GPI-anchored proteins 
or fluorescently labeled aerolysin (FLAER), according to standards at the time of diagnosis 1. 
Data on PNH granulocyte clone size as assessed by flow cytometry, hemolysis parameters and 
peripheral blood counts at diagnosis were collected and correlated to histological findings 
such as cellularity, iron stores and the presence of hypoplasia in different lineages. The 
presence of hemolysis was defined as increased lactate dehydrogenase (LDH) and decreased 
or undetectable haptoglobin levels. Hemolysis parameters were assessed at first detection of 
the PNH clone. The clinical disease was also followed in time.
H i s t o l o g y
Slides of BMB embedded in paraffin and/or plastic were received from several referral centers 
and were evaluated without knowledge of the clinical data. Stainings that were evaluated 
included hematoxylin and eosin (H&E), periodic acid-Schiff (PAS), Leder, Giemsa, Laguesse or 
Gomori and iron stains. 
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Cellularity was defined as the percentage of BM space occupied by cells other than fat cells. The 
age-related cellularity was defined as normal (<40 years: 50-70%; 40-60 years: 40-60%; >60 years: 
30-50%), decreased or increased 27,28. The ratio between myeloid and erythroid cells (ME ratio) was 
defined as normal when between 4 and 1. Erythroid hyperplasia was defined as a predominance of 
erythroid precursors over myeloid cells (ME ratio < 1). Fibrosis was graded according to Thiele et al. 29.
Inflammatory cells were evaluated by counting the average number of mast cells per high power 
field (HPF, 40x) in at least 10 fields, and recording the number of lymphoid nodules and increased 
numbers of plasma cells (at least 3 groups of >8 cells). The slides of 8 PNH BMB (n = 3 cPNH, n= 5 
AA-PNH) were stained with an antibody to mast cell tryptase (clone AA1, DAKO, Cambridgeshire, 
UK) to check for degranulated mast cells that are not identified by Giemsa staining. 
c d 5 9  i m m u n o h i s t o c h e m i c a l  s t a i n i n g
To determine the percentage of GPI-deficient cells in the various lineages and stages of 
hematopoietic differentiation, an immunohistochemical CD59 staining was performed on BMB of 
5 cPNH, 3 AA-PNH patients with sufficient cellularity, and 5 healthy control BMB. CD59 was chosen 
as it is expressed at high levels in all lineages and stages of differentiation in the bone marrow 30.
Antigen retrieval was performed in pH 6.0 sodium citrate at 96°C on 4 μm thick paraffin 
embedded BMB sections. After blocking of endogenous peroxidase, slides were exposed to 
the primary CD59 antibody (Clone MEM43/5, Exbio, Vestec, Czech Republic) for 1 hour at room 
temperature. After incubation with the secondary HRP-conjugated goat anti-mouse/rabbit/
rat antibody (PowerVision, Immunologic, Duiven, the Netherlands) slides were developed with 
DAB and counterstained with haematoxylin. CD59 negative cells were microscopically analyzed 
and scored by the morphological appearance of megakaryocytes, late stage myeloid, plasma 
cells, erythrons and capillaries. 
s t a t i s t i c a l  a n a l y s i s
Fisher’s exact test or Chi square test was used to determine differences between the frequency 
of histological characteristics in the AA-PNH versus the cPNH, and in the AA-PNH versus the 
AA group. Linear regression analysis was performed to determine correlations between clinical 
parameters and/or histological parameters. 
r e s u lt s
Clinical characteristics of the AA-PNH, cPNH, and AA patients without a PNH clone are 
summarized in Table 1. Histological features are summarized in Table 2.
c l i n i c a l  f e a t u r e s
Median follow-up of cPNH patients was 3 years (range 0.5-19 years), 4 years for AA-PNH patients 
(range 0.5-20 years) and 2 years (range 0.25-12.5 years) for AA patients. 91% of cPNH, 73% of 
AA-PNH and 65% of AA patients were alive at the end of follow-up. Median age at diagnosis was 
comparable in the three groups at 37, 35 and 40 years for AA-PNH, cPNH and AA with a similar 
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range. In the AA-PNH and AA groups, men and women were about equally distributed, whereas 
the cPNH group had a higher proportion of men (61%). 
The size of the PNH granulocyte clone at diagnosis was significantly different (p<0.0001, 
unpaired t test) in AA-PNH and cPNH with medians of 10% (range 1 – 100%) and 75% (range 8 – 
100%) respectively. While the vast majority of cPNH patients (85%) had PNH granulocyte clones 
of more than 30%, this was only the case in 34% of the AA-PNH group. PNH clones below 10% 
were almost exclusively detected in the AA-PNH group (39% of AA-PNH patients) compared 
to only one patient in the cPNH group (Table 1). This particular patient had only laboratory 
evidence of hemolysis, a PNH granulocyte clone of 8% and completely normal peripheral blood 
counts, whereas his BM was hypocellular. 
table 1: clinical features of 67 patients with a PNH clone at presentation
characteristics aa-PNH classic PNH aa P – value1 P – value2
n 39 28 17
M/ F 19/20 (1:1.1) 17/11 (1:0.6) 8/9 (1:1.1) NS NS
Median age at diagnosis in years (range) 36 (11-81) 35 (18-81) 40 (9-78) NS NS
PNH clone (granulocytes)
<10%
10-30%
>30%
1 unknown
15/38 (39%)
10/38 (26%)
13/38 (34%)
1 unknown
1/27 (4%)
3/27 (11%)
23/27 (85%)
0/17 (0%) p < 0.0001 NA
Cytopenias:  
Anemia (Hgb < 10 g/dL)
Trombocytopenia (< 150 x 109/L)
< 50 x 109/L
50-150 x 109/L
Leukopenia (< 3,5 x 109/L) 
Neutropenia (< 1,5 x 109/L): 
< 0,5 x 109/L
0,5 – < 1 x 109/L 
1 - < 1,5 x 109/L
24/39 (62%)
39/39 (100%)
34/39 (87%)
5/39 (13%)
29/39 (74%) 
29/39 (74%) 
2/29 (7%)
14/29 (48%) 
13/29 (45%)
10/28 (36%)
13/28 (46%)
0/13 (0%)
13/13 (100%)
7/27 (26%) 
1 unknown
5/25 (20%) 
3 unknown
0/5 (0%)
1/5 (20%)
4/5 (80%)
12/17 (71%)
17/17 (100%)
15/17 (88%)
2/17 (12%)
16/17 (94%) 
16/17 (94%) 
10/16 (63%)
5/16 (31%)
1/16 (6%)
p 0.08
p < 0.0001
p < 0.0001
p < 0.0001 
p < 0.0001 
p 0.0001
p 0.05
p < 0.0001
p < 0.0001
p  0.0006 
p  0.0001 
NS
Hemolysis 25/37 (67%)  
2 unknown 
28/28 (100%) 0/17 (0%) p 0.00072 NA
Median LDH level (IU/L) 482 1940 281 p < 0.0001 p < 0.0001
Clinical characteristics of 67 patients with a PNH clone who presented either with AA-PNH or cPNH, compared to 
17 AA patients without a PNH clone. Peripheral blood values and PNH granulocyte clones size were determined 
at the time of the diagnostic bone marrow biopsy. In patients in whom a PNH clone was detected later in the 
course of disease, LDH values, PNH granulocyte clone size and the presence of hemolysis were assessed at the 
time of PNH clone diagnosis. 1 P values were determined for the difference between all three groups by Chi 
square test for categorical variables, or by one way Anova for continuous variables. 2 P-values were determined 
for differences between AA-PNH and cPNH determined by Fisher’s exact test for two category variables, or Chi 
square test for three category variables. Unpaired t test was used to calculate differences in continuous variables 
between AA-PNH and cPNH. NS = non significant. NA = not applicable. 
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In the majority of AA-PNH patients (26/39, 67%), the PNH clone was detected at first presentation. 
In the remaining 13/39 (33%) of AA-PNH patients, the presence of a PNH clone was either not assessed 
by flow cytometry at disease onset, or detected later in the course of disease (median duration from 
disease onset to first detection of the PNH clone 0.8 years, range 0.25-3 years).
Patients in the cPNH group had by definition clinical (hemoglobinuria, jaundice) and/or 
laboratory evidence of hemolysis (LDH ≥ 450 U/L, decreased haptoglobin). Hemolysis was also 
observed in 67% of patients who presented with AA-PNH. However, compared to the cPNH 
group, hemolysis was generally mild and LDH levels were lower (median 482 U/L in AA-PNH 
versus 1940 U/L in cPNH). In the majority of AA-PNH patients, hemolysis was subclinical and 
only detected by elevated LDH levels and/or undetectable haptoglobin levels (in 54% and 55% 
of AA-PNH patients respectively). A significant correlation (r2 0,22, p < 0.0001, linear regression 
analysis) between LDH levels and PNH granulocyte clone size was found in the combined 
AA-PNH and cPNH patient group (Supplementary Fig. 1).  
Cytogenetic abnormalities were found in the BM of three of 30 AA-PNH patients (loss of 
the Y chromosome in 2 patients in 15% of metaphases, monosomy 21 in 3% in the other), in one 
of 19 cPNH patients examined (trisomy 8 in 1.5% of cells by FISH analysis), and in one of 12 AA 
patients (t 5;13 in 20/20 metaphases). None of the patients with cytogenetic abnormalities had 
abnormalities in BM morphology (data not shown) and histology consistent with a diagnosis 
of MDS, nor did they develop MDS later during follow-up (median 2.5 years, range 1-7 years). 
One AA-PNH patient developed chronic myelomonocytic leukemia (CMML), another refractory 
anemia with excess blasts (MDS-RAEB), 5 and 3 years after initial diagnosis of AA-PNH respectively. 
Remarkably, in both cases, the PNH clone could not be detected anymore at the time of CMML/
MDS diagnosis, suggesting that the malignant clone did not arise from the PNH clone. None of the 
cPNH patients developed hematological malignancies in the course of the disease.  One AA patient 
developed a T cell large granular lymphocytic leukemia one year after diagnosis of AA.
b o n e  m a r r o w  c e l l u l a r i t y
As expected, in the AA-PNH group, cellularity was decreased in 95% of patients. The cPNH 
group differed significantly from the AA-PNH group with decreased cellularity present in only 
36% of patients (p < 0.0001, Chi square test). Instead, most cPNH patients had a normal (29%) 
to hypercellular (36%) BM that was dominated by a hyperplastic erythropoiesis (Fig. 1a-b). We 
found no differences in peripheral blood WBC, platelet count or PNH clone size between cPNH 
patients with normal or increased versus those with decreased BM cellularity (data not shown). 
By definition, all AA patients had decreased BM cellularity. In 82% of AA-PNH and 100% of AA 
patients the BM showed patchy areas with <10% cellularity (Fig. 1c), whereas in only 2 (7%) of cPNH 
patients this was the case. Relative erythroid hyperplasia with ME ratios ranging from 1 to 0.2 was 
seen in the majority of cPNH (86%), AA-PNH (76%) and evaluable AA patients (50%). However, an 
absolute increase in erythropoiesis was predominantly observed in cPNH patients (64%, Fig. 1a-b) 
compared to only 13% of AA-PNH patients (p < 0.0001, Fisher’s exact test) and none in AA.
Interestingly, in the cPNH patient group, despite a hypercellular BM, myeloid hypoplasia was 
histologically present in the vast majority of patients (86%) (Fig. 1d), even in those with normal 
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absolute neutrophil (ANC > 1.5 x 109/l) and white blood cell (WBC) counts (> 3.5 x 109/l). In only 9 of 24 
cPNH patients (38%) with myeloid hypoplasia, neutropenia and/or leukopenia was observed. Myeloid 
hypoplasia was frequently observed in AA-PNH BMB (85%) and in all AA patients. The remaining 
AA-PNH patients showed a left-shifted myelopoiesis. Both the prevalence (74%, 20%, and 94% for 
AA-PNH, cPNH and AA respectively) and severity of peripheral blood neutropenia were generally 
higher in the AA-PNH group compared to the cPNH group and highest in the AA group (Table 1). In 
the AA-PNH group the majority of patients (82%) had non severe AA (NSAA), and the remainder had 
severe AA (SAA). In the AA group, AA was non severe in 24%, severe in 47% and very severe in 29%. 
The number of megakaryocytes was decreased in 13/28 (46%) cPNH patients. In the majority 
of these patients (9/13, 69%), megakaryocyte hypoplasia corresponded to mild peripheral blood 
thrombocytopenia (platelet count between 50 and 150 x 109/l). In the other 4 patients with 
megakaryocyte hypoplasia, normal platelet counts were found. Significantly different from cPNH (p < 
0.0001), megakaryocytes were decreased or absent in all patients with AA-PNH and AA. This was also 
reflected in more severe thrombocytopenia in AA-PNH and AA patients (< 50 x 109/L in 87 and 88%, 
and between 50 and 150 x 109/L in 13 and 12% of AA-PNH and AA respectively) than in cPNH patients. 
A B
C D
Figure 1: cPNH patient bmb have normal to increased cellularity, erythroid hyperplasia and myeloid hypoplasia 
whereas aa-PNH patients show hypocellular bm with myeloid and erythroid hypoplasia. Fig. 1a-b, d: BMB of a 
71 year old male cPNH patient, showing increased BM cellularity and erythroid hyperplasia (Fig. 1a: HE 5x, Fig. 1b: HE 
20x) and myeloid hypoplasia (Fig 1d: Leder staining 5x). Fig. 1c: BMB of a 61 year old male AA-PNH patient with overall 
patchy BM cellularity and central BM spaces with less than 5% cellularity and hemosiderosis (HE 2.5x). 
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i n f l a m m a t o r y  i n f i l t r a t e s
Lymphoid nodules were more frequently observed in AA-PNH (38%) compared to cPNH (20%; 
p 0.05, Fisher exact test), and AA patients (13%; p 0.02, Fisher exact test) (Fig. 2a-b). In the 
patients with lymphoid nodules and available immunohistochemical stains (n = 3; 2 AA-PNH, 1 
cPNH) lymphoid nodules were shown to consist of either B and T cells (n = 2, Fig. 2c) or T cells 
only (n = 1). In 10 AA-PNH patients and 3 cPNH patients, large numbers of interstitial T cells (n = 
10, Fig. 2d), or B and T cells (n = 4) were found. 
Increased numbers of mast cells were observed more often in AA-PNH (73%) than in cPNH 
(43%; p 0.05, Fisher’s exact test) (Fig. 3a-b). Up to an average of 10 mast cells/HPF were seen. 
Although anti-tryptase immunohistochemistry was more sensitive than the Giemsa stain in 
detecting mast cells (overall average 5.9 compared to 2.8 cells/HPF with Giemsa), both stains 
correlated well in 8 BMB tested (r2 0.93, p < 0.0001, linear regression analysis, Fig. 3b). The AA 
control group did not differ significantly from the AA-PNH group with 76% of patients having 
increased mast cells. The plasma cell infiltrate in the AA-PNH group was comparable to the AA 
group with 17% and 20% of patients having an increased number of plasma cells respectively. 
A B
C D
Figure 2: lymphoid nodules and/or increased numbers of t cells are mainly present in aa-PNH patient 
bmb. Figure 2a-b: BMB of two different AA-PNH patients showing lymphoid nodules (arrows) (Fig. 2a: 61 year old 
male, HE 2.5x, Fig. 2b: 67 year old female, HE 10x). Fig. 2c: Immunohistochemical staining of the same BMB as 2a 
showing that the lymphoid nodule consists of B cells (CD20, 5x). Fig. 2d: Immunohistochemical staining of a BMB 
of a 42 year old female with AA-PNH, showing a diffuse T cell infiltration throughout the BM (CD3, 10x). 
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Figure 3: comparison of increased numbers of mast cells in 
aa-PNH bmb by conventional and immunohistochemical 
staining. BMB of a 48 year old female AA-PNH patient showing 
increased numbers of mast cells (average number 5.4 cells/HPF) in 
Giemsa staining 40x (Fig. 3a) and 11.1 cells/HPF in tryptase staining 
40x (Fig. 3b). Fig. 3c: correlation between average numbers of mast 
cells/HPF counted in Giemsa staining (x-axis) and average numbers 
of mast cells/HPF counted in anti-tryptase stainings (y-axis). 
One of the patients in the AA-PNH group fulfilled the clinical diagnosis of monoclonal 
gammopathy of unknown significance (MGUS). By flow cytometric analysis it was determined 
that the plasma cells in this patient did not belong to the PNH clone (data not shown). None of 
the cPNH patients had an increased number of plasma cells.
i r o n
The majority of both AA-PNH (64%) and AA patients (100%) had increased iron stores in 
macrophages. In contrast, iron was decreased or completely absent in 88% of cPNH patients, 
significantly differing from AA-PNH patients (p < 0.0001). In AA-PNH patients with decreased 
iron, no correlation was found with the presence of hemolysis (p 0.43, Fisher’s exact test).  
H e m o r r h a g e  a n d  c o n g e s t i o n
Congestion of BM sinusoids was present in both AA-PNH (55%, Fig. 4a), cPNH (73%, Fig. 4b) 
and AA patients (75%). In part of these patients (52% of AA-PNH, 59% of PNH), large numbers 
of mature erythrocytes were found extravascularly in otherwise intact BM specimens, possibly 
representing vascular damage and resulting hemorrhage. There was no correlation with either 
low platelet counts or use of anticoagulant medication (data not shown).
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A
B
Figure 4: congestion of blood vessels is a frequent finding 
in both aa-PNH and cPNH patients. Fig. 4a: Congested blood 
vessel (arrow) in an AA-PNH BMB containing both intact and 
possibly lysed erythrocytes (Giemsa 40x). Fig. 4b: Large numbers 
of mature erythrocytes present in the interstitium in otherwise 
intact specimen of a cPNH patient (Fig. 4b) (Giemsa 20x).
c d 5 9  s t a i n i n g 
In all AA-PNH (n = 3) and cPNH BMB (n = 5) tested, CD59 deficient late stage myeloid cells 
(median 92 and 60% respectively), erythrons (median 80 and 96%) and megakaryocytes 
(median 85 and 75%) dominated. In contrast, in healthy controls CD59 negative late stage 
myeloid cells, erythrons, megakaryocytes and plasma cells were rarely detected (medians 
1%, 0%, 16% and 0% respectively, Table 3, Fig. 5). The percentage of CD59 deficient late stage 
myeloid cells as determined by immunohistochemistry correlated to the peripheral blood PNH 
granulocyte clone size as measured by flow cytometry (r2 0.53, p 0.03, linear regression analysis, 
Fig. 5e). The percentage of CD59 deficient plasma cells was highly variable but generally lower 
than the percentage of CD59 deficient cells in other lineages (Table 3). Interestingly, similar to 
healthy controls, capillaries in AA-PNH and cPNH patients were uniformly strongly positive, 
indicating that endothelial cells in PNH BM are not derived from GPI-deficient hematopoietic 
stem cells (Table 3, Fig. 5). The staining pattern of CD59 was not only membranous but also 
cytoplasmic in all positive cells, both from PNH patients and controls.
d i s c u s s i o N
The clinical spectrum of PNH is highly variable, ranging from patients with predominant 
hemolysis to patients with prominent BM failure without clinically relevant hemolysis. Here, 
we reviewed BMB of 67 patients with a PNH clone, subdivided in cPNH and AA-PNH based on 
clinical characteristics. Although AA-PNH and cPNH patients have obvious differences in BM 
histology, these patient groups also show remarkable histological similarities. 
We observed decreased overall cellularity in almost all AA-PNH patients, whereas 
cellularity was increased in the majority of cPNH patients, mainly due to a strongly enhanced 
erythropoiesis. However, despite increased erythropoiesis, some cPNH patients show overall 
decreased BM cellularity. Theoretically, this interesting group may represent patients at an 
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earlier stage of disease currently undergoing clonal expansion, and thus having a smaller PNH 
clone. Alternatively, these patients may currently develop AA. However, neither peripheral 
blood values nor clone sizes were lower in cPNH patients with decreased cellularity versus those 
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Figure 5: cd59 expression in the bone marrow of PNH patients and controls. CD59 immunohistochemistry 
on BMB of cPNH, AA-PNH patients and healthy controls. Fig. 5a: overview of CD59 staining in a BMB of a 36 
year-old male AA-PNH patient (left panel) with the majority of cells CD59 negative (blue), but strongly positive 
(brown) endothelial cells, compared to a healthy control (right panel) with expression of CD59 on all cells (20x) 
. Fig. 5b: Both CD59 positive (left panel) and CD59 negative (right panel) erythrons in a 35 year-old female cPNH 
patient (40x). Fig 5c (arrows from left to right, 40x): CD59 positive myeloid cells (left two arrows), CD59 negative 
megakaryocyte, CD59 positive plasma cells surrounding CD59 positive endothelial cells, and CD59 negative 
myeloid cells (right two arrows) in a 18-year-old female cPNH patient. Fig 5d: CD59 positive megakaryocyte in a 
35-year-old female cPNH patient (40x). Fig 5e: PNH granulocyte clone size in the blood (%) versus CD59 negative 
late stage myeloid cells in the BMB determined by CD59 immunohistochemistry (%). 
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with normal or increased cellularity, arguing against this hypothesis. Concurrent viral infections 
could be an alternative explanation in occasional patients. A prospective study and longer 
follow-up is required to see whether these patients are more prone to develop AA in the future.
As expected we found an absolute decrease of the myeloid lineage in the AA-PNH and AA 
group. Myeloid hypoplasia was however also observed in the majority of cPNH patients, even 
in those with normal WBC counts. In cPNH patients myeloid hypoplasia was often masked by 
a strongly increased erythropoiesis, resulting in an overall normal or increased BM cellularity. 
In addition, megakaryopoiesis was also decreased in 46% of cPNH patients, even in occasional 
patients with normal platelet counts. Histological findings thus confirm that BM hypoplasia is 
a frequent feature of cPNH, although more subtle, not always clinically apparent and easily 
overlooked due to the prominent erythropoiesis. These results are possibly biased by the fact 
that a BMB is more likely performed in cPNH patients with cytopenias.
Our findings underline that the current working classification for PNH is of limited clinical 
utility. According to the IPIG classification, classic PNH patients do not have a defined bone 
marrow abnormality. Yet, in this study marrow hypoplasia was demonstrated in the vast 
majority of cPNH patients. Thus, discriminating PNH in the setting of another BM disorder 
and classic PNH is extremely difficult. Hypoplasia in cPNH patients is usually subtle, and the 
clinical picture often does not correspond to BM findings. In such cases, our finding of areas of 
severely hypocellular BM interspersed with areas of normal cellularity, which occurred almost 
exclusively in AA-PNH, might contribute to the distinction with cPNH. 
Diagnosis of BM failure disease relies on integrated histological, morphological, cytogenetic 
and clinical findings. In this study, unfortunately we did not have the opportunity to revise BM 
aspirate morphology. We excluded patients who were diagnosed with MDS at or before the 
time of PNH diagnosis. None but two patients developed MDS during follow-up; however at 
that time the PNH clone had disappeared. Therefore, we think it is unlikely that our cohort 
contained MDS patients at the time of diagnosis of PNH. However, we may have missed subtle 
morphological abnormalities insufficient to diagnose MDS. As shown by Araten et al., such 
abnormalities are often found in patients with a PNH clone 31. Also in AA, dyserythropoiesis 
is a frequent finding 32. We identified cytogenetic abnormalities in 9% of patients with a PNH 
clone, which was less frequently than in the series of Araten et al. 31. Especially in patients with a 
hypocellular BM, a BMB has additional value in excluding or confirming MDS as another means 
to assess cellularity, the presence of fibrosis, abnormally localized immature precursors (ALIPs) 
and increases in CD34+ blast counts 33,34. In our study, none of the patients had increased CD34+ 
blast percentages (immunohistochemical staining available in 37%), fibrosis, or ALIPs. 
Interestingly, in this study we found a pronounced presence of inflammatory infiltrates 
involving increased mast cells, lymphoid nodules, and plasma cells in the AA and AA-PNH BMB, 
but also in some cases of cPNH. Previous studies already showed oligoclonal T cell expansions in 
peripheral blood in AA, AA-PNH and cPNH 11-16. The T cell infiltrates found in some AA-PNH and 
cPNH patients in our study fit the hypothesis of T cell mediated BM damage in PNH. Increased 
BM mast cells and plasma cells were previously reported in various BM failure syndromes, 
including PNH 35-37. These may suggest an additional role of the B cell compartment and innate 
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immunity in the suppression of hematopoiesis in AA-PNH. Several autoantibodies have been 
found in AA and AA-PNH; however a causal role for these antibodies was never proven 38-42.
The mechanism behind the expansion of PIG-A mutated HSC in PNH at the expense of 
normal HSC remains elusive. As supported by evidence from several experimental studies, 
immune-mediated BM failure may play a role in PNH clonal expansion by selective damage 
to normal HSC. Confirming other studies 43,44, we found larger PNH clones in cPNH than in 
AA-PNH patients. In addition, in cPNH we found a higher BM cellularity and significantly less 
pronounced signs of inflammation. These differences may reflect variations in the nature or 
timing of HSC injury. In this series, lymphoid nodules were also less frequent in AA than in 
AA-PNH. No other significant clinical or histological differences were found between AA-PNH 
and AA patients that might account for the occurrence of a PNH clone in AA-PNH.  
In 67% of AA-PNH patients hemolysis was recorded, and by definition in all cPNH patients. 
As shown previously, the degree of hemolysis as determined by LDH levels correlated with PNH 
clone size 44. Bone marrow iron stores were decreased in most cPNH patients, probably due to 
increased hematopoiesis and iron loss by hemoglobinuria. In contrast, the majority of AA-PNH 
patients had increased iron deposition in BM macrophages. This is unlikely to be explained 
by transfusions since in this study diagnostic BMB were evaluated. Alternatively, decreased 
iron usage due to diminished hematopoiesis may lead to excess deposition in macrophages, 
as described in other conditions of ineffective hematopoiesis. Impaired erythropoiesis may 
also result in increased Growth Differentiation Factor 15 (GDF15) levels which block hepcidin 
production leading to increased iron absorption in the gut 45.  
The remarkable finding of congested blood vessels and hemorrhage in the majority 
of BMB in all patient groups is unexplained. This phenomenon was previously described in 
a series of aplastic anemia, however in that study the presence of a PNH clone could not be 
assessed reliably as flow cytometry was not available yet 36. It could point to an inflammatory 
response with subsequent endothelial damage, and may be aggravated by thrombocytopenia. 
Complement-mediated damage of GPI-deficient endothelial cells is an unlikely explanation, as 
we show that endothelial cells uniformly express CD59 in both AA-PNH and cPNH.
Our results on CD59 expression in a limited set of healthy and patient BMB indicate that CD59 
is a useful marker for immunohistochemical assessment of GPI deficiency in sufficiently cellular 
BMB. The cytoplasmic staining in addition to the membranous expression was unexpected, but 
a well known pattern for several other anti-CD59 antibodies 46. The reason for this cytoplasmic 
staining is unknown. A variable intensity of the positive staining cells can be attributed to varying 
expression levels for CD59 in PNH cells within one patient, as known from flow cytometry. A 
partial deficiency in GPI anchors (type II cells) results in a lower (but not absent) expression 
of CD59, while type III cells are completely devoid of CD59. Interestingly, both in AA-PNH 
and cPNH, compared to other lineages, plasma cells contained a lower percentage of CD59 
negative cells. Others have previously shown smaller PNH lymphocyte clones than red cell and 
granulocyte clones, possibly explained by the longer life span of lymphocytes, which may have 
been generated before the onset of PNH 47. In contrast to peripheral blood, where the PNH 
erythrocyte clone is smaller than the PNH granulocyte clone size due to continuous lysis of PNH 
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red cells, we did not find a similar difference between the proportion of GP-deficient erythroid 
precursors and late stage myeloid cells in BM. This is consistent with the previous observation 
that in PNH patients the proportion of GPI-deficient cells in reticulocytes is comparable to 
neutrophils and higher than in erythrocytes 48. It might indicate that complement-mediated 
destruction of PNH red cells mainly takes place in the peripheral blood and not in the BM.  
To our knowledge, this is the first large series describing various aspects of BM histology in 
patients with a PNH clone. We have demonstrated that BM histology at presentation cannot clearly 
differentiate between AA and AA-PNH. cPNH and AA-PNH however are obviously different with 
respect to a lower BM cellularity and a more pronounced inflammatory infiltrate in AA-PNH. When 
looking more closely though, cPNH resembles AA-PNH more than initially apparent, as AA features, 
such as myeloid and megakaryocyte hypoplasia, increased inflammatory cells and decreased 
cellularity are also found in many cPNH patients. This further contributes to the notion that both 
entities need to be considered as different ends of a continuous spectrum of immune mediated BM 
failure syndromes rather than separate entities as the current clinical working classification suggests. 
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supplementary figure 1: correlation 
between ldH levels and PNH granulocyte 
clone size. PNH granulocyte clone size (%) 
versus LDH levels (U/l) in the total group of 
AA-PNH and cPNH patients with available 
LDH levels at the time of first detection of 
the PNH clone (n = 64). Each dot represents 
a single patient. r2 and p value were 
calculated by linear regression analysis. 
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a b s t r ac t
objective: Natural Killer cell receptors (NKR) have been implicated in rheumatoid (RA) and 
psoriatic arthritis (PsA) pathogenesis. To gain more insight in their role, we have determined 
NKR (co-)expression patterns on NK and T cells and NK cell function in RA and PsA.
methods: The frequency of NK and T cells expressing Killer-cell immunoglobulin-like receptors 
(KIR) and NKG2 receptors was assessed by 10-color flow cytometry in peripheral blood of 31 RA, 
12 PsA and 26 healthy donors (HD). NK cell cytotoxic capacity and IFN-γ production was assessed. 
results: In RA but not PsA, the frequency of NK cells (median; range) expressing NKG2A (42%; 
14-81%) was elevated compared to HD (23%; 9-58%). These NKG2A+ NK cells predominantly 
lack KIR, but display normal cytotoxicity and IFN-γ production. In contrast, RA patients 
with normal NKG2A+ NK cell frequency have less functional NK cells compared to HD. T cells 
expressing the Fcγ receptor CD16 were elevated in RA (median 0.75%) versus HD (0.3%) (p = 
0.004). Furthermore, T cells expressing the KIRs CD158ah in both RA (0.7%) and PsA (0.3%), and 
CD158e1e2 in RA (1.5%) were elevated compared to HD (0.2% and 0.4% respectively; p<0.05). In 
RA, CD4+ T cells expressing the KIRs CD158ah, CD158b1b2j and CD158e1e2 were low (<2%) but 
significantly elevated compared to HD (p < 0.01). 
conclusions: This study demonstrates the presence of an elevated, functionally active NKG2A+ 
KIR- NK cell population in RA. Together with an elevated frequency of NKR-expressing T cells 
these changes may reflect differential pathogenetic involvement. 
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i N t r o d u c t i o N
Natural Killer (NK) cell biology is regulated by the balance between activating and 
inhibitory NK receptors (NKR). Inhibitory receptors, including inhibitory isoforms of Killer-
cell immunoglobulin-like receptors (KIRs/CD158 isoforms), generally recognize Major 
Histocompatibility Complex Class I (MHC-I) molecules. Activating receptors, including 
activating isoforms of KIRs and NKG2 receptors, bind with lower affinity to MHC-I molecules or 
other ligands. Together, they tune NK cell response upon NKR binding 1. In contrast to NK cells, 
NKR function on T cells is not fully elucidated. Normally, NKR expressing T cells are infrequent, 
typically <5 % of CD8+ T cells 2. However, in conditions of chronic immune activation such as 
autoimmune disease, elevated numbers are found 3. 
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are two hallmark chronic inflammatory 
diseases sharing clinical features such as chronic synovial inflammation leading to destruction 
of the joints. Accumulating evidence suggests a role for NK cells in both conditions. How NK 
cells contribute to their pathogenesis and/or the difference in clinical features between RA 
and PsA is however unknown. Studies in PsA showed that the activating KIR genes KIR2DS1 
and/or KIR2DS2 increase disease susceptibility, particularly when the HLA ligands for the 
corresponding inhibitory receptors KIR2DL1 and KIR2DL2/3 are lacking 4-6. In RA, the KIR2DS2 
gene was associated with a subgroup of patients with vasculitis 7. In addition, polymorphisms 
in other NKR genes modify disease risk, including NKG2A, NKG2C, NKG2D and CD244 8,9. For 
PsA, associations with HLA-Cw*0602, a KIR ligand 10, and MIC polymorphisms were reported 11. 
Besides genetic associations, immunophenotypical studies revealed a different NKR 
expression between RA patients and their healthy counterparts. In RA, CD4+ T cells lacking 
CD28 are increased. This subset partially expresses activating KIRs and NKG2D, whereas 
CD4+CD28- T cells from healthy donors do not 12,13. Importantly, RA synoviocytes also express 
the NKG2D ligand MIC 13. A higher frequency of CD28- T cells expressing the general NK cell 
marker CD56 was shown in RA patients compared to HD, particularly in those with extra-
articular manifestations 14. The role of NK cells in RA pathogenesis is still unclear. Depletion of 
NK cells in mouse models of collagen-induced arthritis (CIA) has shown both protection and 
exacerbation of arthritis 15,16. In RA synovial fluid, CD56bright NK cells are abundant. This subset 
potently produces TNF-α and IFN-γ, and expresses CD94/NKG2A and low levels of KIRs 17-19. 
Altogether, phenotypical, functional and/or genetic studies suggest a role for NK cells and NKR 
expressing T cells in RA and PsA pathogenesis. Given the role for NKR, it is tempting to speculate 
that the fact that RA is considered an autoimmune disease but PsA as an autoinflammatory 
condition could be determined by NK & NKR biology that is different in these conditions. To study 
this, we investigated the phenotype and function of NK and NKR expressing T cells in RA and 
PsA. In RA, but not PsA, we observed differences in NK cell phenotype and function compared 
to healthy individuals. Furthermore, KIR expression by T cells was elevated in both RA and PsA 
whereas the frequency of CD16+ T cells was significantly increased in RA.  
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m e t H o d s
P a t i e n t s  a n d  c e l l  i s o l a t i o n
Blood samples from 31 RA, 12 PsA patients and 26 HD were collected after obtaining written 
informed consent. All patients fulfilled the American College of Rheumatology 1987 revised 
criteria for RA 20 or the Classification of Psoriatic Arthritis Study Group criteria for PsA 21. This 
study was approved by the local medical ethics committee and performed in accordance with 
the Declaration of Helsinki. Clinical characteristics of patients and HD included for phenotypical 
analysis and in vitro cellular assays are shown in Table 1 and Table 2 respectively. For functional 
assays, RA patients were stratified according to their frequency of NKG2A+ NK cells. NKG2Ahigh 
are patients with a frequency of NKG2A+ NK cells > 1 standard deviation (SD) higher than the 
mean frequency of NKG2A+ NK cells in HD; all other patients were defined as NKG2Anorm 
and have a frequency of NKG2A+ NK cells similar to HD. Patients receiving biologicals and/
or hydroxychloroquine were excluded from the in vitro cellular assays. Peripheral blood 
table 1: clinical characteristics of patients and healthy donors included for phenotyping 
Hd ra Psa 
Number 18 23 12
Age (y; median, range) 44 (25-60) 59 (15-79) 44 (25-78)
M/F (number of patients; ratio) 8/10 (0.80) 10/13 (0.77) 5/7 (0.71)
Disease duration (y; median, range) NA 2 (0.08-23.1) 2.4 (0-11)
Disease activity:
DAS28 score (median, range)
TJC (median, range)
SJC (median, range)
ESR (mm; median, range)
CRP (g/l; median, range)
NA
3.3 (2.38-4.93)
NA
NA
9 (2-29)
<5 (5-23)
NA
1 (0-7)
1 (0-7)
6 (0-44)
<5 (<5-22)
Therapy (number of patients):
None
MTX
MTX + anti- TNF-α + HCQ
MTX + anti- TNF-α
MTX + rituximab
MTX + sulfasalazine
MTX + HCQ
MTX + prednisolone
anti- TNF-α
sulfasalazine
anti- TNF-α + sulfasalazine
abatacept
NA
2
6
1
6
2
2
1
1
0
1
1
1
2
4
0
1
0
0
0
1
3
1
0
0
y = years. NA = not applicable. DAS = disease activity score. TJC = tender joint count. SJC = swollen joint count. ESR 
= erythrocyte sedimentation rate. CRP= C-reactive protein. MTX = methotrexate. HCQ = hydroxychloroquinine. 
HD = healthy donor. RA = rheumatoid arthritis. PsA = psoriatic arthritis. 
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mononuclear cells (PBMC) were freshly isolated from whole blood by Ficoll Hypaque gradient 
separation and used for flow cytometry or cellular assays.
F l o w  c y t o m e t r y
PBMC were stained with 3 different antibody panels. Antibody panel composition and antibody 
details are shown in Table 3. Samples were measured on a 10-color, 3-laser Navios flow cytometer 
(Beckman Coulter, Fullerton, CA, USA). After optimizing the PMT settings, spectral overlap was 
compensated using single antibody stainings. Cells were gated on peripheral blood lymphocytes 
(PBL) based on characteristic forward scatter (FSC) and sideward scatter (SSC) properties and 
CD45 positivity (Supplementary figure 1A). Percentages of positive cells were determined within 
CD3+ (T cells), CD3+CD4+CD8- (CD4+ T cells), CD3+CD8+CD4- (CD8+ T cells) and CD3-CD56+ (NK) cells. 
A minimum of 400.000 cells was measured. In each T and NK cell subpopulation, at least 2.500 
cells were analyzed. Data were analyzed with Kaluza software (Beckman Coulter).
c e l l u l a r  a s s a y s
NK cells were enriched from PBMCs by negative selection with an NK Cell Isolation Kit 
(Miltenyi Biotec, Bergisch Gladbach, Germany). The human erythroleukemic target cell 
line K562 was maintained in IMDM (Invitrogen, Carlsbad, CA, USA) containing penicillin/
streptomycin (50 U/50 μg/ml; MP Biomedicals, Solon, OH, USA) and 10% FCS (Integro, 
Zaandam, The Netherlands). Flow cytometry-based cytotoxicity assays were performed as 
described previously 22. Briefly, target cells were labeled with 5 μM carboxyfluorescein diacetate 
succimidyl ester (CFSE; Molecular Probes Invitrogen, Eugene, OR, USA) in a concentration of 
1x107/mL for 10 minutes at 37°C. CFSE-labeled target cells were resuspended in IMDM with 2% 
table 2: clinical characteristics of patients and healthy donors included for cellular assays
Hd ra Nkg2anorm ra Nkg2ahigh ra
Number 8 8 5 3
% of NKG2A+ NK cells (mean, SD) 46 (±10.3) 54.3 (±10.8) 48.1 (±7.4) 64.6 (±6.5)
Age (y; median, range) 47 (44-60) 48 (44-59) 47 (44-59) 48 (44-50)
M/F (number of patients; ratio) 3/5 (0.6) 3/5 (0.6) 1/4 (0.25) 2/1 (2)
Disease duration (y; median, range) NA 11 (2.1-28) 16 (4-28) 11 (2.1-14)
Disease activity (DAS28; median, range) NA 2.71 (1.13-3.44) 3.03(1.13-3.44) 2.45 (1.27-2.97)
Therapy (number of patients):
none 
MTX
MTX + NSAID
MTX + prednisolone
Leflunomide + prednisolone
NA
1
2
3
1
1
1
1
2
1
0
0
1
1
0
1
SD = standard deviation. y = years. NA = not applicable. MTX = methotrexate. NSAID = non-steroidal, anti-
inflammatory drugs. 
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human serum (PAA Laboratories GmbH, Pasching, Austria) at a final concentration of 0.3-3x105/
ml. NK cells were resuspended at a final concentration of 3x105/ml and cocultured with target 
cells at different effector:target (E:T) ratios in 96-wells round-bottom plates. After 18 hours, the 
number of viable target cells was quantified by flow cytometry based on FSC/SSC and exclusion 
of dead/apoptotic cells using the plasma membrane integrity marker DRAQ7 (Biostatus Ltd., 
Shepshed, UK). Samples were acquired on a FC500 flow cytometer (Beckman Coulter). Target 
cell survival was calculated as follows: % survival = (absolute no. viable CFSE+ DRAQ7- target 
cells co-cultured with NK cells / absolute no. viable CFSE+ DRAQ7- target cells cultured in 
medium)*100. The percentage of specific killing was 100 − % survival. 
To determine IFN-γ production by IL-12/IL-18 stimulated NK cells (IL-12 10 ng/ml, IL-18 100 
ng/ml; Immunotools, Friesoythe, Germany), NK cells were seeded in a final concentration of 
2.5x105/ml in 96-wells round-bottom plates. After 1 hour, GolgiPlug (1 μl/ml, BD Biosciences, 
San Diego, CA, USA) was added. After overnight incubation at 37°C, cells were stained for cell 
surface markers (anti-CD56-BV510, clone HCD56; anti-CD158e1-PE, clone DX9; anti-CD158b-
PE, clone DX27; anti-CD158a/h/g-PE, clone HP-MA4; all purchased from Biolegend, San Diego, 
CA, USA; anti-NKG2A-APC, clone Z199; Beckman Coulter, Marseille, France; and the eFluor780 
Fixable Viability Dye; eBioscience, San Diego, CA, USA). NK cells expressing at least one 
among KIR2DL1/KIR2DS1 (CD158 a/h), KIR2DS3, KIR2DS5 (CD158g), KIR2DL2/KIR2DL3 (CD158b) 
or KIR3DL1 (CD158e) were considered KIR+; all other cells were considered KIR-. Subsequently, 
cells were treated with fixation/permeabilization buffer (eBioscience), stained for intracellular 
IFN-γ (FITC-coniugated, clone B27; BD Biosciences) and acquired on a Gallios flow cytometer 
(Beckman Coulter). Analysis was performed with Kaluza software (Beckman Coulter) using 
unstimulated cells as control. The gating strategy is shown in Supplementary Figure 2A.
table 3: antibody panels 
channel (antibody conjugate) Panel 1 Panel 2 Panel 3
FL1 (FITC) CD4 CD28* CD16*
FL2 (PE) CD56* NKG2C† CD336 (NKp44)
FL3 (ECD) CD8 CD8 CD3
FL4 (PE-Cy5.5) CD158i CD4 CD337 (NKp30)
FL5 (PE-Cy7) CD158b1b2j CD56 CD335 (NKp46)
FL6 (APC) NKG2D CD158e1e2 NKG2D
FL7 (APC-Alexa700) CD158ah CD244 CD8
FL8 (APC-Alexa750) CD3 CD3 CD56
FL9 (Pacific Blue) NKG2A NKG2A CD94
FL10 (Krome Orange) CD45 CD45 CD45
Unless otherwise specified, all antibodies were purchased from or kindly provided by Beckman Coulter Inc. (Marseille, 
France). * Obtained from BD Biosciences, Franklin Lakes, NJ, USA. † Obtained from R&D systems, Minneapolis, MN, USA. 
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s t a t i s t i c s
Mann-Whitney U test or Kruskal-Wallis test was used to compare T and NK cell subset 
frequencies, killing and IFN-γ expression, as appropriate. Statistical significance was accepted 
for p values below 0.05. Correlations between lymphocyte subset frequencies and clinical 
characteristics were determined by linear regression analysis. 
r e s u lt s
i n c r e a s e d  f r e q u e n c y  o f  N kg 2 a  e x p r e s s i n g  N k  c e l l s  i n  r a  
b u t  n o t  P s a  p a t i e n t s
NK cell frequency (median; range) within PBL was similar in RA (12%; 2-32%), PsA (10%; 2-27%) 
and healthy donors (HD) (11%; 4-27%). No significant differences were found in the median 
frequencies of CD56bright NK cells in RA (8.6%, range 1-16%), PsA (6.7%, range 3-25%) and HD 
(6.1%, range 1-15%), nor in CD56dim NK cells (Supplementary figure 1B). In RA patients, the 
frequency of NK cells expressing NKG2A (median 42%, range 14-81%) was significantly higher 
than in HD (median 23%, range 9-58%, p<0.01, Figure 1A-B). This also accounted for CD94, 
the other component of the NKG2A/CD94 heterodimer (p = 0.02, Figure 1A-B). The median 
frequency of NKG2A+ NK cells was higher in patients with rheumatoid factor (RF) (49%, range 
36-71%) than in those without (34%, range 14-81%, Figure 1C). No correlations were found with 
other clinical parameters such as disease activity (DAS28 score, ESR, CRP, erosiveness), the 
presence of anti-citrullinated protein antibodies (ACPA), duration of disease, patient age, or 
type of treatment (data not shown). 
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Figure 1: increased frequency of Nkg2a and cd94 expressing Nk cells in ra patients compared to Hd. Figure 
1A: Expression of NKG2A and CD94 within NK cells of RA patients, PsA patients and healthy donors (HD). Cells were 
gated on peripheral blood lymphocytes based on characteristic forward scatter (FSC) and sideward scatter (SSC) 
properties and CD45 positivity. Percentages of positive cells were determined within CD3-CD56+ (NK) cells. Lines 
represent the median percentage of positive cells within the CD56+CD3- NK cell population, boxes indicate 25th 
and 75th percentiles, and outer whiskers indicate the most extreme data points of 23 RA patients, 12 PsA patients, 
and 18 HD. Figure 1B: A representative example of a RA patient with NKG2A+ and CD94+ NK cells. Flow cytometry 
dot plots were gated on NK cells and show log fluorescence intensity of NKG2A/CD94 (y-axis) and CD56 (x-axis), 
demonstrating that NKG2A+ and CD94+ NK cells are predominantly CD56dim. Percentages indicate the percentage of 
cells within a specific quadrant. Quadrants were set to define NKG2A+ and CD94+ cells, and to distinguish between 
CD56dim and CD56bright NK cells.  Figure 1C: Scatter dot plot comparing the frequency of NKG2A+ NK cells in RA patients 
with or without RF or ACPA. Lines represent median percentages. * = p < 0.05, ** = p < 0.01, Mann-Whitney U test. 
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Although in both RA and PsA the frequency of KIR, Natural cytotoxicity receptors (NCR; 
Nkp 30, 44 and 46), NKG2C, NKG2D and CD244 expressing NK cells was similar to HD (data 
not shown), we found differences in co-expression patterns of combinations of NKR in RA 
but not PsA (Figure 2). In RA, the frequency of NKG2A+ NK cells negative for CD158e1e2 and 
NKG2C (median 47%, range 14-74%) was elevated compared to HD (median 26%, range 
13-56%, p<0.05). Though typically below 10%, the median percentage of NKG2A+ CD158e1e2+ 
NKG2C+/- cells was higher than in HD (p<0.05, Figure 2A). In addition, CD158ah+ NKG2A- 
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Figure 2: Nkg2a, kir, Nkg2c co-expression patterns on Nk cells differ in ra patients and Hd. Figure 2A: Scatter 
dot plots comparing NKR co-expression patterns between RA patients (●) and HD (○) within the total population 
of NK cells. Lines represent the median percentage of positive cells within the CD56+CD3- NK cell population. Below 
each column set of RA patients and HD, the presence or absence of a certain NKR is indicated by + or -. Left panel: 
co-expression patterns of NKG2A, CD158e1e2 and NKG2C. Right panel: co-expression patterns of NKG2A, CD158ah, 
CD158b1b2j and CD158i. NKG2A+ NK cell subsets with expression of either CD158ah or CD158b1b2j were not shown 
since their frequency was low (generally <10%) and identical to HD. Figure 2B: Scatter dot plots characterizing NKR 
co-expression patterns within NKG2A+ NK cells and compared between RA patients (●) and HD (○). Lines represent 
the median percentage of cells within the NKG2A+ NK cell population expressing (+) or lacking the NKR (-) as indicated 
below the graphs. Left panel: co-expression patterns of CD158e1e2 and NKG2C within CD56dim NKG2A+ NK cells (left 4 
columns) and CD56bright NKG2A+ NK cells (right 4 columns). Right panel: co-expression patterns of CD158ah, CD158b1b2j 
and CD158i within CD56dim NKG2A+ NK cells (left 8 columns) and CD56bright NKG2A+ NK cells (right 2 columns). CD56bright 
NKG2A+ NK cell subsets with expression of CD158ah, CD158b1b2j or CD158i were omitted from the figure since their 
frequency was low (generally <10%) and similar to HD. * = p < 0.05, ** = p < 0.01, Mann-Whitney U test. 
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CD158b1b2j- CD158i- NK cells were increased in RA (median 6%, range 0-24%) compared to 
HD (median 0%, range 0-43%, p = 0.001).  
Subsequent characterization of NKR co-expression within the NKG2A+ NK cell population 
did not reveal differences between RA and HD (Figure 2B). The majority of NKG2A+ NK cells 
(median; range) in RA is CD56dim and does not express any other receptor tested (CD158e1e2- 
NKG2C- 70.1%; 28-90%,  CD158a- CD158b1b2j- CD158i- 53.9%; 40-87%), apart from CD244 and 
NKG2D which were present on virtually all NK cells (data not shown). Collectively, these data 
indicate that in a subset of RA patients, especially those with elevated RF, NKG2A+ KIR-  CD56dim 
NK cells are elevated compared to HD.
N k  c e l l  s u b s e t s  o f  r a  p a t i e n t s  w i t h  h i g h e r  f r e q u e n c y  o f  N k 2 a + 
N k  c e l l s  ( N kg 2 a h i g h )  h a v e  n o r m a l  f u n c t i o n a l i t y
To assess whether the higher frequency of NKG2A+ NK cells in RA patients is associated with 
altered functionality, we first tested cytotoxicity of NK cells against K562 target cells in RA patients 
and HD. The killing capacity of unstimulated NK cells in RA patients (mean at E:T 10:1 ratio 75%, 
range 42-92%) was lower than in HD (mean 90%, range 85-98%, p<0.05; Figure 3A). Given the 
variability in the NKG2A+ NK cell frequency within RA patients, we next discriminated between the 
killing potential of NKG2Anorm and NKG2Ahigh RA patients. Only NKG2Anorm patients displayed 
lower lysis capability compared to HD and NKG2Ahigh RA patients (both P < 0.05, Figure 3B). 
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Figure 3: Normal cytotoxicity by Nk cells of Nkg2ahigh, but not Nkg2anorm ra patients. Cytotoxicity of NK 
cells isolated from HD and RA patients against K562 target cells. Specific lysis was determined after 18 hours of 
co-culture in a FCM-based cytotoxicity assay at E:T 1:1 and 10:1 ratios. Data are displayed as means ± standard error 
of the mean (SEM) of the means of triplicate wells from 8 different experiments. Figure 3A: Specific cytotoxicity 
compared between HD and RA patients overall. * = p < 0.05, Mann-Whitney U test. Figure 3B: Specific cytotoxicity 
compared between HD, NKG2Ahigh and NKG2Anorm RA patients. * = p < 0.05, Kruskal-Wallis test.
97
H
ig
H
 freq
u
en
c
y
 o
f fu
n
c
tio
n
a
l n
Kg
2a
+ n
K
 c
ells in
 r
a
4
NK IFN-γ response to IL-12/IL-18 was similar between RA patients and HD (Figure 4A). Upon 
stratification for NKG2Anorm and NKG2Ahigh patients we observed a seemingly lower but non-
significant difference in IFN-γ expression in NKG2Anorm patients compared to NKG2Ahigh patients 
as well as healthy controls (Figure 4B). Further analysis of NK cell subsets (NKG2A-/KIR-, NKG2A+/
KIR-, NKG2A+/KIR+, NKG2A-/KIR+) showed a similar distribution within NKG2Anorm, NKG2Ahigh RA 
patients and HD (Supplementary Figure 2B-C). NK cell subsets in the NKG2Anorm RA patients, which 
have a similar distribution compared to HD, appear less capable of IFN-γ production but again this 
difference was not significant (Figure 4C). In contrast, the different NK cell subsets in NKG2Ahigh RA 
patients produce IFN-γ equally efficient as HD. These data indicate that the elevated NKG2A+ NK cell 
population found in part of RA patients is functionally responsive to IL-12/IL-18 stimulation.
i n c r e a s e d  f r e q u e n c y  o f  k i r  a n d  c d 1 6  e x p r e s s i n g  t  c e l l s  
i n  p a t i e n t s  w i t h  r a  b u t  n o t  P s a
As NKR expressing T cells have been implicated in pathology we determined their frequency 
in RA and PsA patients. No differences were found in the relative frequencies of CD4+CD8-, 
CD8+CD4-, CD4CD8 double negative (DN) and CD4CD8 double positive (DP) T cells (data not 
shown). The frequencies of CD56, NKG2, NCR, CD16 and CD244 expressing T cells were similar 
between RA, PsA and HD (data not shown). Moreover, the frequency of CD4+CD28- T cells 
was equal to HD (data not shown). In contrast, KIR expression on T cells in RA was different as 
CD158ah expressing T cells were more frequent in both RA (median 0.7%, range 0.2-6%) and 
PsA (median 0.3%, range 0.1-1.4%) than in HD (median 0.2, range 0.1-0.5%) (p<0.0001 and p = 
0.05 respectively, Figure 5A). In RA patients, the median frequency of CD158e1e2 expressing 
cells within the total T cell population (1.5 vs 0.4%, range 0-9.1% vs 0-2.8%) and within CD8+ 
T cells (1.5%, range 0-9.1%) was increased compared to HD (0.35/1.5%, range 0-1.2/0-2.8% 
respectively) (p = 0.02 and p = 0.04, Figure 5A). The frequencies of KIR+CD4+ T cells were 
generally below 1% in both patients and controls. Nevertheless, in RA patients the median 
frequency of CD158ah+ (0.3%, range 0.1-0.8%, p<0.0001), CD158b1b2j+ (0.2, range 0-1.7%, p = 
0.001) and CD158e1e2+ (0.1%, range 0-0.1%, p = 0.0001) CD4+ T cells was significantly higher 
than in HD (medians 0.1/0.1/0%, range 0-0.2/0-1.1/0-0.3% respectively) (Figure 5B-C). Neither 
in RA nor PsA, elevated NKR expressing T cell numbers correlated to clinical parameters such 
as disease activity (DAS28 score or tender and swollen joint counts, ESR, CRP, erosiveness), the 
presence of ACPA or RF, duration of disease, patient age, or type of treatment (data not shown).
Finally, we investigated CD16 expression on T cells. CD16+ T cells were significantly higher in 
RA patients (median 0.75%, range 0.2-11.4%) than in HD (median 0.3%, 0.1-0.7%) (p = 0.004, Figure 
6A-B). Also among CD8+ T cells, the percentage of CD16+ T cells was increased (median 1.5%, range 
0.3-21.3%) compared to HD (median 0.6%, range 0.1-0.3%) (p = 0.005, Figure 6A-B). The majority 
of CD16+ T cells (69%) were γδ T cells, as was shown in one RA patient with a high frequency 
of CD16+ T cells (11.7%, Figure 6C). We did not find significant correlations between CD16+ T cell 
numbers and disease activity (DAS28 score, ESR, CRP, erosiveness), the presence of ACPA or RF, 
duration of disease, patient age, or type of treatment (data not shown). Taken together, these 
data indicate that several T cell populations with expression of NKR are elevated in RA patients. 
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Figure 4: Normal iFN-γ production in il-12/il-18-stimulated Nk cell subsets of Nkg2ahigh, but not 
Nkg2anorm ra patients. IFN-γ expression in NK cells isolated from HD and RA patients after overnight 
stimulation with IL-12/IL-18. Data are displayed as means ± SEM of the means of triplicate wells from 8 different 
experiments. All data are shown after subtracting the baseline level of IFN-γ expressed by unstimulated NK 
cells. Figure 4A: IFN-γ expression compared between HD and RA patients overall. Figure 4B: IFN-γ expression 
compared between HD, NKG2Ahigh and NKG2Anorm RA patients. Figure 4C: IFN-γ expression compared 
between HD, NKG2Ahigh and NKG2Anorm RA patients stratified within the different NKG2A/KIR subsets: NKG2A-/
KIR-, NKG2A+/KIR-, NKG2A+/KIR+, NKG2A-/KIR+.
d i s c u s s i o N
As solid evidence points towards the role of NK cells and NKR-expressing T cells in autoimmune 
disease 3,23 we set forth to determine potential differences in the phenotype and/or behavior of 
these cells in two archetypical chronic inflammatory diseases RA and PsA. We demonstrated that the 
NK cell phenotype in peripheral blood from RA but not PsA patients differs from healthy individuals. 
We found elevated frequencies of NKG2A+ NK cells in RA patients which were predominantly 
CD56dim and lacked expression of KIRs and activating NKG2C, possibly indicative of a relatively 
immature status. Intriguingly, only RA patients with normal frequency of NKG2A expressing NK 
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cells (NKG2A
norm
) displayed impaired cytotoxicity and possibly IFN-γ production. In the NKG2Ahigh 
subgroup, the NKG2A+/KIR- and NKG2A+/KIR+ NK cell populations were mostly responsible for IFN-γ 
production which is in line with the notion that NKG2A+/KIR- NK cells are more immature, yet highly 
activated NK cells with potent IFN-γ production capacity in HD upon IL-12/IL-18 stimulation 24. De 
Matos et al. previously described the presence of IFN-γ-producing NKG2A+KIR- CD56bright NK cells 
in the synovium in different types of arthritis 17. In addition, they showed that this synovial NK cell 
population expressed specific chemokine receptors suggestive of preferential recruitment from 
peripheral blood, rather than local maturation 19. The fact that NKG2Anorm RA patients seem to 
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Figure 5: increased frequency of kir expressing t cells in ra and Psa. KIR expression on T cells in patients with 
RA and PsA and in HD. Cells were gated on peripheral blood lymphocytes based on characteristic forward scatter 
(FSC) and sideward scatter (SSC) properties and CD45 positivity. Percentages of positive cells were determined 
within CD3+ (T cells), CD3+CD4+CD8- (CD4+ T cells), CD3+CD8+CD4- (CD8+ T cells). Figure 5A: Frequency of T cells 
(left panel) and CD8+ T cells (right panel) expressing CD158ah and CD158e1e2 in patients with RA (●), PsA (▲), and 
HD (○).  Bars represent median percentages. Figure 5B: Frequency of CD4+ T cells expressing the KIRs CD158ah, 
CD158b1b2j, CD158e1e2 and CD158i. Lines represent the median percentage of positive cells within the CD4+ T 
cell population, boxes indicate 25th and 75th percentiles, and outer whiskers indicate the most extreme data 
points of 23 RA patients, 12 PsA patients, and 18 HD. Figure 5C: Flow cytometry dot plots of RA patients with high 
proportions of CD4+ T cells expressing KIR. Plots were gated on CD4+ T cells and show log fluorescence intensity 
for CD3 (y-axis) and CD158ah (top panel), CD158b1b2j (middle panel) and CD158e1e2 (lower panel). Percentage 
within the plot indicates the proportion of CD4+ T cells positive for the NKR indicated on the X-axis. * = p < 0.05, ** 
= p < 0.01, *** = p < 0.001, Mann-Whitney U test. 
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have NK cells with impaired cytotoxic potential and cytokine production, could reflect the results of 
Aramaki et al., who found decreased NK cell cytotoxicity in RA patients 25. 
Notably, NK cell functionality in NKG2Ahigh patients in our study was comparable to HD. 
However, pathogenic implications as opposed to protective effects of elevated functionally active 
NKG2A+ NK cells remain to be uncovered. Both in vitro and in vivo studies suggest that blocking 
NKG2A may be beneficial in RA. Leavenworth et al. showed in murine CIA that NK cells are capable 
of killing pathogenic T
helper
 (T
h
) subsets and that anti-NKG2A blocking increased joint infiltration 
by NK cells, decreased pathogenic T
h
 cell numbers, and importantly, improved arthritis 26. In 
vitro blocking of NKG2A enhanced NK cell degranulation against autologous activated CD4+ T 
cells and RA fibroblast like synoviocytes (FLS) 27,28. Other than RF positivity, we did not find other 
correlations between NKG2A+ NK cell frequency and clinical characteristics, such as disease 
activity score (DAS28), presence of erosions, elevated inflammatory markers or length of disease.
Our study revealed several novel observations. First, increased KIR expression on T cells 
in both RA and PsA was observed. Assuming these receptors are activating, as shown for KIR 
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Figure 6: increased frequency of t cells expressing cd16 in ra. CD16 expression on T cells in RA. Cells were 
gated on peripheral blood lymphocytes based on characteristic forward scatter (FSC) and sideward scatter (SSC) 
properties and CD45 positivity. The percentage of positive cells was determined within CD3+ (T cells). Figure 6A: 
Frequency of T cells (left panel) and CD8+ T cells (right panel) expressing CD16 in patients with RA (●), PsA (▲), 
and HD (○). Lines represent median percentages. Figure 6B: Flow cytometry dot plot of a RA patient with a high 
proportion of CD16+ T cells. The plot was gated on CD45+ lymphocytes and shows log fluorescence intensity of 
CD3 (y-axis) and CD16 (x-axis). Figure 6C: Flow cytometry dot plot gated on CD3+ T cells of a RA patient showing 
CD16 (y-axis) and TCR γδ (x-axis). * = p < 0.05, Mann-Whitney U test.
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expressing CD4+ T cells in RA 12, these T cells may represent autoimmune effectors. Secondly, we 
observed a markedly increased frequency of CD16+ (CD8+) T cells in RA but not PsA patients. CD16 
is a low-affinity Fc receptor for IgG (Fcγ receptor IIIa), present on virtually all NK cells and involved 
in antibody mediated cellular cytotoxicity (ADCC). Its role on T cells is less well characterized. It 
is found on the majority of healthy donor TCR γδ T cells 29, as well as a small proportion of TCR αβ 
T cells 30. Our finding of elevated CD16+ (CD8+) T cells in RA patients builds further on  the study 
of Bodman-Smith et al. who reported a trend towards increased frequency of CD16+ TCR γδ T 
cells in RA patient peripheral blood 31. CD16+ γδ T cells are capable of phagocytosis and antigen 
presentation via MHC class II 32. CD16+ TCR αβ T cells are predominantly CD8+, perforin+ effector 
memory T cells, present at increased frequency in patients with chronic hepatitis C infections 
and other causes of reactive lymphocytosis 30,33. Triggering of CD16 on TCR αβ T cells results 
in production of effector molecules such as perforin, granzyme B, IFN-γ and TNF-α 33,34. The 
increased frequency of CD16+ T cells reported here, together with the effector phenotype and 
functional properties reported elsewhere, might very well fit a pathogenetic role in autoimmune 
disease. Therefore, in our view, this cell population requires functional characterization in RA. 
Our study does not confirm the previously reported increased frequencies of T cells expressing 
the general NK cell marker CD56 in either RA or PsA patients 14 nor could we confirm an expansion 
of CD4+CD28- T cells in RA patients as initially reported by Schmidt et al., particularly in those 
with extra-articular manifestations 35,36. This may be explained by differences in treatment and the 
absence of extra-articular complications in our cohort. Our study included patients on different 
therapies. It cannot be excluded that the type of treatment negatively affects NK cell phenotype or 
function. However, the most common treatment modalities in our cohort, i.e. methotrexate and 
anti-TNF-α, rather seem to enhance NK cell cytotoxicity and IFN-γ production 37,38. Furthermore, 
there were no substantial differences in therapeutic regimen between NKG2Anorm and high 
patients that could explain the observed functional differences.  
In summary, this study demonstrates the presence of an elevated, functionally active 
NKG2A+ KIR- NK cell population in RA but not PsA, in addition to a different subset of RA patients 
with decreased NK cell functionality. Furthermore, we demonstrated increased KIR expression 
by T cells in both RA and PsA and a higher frequency of CD16+ T cells in RA. These changes in NK 
and T cell phenotype and function may reflect differential pathogenetic involvement; however 
their precise role remains to be determined.   
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supplementary Figure 2. Supplementary Figure 2A: gating strategy. Dot plots showing from left to right: peripheral 
blood lymphocytes (PBLs) gated based on characteristic FSC and SSC properties; selection of singlets; exclusion 
of dead cells on the basis of positive staining for eF780 Fixable Viability Dye; NK cell gate. Supplementary Figure 
2B: NKG2A/KIR NK subsets gating strategy. Subsets were defined as NKG2A-/KIR- (gate A), NKG2A+/KIR- (gate B), 
NKG2A+/KIR+ (gate C), NKG2A-/KIR+ (gate D) within the NK cell gate. Supplementary Figure 2C: NKG2A/KIR NK 
subsets frequency in HD, RA NKG2Ahigh and RA NKG2Anorm patients. Columns represent the mean percentage 
of the mean of triplicate measurements in each HD/patient; error bars show the standard error of the mean (SEM).
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supplementary Figure 1. Supplementary Figure 1A: gating strategy. Left panel: forward (FSC) sideward scatter 
(SSC) dot plot. Cells were gated on peripheral blood lymphocytes (PBLs, gate A) based on characteristic FS and 
SS properties. Middle panel: dot plot showing CD45 staining (y-axis) versus SS within gate A as determined by 
characteristic FSC and SSC properties. Right panel: dot plot showing CD3 (x-axis) and CD56 (y-axis) staining within 
gate B (CD45+ PBLs). Gate C: NK cells (CD3-CD56+); gate D: CD56bright NK cells (CD3-CD56bright); gate E: T cells (CD3+); 
gate F: CD56+ T cells (CD3+CD56+).  Supplementary Figure 1B: Frequencies of CD56bright and CD56dim NK cells within 
NK cells (gate C) of RA patients, PsA patients and HD. Lines represent the median percentages, boxes indicate 
25th and 75th percentiles, and outer whiskers indicate the most extreme data points. 
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a b s t r ac t
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired disease characterized by 
a clone of blood cells lacking glycosyl inostitol phosphatidyl (GPI) anchored proteins at the 
cell membrane. Deficiency of GPI-anchored complement inhibitors CD55 and CD59 on 
erythrocytes leads to intravascular hemolysis upon complement activation. Next to hemolysis, 
another prominent feature is a highly increased risk of thrombosis. Thrombosis in PNH results 
in high morbidity and mortality. Often, thrombosis occurs at unusual locations, with the Budd-
Chiari syndrome being the most frequent manifestation. Primary prophylaxis with vitamin K 
antagonists (VKA) reduces the risk, but does not completely prevent thrombosis. Eculizumab, a 
monoclonal antibody to complement factor C5, effectively reduces intravascular hemolysis and 
also thrombotic risk. As such, eculizumab treatment has dramatically improved the prognosis 
of PNH. The mechanism of thrombosis in PNH is still unknown, but the highly beneficial effect of 
eculizumab on thrombotic risk suggests a major role for complement activation. Additionally, 
deficiency of GPI-anchored proteins (GPI-AP) involved in hemostasis may be implicated. 
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i N t r o d u c t i o N
PNH is a rare disease characterized by chronic intravascular hemolysis and hemoglobinuria, an 
increased risk of thrombosis, and a variable degree of bone marrow failure. The disease is caused 
by an acquired mutation of the X-linked PIG-A gene in the hematopoietic stem cell (HSC). The 
PIG-A gene product is essential for proper assembly of GPI anchors, linking several proteins to 
the cell membrane. Therefore, this mutation results in a clone of blood cells deficient in GPI-AP. 
Lack of GPI-anchored complement inhibitors CD55, and particularly CD59 on erythrocytes results 
in increased sensitivity to complement-mediated lysis. CD55 inhibits C3 convertases and CD59 
prevents the assembly of the membrane attack complex (MAC) at the cell surface. 
The clinical spectrum of PNH is highly variable. It ranges from classic PNH patients with 
large PNH clone sizes, massive hemolysis and a high risk of thrombosis, to patients with 
relatively small clone sizes and only mild or subclinical hemolysis. The latter group often has 
an underlying bone marrow failure disease such as aplastic anemia (AA), resulting in more 
prominent pancytopenia1. 
Especially classic PNH patients suffer from intravascular hemolysis, resulting in anemia, fatigue, 
and hemoglobinuria. Paroxysms result from complement activation above basal levels as occurs 
during infections. Such a hemolytic crisis may enhance hemoglobinuria, and elicit acute renal failure 
and thrombotic events. Thrombosis is one of the most severe complications, seriously affecting 
quality of life, and a major cause of death in PNH 2. Many patients suffer from multiple thromboses in 
vital organs such as liver, brain or gut, sometimes even during anticoagulant prophylaxis 2,3.
The mechanism of thrombosis in PNH is still not elucidated. In this review, we report on 
the current state of knowledge on the pathogenesis of thrombosis and its treatment in PNH. 
Various mechanisms proposed to play a role in thrombosis in PNH will be discussed (summarized 
in Figure 1). Special attention will be given to eculizumab, a monoclonal antibody directed 
to complement factor C5 that efficiently blocks intravascular hemolysis and its sequelae. 
Importantly, strong retrospective evidence suggests that eculizumab reduces thrombotic risk 
in PNH 3 and it is therefore currently regarded as the best known prophylaxis. 
e P i d e m i o lo g y  o F  t H r o m b o s i s  i N  P N H
The cumulative 10-year incidence of thrombosis in a retrospective study of 460 PNH patients was 
31% 2. In another retrospective series of 80 patients, 39% had one or more episodes of either venous 
or arterial thrombosis 4. However, these series included PNH patients diagnosed by less sensitive 
methods than flow cytometry, leading to overrepresentation of PNH patients with larger clones, 
and thus a potential overestimation of thrombotic risk 4,5. On the other hand, as shown by Hill et al. 
subclinical thrombosis is frequent, which implies an underestimation of thrombosis risk. They found 
evidence of subclinical pulmonary embolism or myocardial ischemia in 6 out of 10 patients 6.
The risk of venous thrombosis correlates to PNH granulocyte clone size. The study of Hall et 
al. reported a 44% 10-year risk of venous thrombosis in patients with a PNH granulocyte clone of 
> 50%. In patients with smaller clone sizes this was only 5.8%, which is however still higher than 
in healthy controls 7. Moyo et al. confirmed the association between PNH granulocyte clone 
111
Th
ro
m
bo
sis in
 Pn
h
5
size and thrombosis and estimated an odds ratio of 1.64 for every 10% increase in clone size 8. 
Whether PNH clone size in other lineages also correlates to thrombotic risk is unknown. However, 
for PNH platelet clone size this is expected as it correlates strongly to PNH granulocyte clone 
size 9. Another open question is whether PNH clone size independently increases thrombotic 
risk or via affecting the level of hemolysis. It was never systematically studied what proportion of 
thrombotic events occur during hemolytic crises. However, cases reports provide evidence that 
thrombosis may occur in patients with large clones even when little or no hemolysis is present 10,11. 
A higher risk of venous thrombosis was reported in patients from African-American or Latin-
American descent, and a lower risk in Chinese and Japanese patients 12-14. In Japanese patients, this is 
likely explained by a significantly lower PNH granulocyte clone size compared to western patients 14. 
The risk for arterial thrombosis is probably also increased compared to age-matched healthy 
controls. Ziakas et al. described 38 reports on patients with arterial thrombosis, mainly in the 
central nervous system or coronary arteries, occurring in relatively young patients, with a median 
age of 35 years (range 22-47) for acute coronary syndromes, and 37-41 years (range 11-76) for stroke 
15;16. Three arterial thrombotic events were reported in a cohort of 209 Japanese patients (1.4%) 14, 
none in the series of 220 patients of Socié et al. 5, 8 in the cohort of 80 patients of Hillmen et al. 
(10%) 4, and 7 in our own cohort of 97 patients (7.2%) diagnosed between 1990-2011 (unpublished 
data). In the classic PNH patient population that participated in the various eculizumab trials, 15% 
of pretreatment thrombotic events were arterial, located in either the cerebral vasculature (13.6%) 
or coronary arteries (1.4%) 3. The International PNH registry (www.pnhsource.com), a prospective 
follow-up study including now over 1000 patients worldwide, may provide a more definite answer 
on incidence and prevalence of arterial and venous thrombosis in PNH 17. 
Thrombosis is the most important prognostic factor affecting survival. This accounts even 
more for the subcategory of PNH patients in whom bone marrow failure is prominent (hazard 
Figure 1: Hypothetical mechanisms for thrombosis in PNH. The hemostatic balance is maintained by 
coagulation and fibrinolysis and is influenced by factors derived from the vessel wall and blood cells. Several 
mechanisms have been suggested to determine the direction of the balance towards a prothrombotic state 
in PNH. These include the release of free hemoglobin which activates the endothelium and scavenges nitric 
oxide (NO). In addition, complement-mediated damage of GPI-deficient blood cells may result in the release 
of procoagulant microparticles in the circulation and platelet activation. Lastly, deficiency of GPI-anchored 
fibrinolytic factors such as urokinase Plasminogen Activator Receptor (uPAR), and anticoagulant factors such as 
Tissue Factor Pathway Inhibitor (TFPI) and potentially Proteinase 3, may further disturb the hemostatic balance. 
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ratio for classic PNH 7.8, for AA-PNH 33) 2. Data from several older retrospective studies showed 
that in 22.2% of PNH patients the cause of death is related to thrombosis and in Western European 
patients this proportion was even higher (37.2 %) 18. The extremely high incidence of thrombosis 
in PNH and its major effect on morbidity and mortality underline its clinical importance.  
w H y  i s  t H e  r i s k  o F  t H r o m b o s i s  i N c r e a s e d  i N  P N H ?
Multiple mechanisms have been proposed to explain thrombophilia in PNH (Figure 1); however 
none of these mechanisms on its own sufficiently explains the extremely high thrombotic risk in 
PNH. Below, each mechanism and its proposed relative contribution will be discussed in detail. 
r o l e  o f  t h e  e n d o t h e l i u m
Endothelial cell (EC) damage is an important factor that can contribute to thrombosis. Free 
hemoglobin released from lysed PNH erythrocytes may be directly toxic to EC 19. Alternatively, EC 
damage could result from the uptake of monocyte derived microparticles, which may be released 
from GPI-deficient monocytes upon complement damage and contain tissue factor (TF), thus 
increasing TF expression on EC, as was shown by Aharon et al. 20. In the studies of Simak (n=9) and 
Helley et al. (n=23), EC microparticles with a pro-thrombotic and pro-inflammatory phenotype, 
indicating EC damage, were significantly increased in PNH patients compared to healthy 
controls 21. Levels of EC activation markers von Willebrand factor (vWF) and soluble vascular cell 
adhesion molecule (sVCAM-1) were increased 22;23, whereas others reported normal vWF levels 
and activity in a smaller study 24 . These results suggest endothelial damage or stimulation in PNH, 
either indirectly by free hemoglobin or directly by complement-mediated damage. 
It is yet unknown whether PNH patient EC harbor the PIG-A mutation, and thus are more 
susceptible to complement damage than normal EC. Nevertheless, even in normal EC, the MAC 
upregulates TF expression and adhesion molecules 25. Endothelial progenitor cells can arise from 
the bone marrow (reviewed in 26). In myelodysplastic syndrome, it has been shown that circulating 
EC (CEC) and hematopoietic progenitor cells harbor identical chromosomal abnormalities, 
indicating common origin 27.  Preliminary evidence suggests that also in PNH this may be the case. 
Helley et al. cultured endothelial colony-forming cells (ECFC) from PNH patient mononuclear 
cells and demonstrated CD55 and CD59 deficient populations within these ECFC 23. Further 
research is required to determine whether PNH CEC or ECFC indeed harbor PIG-A mutations, 
and whether and where such cells are incorporated into the endothelium. A recent study on the 
frequency of donor derived EC in various tissues in allogeneic transplant recipients demonstrated 
that only a minority of EC originate from donor HSC 28. A high frequency of GPI-deficient EC in 
PNH thus seems unlikely, which suggests that direct complement damage to GPI-deficient EC 
is relatively less important in endothelial activation. However, studies in liver transplant patients 
showed that recipient-derived EC do repopulate the liver allograft 29. Also, this study showed that 
in bone marrow transplanted mice, in contrast to other organs, the liver endothelium is partially 
or completely composed of donor-derived EC. These results indicate that particularly in the liver, 
there might be a role for GPI-deficient bone-marrow derived EC in PNH. 
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d e f i c i e n c y  o f  t i s s u e  f a c t o r  p a t h w a y  i n h i b i t o r  ( t F P i )  a n d  o t h e r 
g P i -a P  i n v o l v e d  i n  c o a g u l a t i o n
TFPI limits coagulation initiation by inhibiting TF formation. TFPI forms a quaternary complex with 
TF, activated factor VII (FVIIa) and activated factor X (FXa). It is mainly produced by endothelium 
of the microvasculature (85%), but other sources include activated platelets, monocytes and 
plasma. The full length isoform TFPIα is most abundant. It is bound either to glycosaminoglycans 
or to the cell membrane via a yet unidentified GPI-anchored cofactor 30;31. The alternatively spliced 
TFPIβ also binds to the membrane via a GPI anchor; however this variant is absent in platelets 32.
Both TFPI isoforms are upregulated in monocytes upon LPS stimulation and blocking TFPI 
enhances monocyte procoagulant properties 33, as may similarly occur in TFPI-lacking GPI-
deficient monocytes. If GPI-deficient EC are indeed present in PNH, lack of TFPI may render such 
EC procoagulant. However, since HSC derived EC are supposedly infrequent, the contribution of 
TFPI deficient endothelium in PNH related thrombosis is probably limited. On quiescent platelets, 
TFPIα is not expressed. Only upon simultaneous stimulation with collagen and thrombin, these 
highly activated platelets express TFPIα and several other procoagulant proteins, and release 
TFPIα in microvesicles 32. GPI-deficient platelets probably lack surface expression of TFPIα upon 
stimulation, which may further enhance their procoagulant properties.
Another protein expressed on neutrophils involved in hemostasis is proteinase 3 (PR3). This 
enzyme binds to the cell membrane using the GPI-anchored cofactor NB1 (CD177) 34. PR3 is absent 
on GPI-deficient neutrophils and circulating PR3 levels were inversely correlated with granulocyte 
clone size. Jankowska et al. demonstrated that PR3 reduced thrombin induced platelet activation, 
suggesting that lacking PR3 in PNH platelets may promote their activation 35. PR3 also modulates 
coagulation in various other ways, for example via cleavage of the endothelial protein C receptor, 
degradation of TFPI, upregulation of EC TF expression and cleavage of vWF 36-39. The net effect of 
deficient PR3 expression in PNH therefore requires further study.  The exact contribution of missing 
GPI-AP to PNH related thrombosis is unclear. Despite a significant reduction in thrombosis risk 
during eculizumab treatment, the proportion of leukocytes and platelets lacking GPI-AP remains 
unchanged and even increases in erythrocytes, arguing against a major role for GPI-AP deficiency 
itself. Alternatively, patients with congenital deficiency of PIG-M, another gene essential in GPI anchor 
synthesis, frequently suffer from thrombosis but do not have hemolysis 40. This would suggest an 
important contribution of GPI-deficient cells to thrombosis independent from hemolysis; however, 
in these patients all EC are supposedly GPI-deficient, and thus these may be the culprit. 
e f f e c t s  o f  f r e e  h e m o g l o b i n  a n d  n i t r i c  ox i d e  ( N o)  d e p l e t i o n 
Intravascular hemolysis increases free hemoglobin levels. Normally, free hemoglobin is rapidly 
cleared from the circulation by several scavenging mechanisms, such as binding to haptoglobin. 
Excessive intravascular hemolysis saturates these scavengers, resulting in free hemoglobin in 
plasma, which mediates direct pro-inflammatory, proliferative and pro-oxidant effects on EC 
41. Free hemoglobin irreversibly reacts with NO to form nitrate and methemoglobin. Lysed 
erythrocytes release arginase, which catalyzes the conversion of arginine, the substrate for 
NO synthesis, to ornithine. Both processes decrease NO availability. NO normally maintains 
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smooth muscle cell (SMC) relaxation, inhibits platelet activation and aggregation, and has anti-
inflammatory effects on endothelium. Via these mechanisms, decreased NO levels may increase 
thrombotic tendency in PNH (reviewed in 19). Levels of free hemoglobin in PNH patients indeed 
strongly correlate to NO consumption and arginase levels. Correlation of thrombotic events 
with low NO levels was however not tested, as this would require large patient numbers 42. 
In venous thrombosis though, a role for NO depletion is doubtful since veins lack SMC and 
platelets contribute relatively little to venous thrombosis. Its definitive role, particularly in 
arterial thrombosis, still requires further research. 
P l a t e l e t  f u n c t i o n 
Platelet activation has been proposed to play a role in PNH-related thrombosis. Whereas normal 
platelets express both CD55 and CD59, these complement inhibitors lack on PNH platelets 43;44. 
However, while complement destroys PNH erythrocytes, it probably does not directly destroy 
PNH platelets, due to their ability to shed the MAC 45. Thrombocytopenia is frequently found 
in PNH but generally attributed to concomitant bone marrow failure and not to complement-
mediated damage. In two small studies of 16 patients, life span of the total platelet population 
was normal in the majority of patients 46;47. Furthermore, the observation that during eculizumab 
treatment PNH platelet clone size and platelet count remain stable, provides further evidence 
that platelets do not succumb to complement-mediated platelet destruction 9;48;49.
Although complement does not directly destroy platelets, it can induce platelet activation. 
Even on normal platelets, the assembly of MAC results in Factor V secretion from α-granules, 
increased prothrombinase activity and release of platelet microvesicles in vitro 50. As blocking 
CD59 on normal platelets enhances these procoagulant responses 51, a similar response to 
MAC assembly would be expected in GPI-deficient PNH platelets. In vitro studies by Wiedmer 
et al. showed that PNH platelets indeed exposed more factor Va binding sites and increased 
thrombin generation more than normal platelets upon MAC stimulation 52. Ex vivo studies 
provided some evidence for in vivo platelet activation 24, but were not confirmed by others 43;53. 
Adhesion and aggregation studies performed by Grünewald et al. showed impaired function 
of PNH platelets 53, which is potentially explained by reactive downregulation in response to 
chronic hyperstimulation. Together with shedding of the MAC from the platelet membrane by 
vesiculation, other receptors may also be lost, resulting in reduced function. 
m i c r o p a r t i c l e  f o r m a t i o n  
Microparticles are small membrane-derived vesicles that are shed upon activation, inflammation or 
cell damage. Under normal conditions, the plasma membrane is composed of anionic phospholipids 
such as phosphatidylserine (PS) on the inner leaflet, and choline-based phospholipids (sphingomyelin 
and phosphatidylcholine), on the outer leaflet. Membrane asymmetry is lost upon cell stimulation, 
leading to PS exposure on the outer leaflet of the cell membrane, followed by cytoskeleton 
degradation and microparticle release. PS exposure on the surface of either microparticles or 
the cell membrane provides a surface for the assembly of the procoagulant enzyme complexes 
prothrombinase (factor Va/Xa) and tenase (VIIIa-IXa), catalyzing coagulation 54;55.
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Complement activation at the cell surface of GPI-deficient cells may stimulate the release 
of procoagulant microparticles, increasing the risk of thrombosis. Several studies have 
investigated this hypothesis. In vivo, the total level of microparticles exposing PS, as measured 
by a prothrombinase based assay, was higher in PNH patients than in healthy controls. These 
microparticles were predominantly of platelet origin. No correlation was found with PNH clone 
size in any lineage 56. In contrast, Simak et al. used flow cytometry to enumerate PS exposing 
microparticles but did not confirm increased levels in PNH 21. A drawback of these studies is that 
they did not quantify microparticle TF content, which strongly enhances their procoagulant 
properties 57. C5a was shown to induce monocyte TF expression and release of TF containing 
microparticles, a phenomenon which might be enhanced on GPI-deficient leukocytes. Simak 
et al. however found normal leukocyte derived microparticle levels, albeit monocyte origin was 
not specified 21. A case report of two PNH patients with severe recurrent thrombosis did show 
increased levels of circulating leukocyte derived TF compared to healthy controls 58. 
In vitro, PNH platelets release significantly more microparticles than normal platelets upon 
MAC stimulation, as was shown by Wiedmer et al. 52. In vivo though, platelet microparticle 
numbers were not significantly different from healthy controls, although variability among 
patients was consistently higher than among healthy donors. This implies that a subgroup of 
patients may have higher microparticle concentrations 21;56. 
Remarkably, the level of erythrocyte microparticles was similar in PNH patients and healthy 
controls 21;56. However, in vitro experiments did show that PNH erythrocytes release higher amounts 
of procoagulant microparticles upon complement stimulation 59;60. The fact that these microparticles 
are not readily detected in vivo may suggest a rapid clearance from the circulation. 
The predictive value of microparticle levels for thrombosis in PNH is unknown. In patients 
with deep venous thrombosis (DVT) and pulmonary embolism levels of TF containing 
microparticles were not elevated 61;62. In cancer patients though, TF containing, but not PS 
expressing microparticles did predict thrombosis 63;64. If relevant in PNH, this probably accounts 
most for TF containing microparticle levels; however these are unknown so far. 
F i b r i n o l y s i s  a n d  a n t i c o a g u l a t i o n
Impairment of fibrinolysis or anticoagulation can increase thrombotic tendency. Such impairment 
may result from deficiency of the GPI-anchored urokinase plasminogen activator receptor (uPAR, 
CD87). uPA converts plasminogen into plasmin and in doing so, is involved in fibrinolysis and 
degradation of extracellular matrix during tissue remodeling and cell migration. Binding of uPA to 
uPAR enhances plasmin formation and via this mechanism fibrinolysis remains localized pericellularly. 
uPAR is indeed deficient on PNH leukocytes and platelets 65;66. Plasma levels of soluble uPAR are higher 
than in healthy controls and correlate to PNH granulocyte clone size 65-67, suggesting that uPAR 
without GPI anchor cannot bind the cell membrane. Thus, it may be released from GPI-deficient cells 
and compete with membrane-bound uPAR for binding of uPA 68. The resulting decrease in local uPA 
availability could increase thrombotic risk in PNH. In a study of 78 patients, high soluble uPAR levels 
were independently associated with thrombotic risk 66. Arguing against a role for uPAR deficiency 
though is the finding that uPAR deficient mice do not display spontaneous thrombosis 69.
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Studies that measured other fibrinolysis parameters in PNH report conflicting results and 
do not unanimously fit with global fibrinolysis impairment as may result from uPAR deficiency 
22-24. Gralnick and Helley et al. found normal levels of fibrinolysis inhibitors α
2
-antiplasmin, 
plasmin-antiplasmin complexes (PAP) and plasminogen activator inhibitor-1 (PAI-1), and of 
the fibrinolysis activator tissue plasminogen activator (tPA) 23;24. In contrast, Grünewald et al. 
demonstrated a slightly lower level of plasminogen, higher levels of D-dimer and the fibrinolysis 
activation markers PAP and tPA-PAI-1 complexes, suggesting active fibrinolysis. These changes 
were inversely correlated to clone size, pointing to progressive impairment in patients with 
higher clone sizes 22. Thrombin activatable fibrinolysis inhibitor (TAFI) thrombomodulin, and 
anticoagulant proteins antithrombin, protein C and S levels were normal in PNH patients 22-24.
role of  the various mechanisms in the local ization of  thrombosis 
in  PNH 
An intriguing but still unresolved question in the pathophysiology of PNH-related thrombosis 
is its predilection for the venous system, in particular in the abdomen and brain. The most 
frequent manifestation is the Budd-Chiari syndrome (41-44% of PNH patients with thrombosis). 
Other frequently affected sites include other intra-abdominal veins, intradermal veins, the 
central nervous system and the limbs 2;5;15;18.  
The key to this question likely involves EC specific pro- and anticoagulant properties, 
which are highly variable in different vascular beds (reviewed in 70;71). The specific localization 
of thrombosis in PNH underlines that the endothelium is probably a major contributor. For 
example, TFPI is preferentially expressed in microvasculature. High TFPI mRNA levels are found 
in human lung and liver tissue, and murine brain EC 70;72. If GPI deficient EC are present in these 
tissues, lacking TFPI may have a great effect. 
The various mechanisms implied in PNH related thrombosis may differentially affect 
vascular beds. NO depletion likely promotes arterial thrombosis via its effects on SMC and 
platelet activation and not, or to a lesser extent venous thrombosis. Bacterial and food antigens 
present in the mesenterial and portal veins may locally activate complement resulting in a higher 
hemolytic rate and consequent endothelial damage, platelet activation and microparticle 
release, and possibly also in direct complement-mediated damage to GPI-deficient EC. 
F r e q u e n c y  o f  c o n g e n i t a l  a n d  a c q u i r e d  t h r o m b o p h i l i a  f a c t o r s  
i s  n o t  i n c r e a s e d  i n  P N H
There is no evidence that the prevalence of known genetic factors predisposing for thrombosis 
is increased in PNH patients. The frequency of Factor V Leiden in 66 PNH patients was similar 
to healthy controls 73. Other studies reported normal levels of antithrombin, protein C, protein 
S and homocystein in small series of PNH patients, and again similar frequencies of factor V 
Leiden, methylenetetrahydrofolate reductase (MTHFR), and prothrombin mutations 74;75. In 
another study of 16 patients, 1 had factor V Leiden, 1 had a heterozygous prothrombin mutation, 
and two patients had a homozygous MTHFR mutation 22. Of these patients with congenital 
thrombophilia factors, 2 experienced thrombotic events, compared to 2 of 12 patients without 
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thrombophilia. Although the frequency of genetic thrombophilia factors in PNH is apparently 
not increased in these relatively small studies, testing for such factors may identify PNH 
patients at additional risk. However, the value in unselected patients with venous thrombosis 
in predicting thrombosis recurrence is limited 76. Its value for treatment decisions in PNH is 
unknown and thus, we do not recommend routine testing. 
Lupus anticoagulans was not found in two studies of in total 26 patients, including patients 
with a history of venous thrombosis 22;77. Dragoni et al. found antiphospholipid (APL) antibodies 
in 5 patients with, and 3 patients without thrombosis in a series of 13 PNH patients, whereas in 
the study of Darnige et al. APL were present in only 3/20 patients  75;77.  Again, patient numbers 
are small and do not allow definitive conclusions. 
The JAK2-V617F mutation is frequently found in myeloproliferative diseases (MPD). Similar to 
PNH, MPD is associated with a high risk of thrombosis at similar locations, raising the question 
whether the JAK2-V617F mutation is involved in PNH as well. No JAK-V617F mutations were found 
by Fouassier et al. in 11 PNH patients with varying clone sizes (range 0.5-92%), including 3 patients 
with thrombosis 78, while Sugimori et al. reported 3 classic PNH patients with JAK-V617F mutations 
among 21 PNH patients with Budd-Chiari syndrome 79. Interestingly, the JAK-V617F mutation was 
only found in PIG-A mutated and not in normal cells. More research on this aspect is warranted.
P r e v e N t i o N  a N d  t r e atm e N t  o F  t H r o m b o s i s  i N  P N H
a n t i c o a g u l a n t  p r o p h y l a x i s
Due to the rarity of the disease, no randomized trials evaluating the effect of anticoagulant 
treatment on the risk of thrombosis have been performed. Hall et al. retrospectively compared 
the frequency of thrombosis in PNH patients with large granulocyte clone sizes (> 50%) between 
those with and without primary prophylaxis with warfarin. They found no thromboembolic 
events in 30 patients taking warfarin, whereas in 39 patients without prophylaxis, the 10-year 
thrombosis rate was 36,5% 7. Although these data suggest that warfarin effectively reduces 
thrombotic risk in PNH, it also represents a risk of bleeding in PNH patients who frequently 
have concomitant thrombocytopenia. In the study of Hall et al., two serious hemorrhages 
were reported in 39 patients on warfarin 7. Nevertheless, this study was the basis for the 
recommendation of the International PNH interest group to consider vitamin K antagonist 
prophylaxis in patients with a PNH granulocyte clone > 50% and no contraindications for 
prophylaxis 1. Literature on the efficacy of anti-platelet agents such as acetyl salicylic acid and 
glycoprotein IIb/IIIa receptor antagonists in preventing arterial thrombosis in PNH is non-
existent, although PNH platelets may have a role in the pathophysiology of thrombosis in PNH.
tr e a t m e n t  o f  t h r o m b o s i s  i n  P N H  p a t i e n t s
PNH patients with a proven venous thrombosis should be treated initially with low molecular 
weight heparin and VKA, according to regular practice for other patients with venous thrombosis. 
Until now, lifelong anticoagulation is recommended for such patients. In rare cases, radiologic 
intervention has been considered in patients with acute onset of the Budd-Chiari syndrome 1. 
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In a series of 15 Budd-Chiari patients, a transjugular intrahepatic portosystemic shunt (TIPS) was 
placed successfully in 6/7 eligible patients 80; however TIPS placement may be associated with 
additional complement activation and does not resolve thrombosis. Thrombolytic therapy with 
tPA can be an alternative in potentially life-threatening thrombotic events, especially when a 
response to conventional anticoagulation is lacking. Araten et al. described 9 patients in whom 
tPA treatment resulted in resolution of the thrombus. However, in one patient, bleeding may 
have contributed to a fatal outcome 81;82. Since eculizumab has been observed to abrogate a 
cascade of thrombotic events, prompt initiation of eculizumab may be attempted, as this is a 
much safer strategy in view of the substantial bleeding risk associated with thrombolysis 83. The 
role of other anticoagulants such as the newly developed thrombin inhibitors in treatment or 
secondary prophylaxis of thrombosis has not been investigated. 
e c u l i z u m a b
The availability of the humanized anti-C5 monoclonal antibody eculizumab has dramatically 
changed the treatment and prognosis of PNH. It effectively reduces hemolysis, hemoglobinuria, 
transfusion requirements, and anemia. In addition, symptoms attributed to hemolysis, such as 
smooth muscle dystonias, pulmonary hypertension and kidney function improved as well, leading 
to higher quality of life 42;48;84-88. Preliminary data also suggest increased life expectancy 49. Though 
only retrospectively studied with limited follow-up, the rate of thromboembolic events was also 
highly significantly reduced during eculizumab treatment in comparison to pretreatment rates 
in the same cohort of PNH patients 3. The event rate in eculizumab treated patients was 1.07/100 
patient years, versus 7.37/100 patient-years in the same patients pre-treatment (p < 0.001).
P r o p o s e d  e f f e c t  o f  e c u l i z u m a b  o n  h e m o s t a s i s  i n  P N H
Eculizumab treatment lowered plasma levels of coagulation activation markers (prothrombin 
fragment 1 and 2), markers of fibrinolysis (D dimer and PAP), and markers of EC activation (t-PA, 
sVCAM-1, vWF and total and free TFPI) 23;89. The reduction in thrombotic risk in eculizumab 
treated PNH patients suggests a major role for complement activation in the pathogenesis of 
thrombosis in PNH. By blocking C5, PNH platelet activation, damage and microparticle release 
may be reduced. Moreover, eculizumab effectively reduces intravascular hemolysis, and thus free 
hemoglobin levels and NO consumption. It may therefore prevent the detrimental effects of free 
hemoglobin on the endothelium, and restore the inhibition of platelet activation and aggregation 
by NO. Unexpectedly though, eculizumab treatment did neither change the total number of PS 
exposing microparticles, nor of EC derived microparticles, further underlining that microparticles 
probably do not play a major role 23. However, a decrease in TF-containing microparticles may 
have been missed by using a prothrombinase-based assay to enumerate microparticles. 
eculizumab in the prevention and treatment of  thrombosis  in  PNH
The major decrease in thromboembolic event rate and improvement in several hemostatic 
parameters in eculizumab treated patients raises the question whether patients on eculizumab 
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without a history of thrombosis still require additional anticoagulant prophylaxis, especially in 
thrombocytopenic patients at risk for bleeding. A randomized controlled clinical trial comparing 
the incidence of thrombosis in eculizumab treated patients without a history of thrombosis with 
and without VKA was never performed. Kelly et al. reported having stopped warfarin prophylaxis 
in 21 patients on eculizumab who never had thrombosis. None of these patients has developed 
thrombosis while on eculizumab (mean follow-up 10.8 months) 49. Although currently few clinical 
data are available, discontinuation of VKA in patients without a history of thrombosis may be 
justified. The international PNH registry may provide more data on this topic. 
A thrombotic event in PNH is now generally considered as a strong indication for 
prompt initiation of eculizumab treatment 81;90. Whether after a thrombotic event additional 
anticoagulant prophylaxis should be continued lifelong in eculizumab treated patients to prevent 
recurrence is still a matter of debate. Until now, only anecdotal evidence that discontinuation 
of anticoagulant treatment is safe has been reported in 3 patients on eculizumab with a history 
of venous and arterial thrombosis (follow-up 10-42 months) 91. On the other hand, recurrence 
of thrombosis during treatment with both eculizumab and warfarin in a patient with a history 
of thrombosis prior to eculizumab has also been reported 49. Such cases again illustrate that 
VKA, but also eculizumab do not offer full protection from recurrent thrombosis, and VKA 
discontinuation should be carefully considered.
s u m m a ry  a N d  c o N c l u s i o N
Thrombosis risk is highly increased in PNH and correlates to PNH clone size. The development 
of thrombosis is one of the most important factors negatively influencing survival. Thrombotic 
events in PNH, for reasons not yet understood, have a predilection for unusual locations in the 
venous system such as the abdomen and the central nervous system. Its pathogenesis is still 
not understood but is likely multifactorial. A major contributor is probably endothelial damage 
by free hemoglobin and possibly by complement itself. Though difficult to investigate, the 
presence and localization of GPI-deficient EC is a key question to be answered in future research. 
Deficiencies of other GPI-AP involved in coagulation, such as uPAR and less well characterized 
proteins in PNH such as TFPI and PR3, possibly add to thrombotic risk. Although extensively 
investigated, the role of complement-mediated procoagulant microparticle release is less well 
established. Lastly, NO depletion is probably particularly relevant in arterial thrombosis.  
Treatment and prevention of thrombosis in PNH is difficult, as prospective studies are 
lacking and even during anticoagulant treatment some patients develop multiple events. 
Eculizumab has dramatically improved PNH quality of life and likely reduces thrombotic risk, 
highlighting the major role for complement or complement-mediated hemolysis in thrombosis 
in PNH. Although great progress has been made, important questions remain unanswered: 
how can we predict which patients will suffer from thrombosis and why does thrombosis occur 
at unusual localizations? Future research is highly needed to provide these answers. 
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a b s t r ac t
Paroxysmal Nocturnal Hemoglobinuria (PNH) is characterized by complement-mediated 
hemolysis and a high risk of thrombosis. Eculizumab, an antibody to complement factor 
C5, inhibits hemolysis and reduces thrombotic risk. The role of neutrophils in PNH-related 
thrombosis is unknown. Activated neutrophils release highly procoagulant neutrophil 
extracellular traps (NETs) which have been implicated in the pathogenesis of thrombosis. 
We have assessed elastase-α1-antitrypsin (EA) complexes and circulating nucleosomes as 
markers of neutrophil activation and NET formation in 51 untreated PNH patients, including 20 
patients who were also assessed during eculizumab treatment.  Nucleosomes (median; range), 
but not EA complexes, were higher in PNH patients with a history of thrombosis (16; 7-264 U/
ml, n = 12) than in those without (6; 6-35 U/ml, n = 39, p < 0.001) or controls (6; 6-23 U/ml, n 
= 17, p < 0.05). Both nucleosomes and EA complexes decreased promptly and markedly upon 
eculizumab treatment (p < 0.01). EA complexes remained low at ≥12 weeks (p < 0.05). 
Increased nucleosome levels in PNH patients with a history of thrombosis may suggest 
enhanced NET formation. The prompt and persistent decrease in EA complexes during 
eculizumab treatment suggests inhibition of neutrophil activation. This may lower susceptibility 
for NET formation, which possibly represents an additional mechanism via which eculizumab 
could reduce thrombotic risk. 
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i N t r o d u c t i o N
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare heterogeneous disease in which 
uncontrolled complement activation causes hemolysis. In addition, PNH is characterized by 
an extremely high risk of thrombosis. It is caused by an acquired mutation in the PIG-A gene 
in a hematopoietic stem cell, encoding an essential enzyme in the synthesis of glycosyl-
phosphatidyl-inositol (GPI) anchors. All cells derived from this stem cell therefore lack proteins 
tethered to the cell membrane via a GPI anchor. Deficiency of GPI-anchored complement 
inhibitors CD59 and CD55 on erythrocytes is responsible for complement-mediated intravascular 
hemolysis and associated symptoms. The implications of deficiency of GPI-anchored proteins 
on other hematopoietic cells derived from the PNH stem cell are less well known. 
Eculizumab, a monoclonal antibody to complement factor C5, effectively reduces hemolysis 
and its symptoms and sequelae 1-3. Before the introduction of eculizumab the estimated 
cumulative 10-year incidence of thrombosis in PNH was 23-31% 4,5. The risk of thrombosis is 
higher in patients with a larger clone size but thrombosis occurs in patients with a smaller 
clone size as well 4,6. Thrombosis (arterial and venous) is the major cause of death in PNH and 
frequently occurs in vital organs such as the liver, intestine or central nervous system, with 
the Budd-Chiari syndrome as the most common manifestation 5,7-10. Primary prophylaxis with 
vitamin K antagonists (VKA) reduces the risk, but nevertheless serious thrombotic events still 
occur 4,5. Thrombotic events in PNH are impossible to predict; it is a presenting symptom in 7.2% 
of patients 5 but can also occur many years after presentation 4. Patients who have suffered one 
thrombotic event are prone to develop other thrombotic events 5. 
Eculizumab is the only available treatment that highly significantly reduces the risk of 
thrombosis in PNH 3. Moreover, case reports suggest that progressive thrombosis, as is 
often observed in PNH, can be abrogated and organ damage reduced by prompt initiation of 
eculizumab treatment 11,12. These observations strongly suggest a role of complement in the 
triggering and progression of arterial and venous thrombosis in PNH.  Thrombosis in PNH is 
likely multifactorial and its pathophysiology (reviewed by Hill 13 and van Bijnen 14) is still unknown. 
Little is known about a possible role of PNH neutrophils in the pathogenesis of PNH-related 
thrombosis. Complement on the surface of normal neutrophils causes their activation 15. Complement-
induced activation of PNH neutrophils is likely enhanced compared to normal neutrophils due to 
deficiency of the complement inhibitors CD55 and CD59. Whereas PNH erythrocytes are lysed upon 
complement activation, PNH neutrophils are probably resistant, as their life span is presumed to 
be normal 16 and neutrophils are capable of shedding the membrane attack complex (MAC) from 
their surface 15. Normal neutrophils release neutrophil extracellular traps (NET) upon activation 17-19. 
During NET formation, DNA and DNA-binding proteins are extruded exposing a mesh consisting 
of nucleosomes, histones and proteases such as elastase 17. Besides a role in microbial killing 20, 
NETs may play a role in coagulation as they form a platform for platelet adhesion, activation and 
aggregation 21. A possible role of NET formation in deep venous thrombosis (DVT) and thrombotic 
microangiopathies was recently shown in both murine and human studies 22-24. NET formation may 
be induced by various stimuli, including complement factor C5 25 and free heme, as was shown in a 
recent study in sickle cell disease 26. These stimuli may induce NET formation in PNH as well. 
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Whether neutrophil activation is enhanced in PNH and contributes to the extreme 
thrombophilia in PNH is unknown. We have assessed neutrophil activation by determining 
plasma levels of elastase-α1-antitrypsin (EA) complexes and circulating nucleosomes as 
established markers of NET formation as published by Fuchs et al. 21. These parameters were 
studied in a large cohort of untreated PNH patients with and without a history of thrombosis 
and in patients before and during treatment with eculizumab.
Pat i e N t s  a N d  m e t H o d s
P a t i e n t s  a n d  s a m p l i n g
A cohort of 51 PNH patients was studied between 2006 and 2011. Twelve patients had a history of 
one or more thrombotic events. Twenty patients commenced eculizumab treatment. None of these 
patients developed thrombosis since commencement of eculizumab treatment. Eculizumab was 
given intravenously at standard doses of 600 mg weekly for 4 weeks and 900 mg biweekly as of week 
5. All participants provided written informed consent in accordance with the Declaration of Helsinki. 
Peripheral blood samples were collected in 7.5% ethylenediaminetetraacetic acid (EDTA). 
At the time of sampling, none of the patients had serious infections. In eculizumab-treated 
patients samples were drawn immediately before and at 1 and 2 hours after the start of the 
first eculizumab infusion. Follow-up samples were drawn immediately before subsequent 
eculizumab infusions at 1, 4 and ≥ 12 weeks. Control blood samples were collected from 17 healthy 
volunteers. Samples were centrifuged at 4oC for 15 min at 2000g within 1 hour. Subsequently, 
plasma was aliquoted and stored at -80 oC.
N u c l e o s o m e  e n z y m e - l i n k e d  i m m u n o s o r b e n t  a s s a y  ( e l i s a )
Nucleosome levels were measured using ELISA as described previously 27. Briefly, monoclonal 
antibody CLB-ANA/60 (Sanquin, Amsterdam, the Netherlands), which binds histone 3, was used as 
a catching antibody. Biotinylated F(ab)2 fragments of monoclonal antibody CLB-ANA/58 (Sanquin), 
recognizing an epitope exposed on complexes of histone 2A, histone 2B and dsDNA, in combination 
with poly-horseradish peroxidase-labeled streptavidin (Sanquin) was used for detection. As a 
standard we used supernatant of apoptotic Jurkat cells (1*106 cells/ml). One unit is defined the 
amount of nucleosomes released by approximately 100 Jurkat cells. The lower detection limit of the 
assay is 6 U/ml. The inter- and intra-assay coefficient of variation is 8.5%% and 4.3%, respectively.
e l a s t a s e -α
1
- a n t i t r y p s i n  ( e a )  c o m p l e xe s 
Elastase-α
1
-antitrypsin (EA) complexes were measured by ELISA, adapted from a previously 
described radioimmunoassay 28. Briefly, plates were coated with a polyclonal rabbit anti-human 
neutrophil elastase antibody (1.5 μg/ml; Sanquin). Samples were diluted in high-performance ELISA 
buffer (HPE) (Sanquin). Bound complexes were detected by a biotinylated monoclonal anti-α
1
-
antitrypsin antibody (1 μg/ml) and poly-horseradish peroxidase-labeled streptavidin. Results were 
expressed in ng/ml by reference to a standard curve of EA complexes generated in normal human 
citrated plasma by incubation for 15 minutes at room temperature with porcine elastase (final 
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concentration 2 μg/ml, Sigma Zwijndrecht, the Netherlands). The lower detection limit of the assay 
was 5 ng/ml. Inter- and intra-assay coefficients of variation were 9.5% and 5.7%, respectively.
s t a t i s t i c a l  a n a l y s i s
Data are expressed as medians ± ranges or means ± standard error of the mean. Mann-
Whitney-U test was used to compare PNH patients and healthy controls. More than 2 groups 
of data were compared using the Kruskal-Wallis test, and if significant, further evaluated 
using Dunn’s test for multiple comparisons. Correlations between nucleosomes, EA complex 
levels, LDH and PNH granulocyte clone size were assessed by the Spearman rank test. To study 
changes in nucleosomes and EA complex levels upon eculizumab treatment, Wilcoxon signed 
rank test was used. P values below 0.05 were considered statistically significant.
r e s u lt s
P a t i e n t  c h a r a c t e r i s t i c s
Clinical data regarding PNH granulocyte clone size, LDH level, history of thrombotic events and 
current anticoagulant treatment at the time of this study for 51 PNH patients are summarized in 
Table 1. Median time (range) since diagnosis of PNH in patients with (n = 12) and without a history 
of thrombosis (n = 39) was 8 (1-33) and 2 (0.2-24) years respectively. The median (range) interval 
between the most recent thrombotic event and the time of sampling was 7.5 (0-240) months. 
c i r c u l a t i n g  n u c l e o s o m e s  a n d  e a  c o m p l e xe s  i n  P N H  p a t i e n t s 
n o t  t r e a t e d  w i t h  e c u l i z u m a b
To determine whether yet untreated PNH patients have enhanced neutrophil activation, we have 
compared EA complex and circulating nucleosome levels between patients and healthy controls. EA 
complex levels (median; range) did not differ significantly between PNH patients (22; 5-263 ng/ml) 
and controls (24.8; 15.8-44.2 ng/ml) (Figure 1A). The level of circulating nucleosomes (median; range) 
was also comparable in PNH patients (7.0; 6-264 U/ml) and controls (8.1; 6-22.7 U/ml) (Figure 1B). EA 
complexes and nucleosomes in PNH patients correlated significantly with each other (Spearman 
correlation coefficient 0.38, p 0.008, Supplementary Figure 1A). EA complexes (Supplementary Figure 
1B), but not nucleosomes (Supplementary Figure 1C), correlated with LDH levels, albeit weakly (r 0.4, 
p 0.004). No correlations were found between PNH granulocyte clone size or neutrophil counts 
with either EA complex (Supplementary Figure 1B) or nucleosome levels (Supplementary Figure 1C). 
No differences were found in EA complex levels or nucleosomes between patients treated with and 
without VKA or low-molecular weight heparins (LMWH) (data not shown). 
Interestingly, in PNH patients who were not (yet) on eculizumab, levels of circulating 
nucleosomes (median; range) were higher in patients with a history of thrombosis (n = 12; 16; 7-264 
U/ml) than in those without (n = 39; 6; 6-35 U/ml) (p < 0.001) and healthy controls (n = 17; 6; 6-23 U/
ml) (p< 0.05) (Figure 2A, left panel). The concentration of nucleosomes was inversely correlated to 
the interval between sampling and the thrombotic event (Spearman rank -0.72, p = 0.009, Figure 2A, 
right panel). EA complexes did not differ between patients with and without thrombosis (Figure 2B).
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ea complex and nucleosome levels during treatment with eculizumab 
Twenty of 51 PNH patients commenced eculizumab treatment during our study. These patients 
differed significantly from patients who did not (yet) commence eculizumab in median PNH 
granulocyte clone size (83% versus 52%, p 0.0005), LDH level (2222 versus 1032 IU/l, p = 0.001) and 
percentage of patients on VKA and/or LMWH (65% versus 29%, p 0.02, Fisher’s exact test) (Table 1). 
Upon treatment with eculizumab, EA complex and nucleosome levels significantly decreased, 
starting as early as 1 hour after the start of the first dose of eculizumab (p = 0.002 and p = 0.0038, 
respectively) (Figure 3A). EA complexes, but not nucleosomes, remained significantly below 
baseline at ≥12 weeks (p 0.0023) (Figure 3A). Within the cohort of patients who commenced 
eculizumab treatment, patients with a history of thrombosis had significantly higher baseline 
nucleosome levels (n = 9; median 25; range 6-264 U/ml) than patients without (n = 11; 6; 6-101 U/
ml; p = 0.026) (Figure 3B). No such difference was found for EA complex levels (Figure 3B). As early 
as 1 hour after the start of eculizumab treatment, EA complexes significantly decreased in both 
patients with and without a history of thrombosis (p < 0.05), whereas for nucleosomes this was 
only the case in the thrombosis group (p = 0.023, Figure 3B). During eculizumab treatment, only 
table 1 clinical features of PNH patients at the time of sampling
all patients
Patients not  
treated with 
eculizumab
Patients who 
commenced eculizumab 
during our study
No 51 31 20
Median age, y (range) 38 (13-82) 37 (19-82) 44 (14-81)
M/F (%) 28/23 (55/45%) 14/17 (45/55%) 14/6 (30/70%)
Median PNH granulocyte clone size, % (range) 62% (5-100%) 52% (5-100%) 83% (50-100%)
Median LDH level, IU/l (range) 1361 (217-7549) 1032 (217-7549) 2222 (550-4661)
Median absolute neutrophil count, *109/l (range) 2.1 (0-8.8) 2.2 (0-7) 1.7 (0.5-6.7)
No of thrombotic events (No of patients)
Arterial:
Central nervous system
Ischemic colitis
Myocardial infarction
Venous:
Deep venous thrombosis
Budd-Chiari/portal vein 
Pulmonary embolism
Mesenteric veins
Subclavian vein
16 (12)
2
1
1
4
4
1
2
1
4 (3)
1
0
1
1
1
0
0
0
12 (9)
1
1
0
3
3
1
2
1
Current anticoagulant treatment (No, %):
None
VKA
ASA
LMWH
26 (51%)
19 (37%)
3 (6%)
3 (6%)
20 (64%)
9 (29%)
2 (6%)
0
6 (30%)
10 (50%)
1 (5%)
3 (15%)
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EA complex levels but not nucleosomes remained significantly decreased in both patients with 
and without thrombosis compared to baseline at ≥12 weeks of eculizumab treatment (p < 0.05). 
d i s c u s s i o N 
In this study, we have assessed markers of neutrophil activation and nucleosomes as markers 
for NET formation in a large heterogeneous cohort of PNH patients, with different clone sizes, 
clinical course, and with and without history of thrombosis. In addition, we have investigated 
whether eculizumab treatment affected these markers. 
Compared to PNH patients who never had thrombosis and healthy controls, we found 
significantly elevated nucleosomes in PNH patients with a history of thrombosis. These findings are in 
line with high nucleosome levels in a baboon model of DVT 21 and in humans with DVT, and may reflect 
enhanced NET formation in PNH 23. Although the kinetics of nucleosome release are unknown, in 
some patients nucleosomes remained high long after the thrombotic event. These data may suggest 
that circulating nucleosomes reflect ongoing subclinical thrombosis, which is known to be a frequent 
complication in PNH 29, and hence may indicate an even more thrombosis prone phenotype. 
Our study showed comparable levels of EA complexes in PNH patients, either with or without 
history of thrombosis, and healthy controls, arguing against enhanced neutrophil activation in 
Figure 1: ea complexes and nucleosomes in PNH patients are similar to healthy controls. Median levels of 
neutrophil elastase-α1-antitrypsin (EA) complexes (Figure 1A) and circulating nucleosomes (Figure 1B) in PNH 
patients not treated with eculizumab (n=51) compared to healthy controls (n=17). 
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PNH patients. The same holds true for lactoferrin levels, another marker of neutrophil activation 
(data not shown). Possibly, enhanced neutrophil activation in PNH patients may only be apparent 
in the presence of additional triggers of complement activation such as infections. In our patient 
cohort, this was not the case. The absence of strong neutrophil activation despite increased 
nucleosomes in PNH patients with a history of thrombosis is in contrast with the study of van 
Montfoort et al.23. They demonstrated increased levels of both EA complexes and nucleosomes 
in patients with DVT. This discrepancy is most likely explained by the fact that we were not able 
to sample during the very acute stage of thrombosis (6/12 patients were sampled more than 3 
months after the thrombotic event). It is important to realize that there is scarce data on the 
kinetics of nucleosome and elastase release from NET in vivo. Most probably, the kinetics of these 
2 markers are different. Upon NET formation, DNA is expelled from the activated neutrophil in 
the form of a mesh consisting of DNA strands, nucleosomes and neutrophilic proteases non-
covalently bound to the DNA strands. One might argue that the half-life of EA complexes is much 
shorter as compared to nucleosomes, since non-covalently bound neutrophilic proteases are 
much easier released from NET as compared to nucleosomes because the release of the latter 
is critically dependent on local DNAse activity 30,31. In addition, it is still a challenge to determine 
the cellular source of nucleosomes. Upon the formation of a thrombus, nucleosomes may be 
released by activated leucocytes such as monocytes or NET-forming neutrophils incorporated 
Figure 2: Nucleosomes, but not ea complexes, are elevated in PNH patients with a history of thrombosis. 
Figure 2A: Left panel: Median levels of circulating nucleosomes in PNH patients not treated with eculizumab 
with a history of thrombosis (n=12) compared to those without (n=39) and healthy controls (n=17). Right panel: 
Correlation between the time elapsed since the thrombotic event and the level of circulating nucleosomes. 
Figure 2B: Median levels of circulating neutrophil elastase-α1-antitrypsin (EA) complexes in PNH patients not 
treated with eculizumab with a history of thrombosis compared to those without and healthy controls. 
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into the thrombus, as well as by cell death of parenchymal and endothelial cells as a consequence 
of thrombosis. In conclusion, the current data argue against a prominent role of neutrophil 
activation in later stages of thrombosis in PNH patients. However, a role of neutrophil activation 
in the acute pathogenesis of thrombosis cannot definitively be ruled out by our data. 
Treatment with eculizumab effectively reduces hemolysis and thrombotic risk in PNH 
patients 2;3. Interestingly, although similar EA complex levels in untreated patients and healthy 
controls argue against marked neutrophil activation in PNH, levels did decrease promptly 
and persistently upon initiation of eculizumab. This was neither explained by a decrease in 
neutrophil counts upon eculizumab treatment, nor did patients who commenced eculizumab 
treatment have higher EA complex levels than those who did not or healthy controls (data not 
shown). This observation suggests that the steady-state level of neutrophil activation, equally 
present in both PNH patients and controls, is further reduced by blocking C5a. Although we 
did observe a short-term decrease in nucleosomes upon eculizumab treatment already after 
1 hour, this decrease did not persist at later time points. Since neutrophil activation at later 
time points is completely suppressed, nucleosomes detected at these time points in some 
Figure 3: ea complex and nucleosome levels  before and during eculizumab treatment. Mean levels of 
neutrophil elastase-α1-antitrypsin (EA) complexes and circulating nucleosomes immediately before and at 
various time points during eculizumab treatment. t = 0: immediately before start of eculizumab treatment, t 
= 1: 1 hour, t = 2: 2 hours, t = 3: 1 week, t = 4: 4 weeks and t = 5: ≥ 12 weeks after start of eculizumab treatment 
respectively. Data points and error bars represent means and (upper range of) SEM respectively. Figure 3A: all 
PNH patients (n=20). Figure 3B: PNH patients with a history of thrombosis (●; n=9) compared to those without 
(■; n=11). * p < 0.05 compared with t =0, in the total patient group (A) or in patients with thrombosis (B). ** p < 
0.01 compared with t=0. # p < 0.05 compared with t=0 in patients without thrombosis. † p < 0.05 for patients with 
thrombosis compared to patients without thrombosis at t=0. 
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of the patients might result from cell death of other hematopoietic- and/or parenchymal 
cells. Our present data argue against a significant role of  marked neutrophil activation in the 
pathogenesis of thrombosis in PNH. However, it is important to realize that the contribution 
of low-grade neutrophil activation to the development of thrombotic complications is largely 
unknown. Therefore it cannot be ruled out that reduction of the basal neutrophil activation by 
eculizumab contributes to attenuation of the prothrombotic state, for example by increasing 
the threshold for NET formation. In addition, it remains to be established whether the decrease 
of neutrophil activation upon C5 blockade further enhances susceptibility for encapsulated 
micro-organisms during eculizumab treatment 2,32. 
This is the first study that has assessed markers of neutrophil activation and nucleosomes, 
their association with thrombosis and the effect of eculizumab treatment in patients with 
PNH. We demonstrate that nucleosomes might be used as a marker for thrombosis in PNH 
patients. Our data argue against a marked activation of neutrophils in PNH patients with and 
without thrombosis. However, we show that eculizumab significantly decreases EA complexes 
indicating that steady-state neutrophil activation is C5a driven.
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supplementary Figure 1a: dot plots of ea complex levels (ng/ml) versus nucleosomes (u/ml). Supplementary 
Figure 1B-1C: PNH granulocyte clone size (%), LDH levels (IU/L) and absolute neutrophil counts (*109/l) versus EA 
complex levels (ng/ml; 1A) or nucleosomes (U/ml; 1B). 
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a b s t r ac t
background: Paroxysmal Nocturnal Hemoglobinuria is characterized by complement-
mediated hemolysis and an increased thrombosis risk. Eculizumab, an antibody to complement 
factor C5, reduces thrombotic risk via unknown mechanisms. Clinical observations suggest that 
eculizumab may have an immediate effect. 
objectives: a better understanding of the mechanism via which eculizumab reduces thrombotic 
risk by studying its pharmacodynamic effect on coagulation and fibrinolysis. 
methods: We measured microparticles (MP), tissue factor (TF) activity, prothrombin fragment 
1+2 (F1+2), D-dimer and simultaneously thrombin and plasmin generation in 55 PNH patients. 
In 20 patients, parameters were compared before and during eculizumab treatment (at 1 and 2 
hours, 1, 4 and ≥ 12 weeks after commencement).
results: Patients with a history of thrombosis had elevated D-dimers (p = 0.02) but not MP. 
Among patients on anticoagulants, those with thrombosis had higher F1+2 concentrations 
(p = 0.003). TF activity was undetectable in plasma MP. Unexpectedly, thrombin peak height 
and thrombin potential were significantly lower in PNH patients than in healthy controls. 
Fibrinolysis parameters were normal. During eculizumab treatment D-dimer levels significantly 
decreased after 1 hour (p = 0.008) and remained decreased at ≥ 12 weeks (p = 0.03). F1+2 
(p = 0.03) and thrombin peak height (p = 0.02) in patients not on anticoagulants significantly 
decreased at ≥ week 12. MP remained unchanged.
conclusions: Eculizumab induces an immediate decrease of D-dimer levels but not of other 
markers. The decrease in thrombin peak height and F1+2 suggests that eculizumab reduces 
thrombin generation. Elevated D-dimer levels in untreated PNH patients with a history of 
thrombosis suggest possible value in predicting thrombotic risk. 
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i N t r o d u c t i o N
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by intravascular 
hemolysis and a highly increased risk of thrombosis 1. The disease results from acquired 
mutations in the X-linked PIG-A gene in the hematopoietic stem cell. The PIG-A gene codes for 
an enzyme essential in the synthesis of glycosyl phosphatidyl inositol (GPI) anchors. The mutated 
hematopoietic stem cell produces a clone of blood cells with partial or complete deficiency of 
GPI-anchored proteins at the cell membrane. The percentage of granulocytes affected by this 
mutation determines the PNH clone size. Deficiency of GPI-anchored complement inhibitors 
CD55 and CD59 on erythrocytes renders these vulnerable to complement-induced hemolysis. 
One of the most serious features of PNH is a high risk of thrombosis, which has a major impact on 
survival and quality of life 2. The cumulative 10-year incidence of thrombosis is estimated at 23-31% 2,3. 
The risk of thrombosis is partly correlated with PNH clone size and is particularly elevated when the 
granulocyte clone size is > 50%. Nevertheless, thrombotic events occur also in patients with smaller 
clone sizes 3,4. Thrombosis occurs frequently in vessels of the liver, mesenterium or central nervous 
system 1,2,5. Primary prophylaxis with vitamin K antagonists (VKA) or low-molecular weight heparins 
(LMWH) (taken together as anticoagulant treatment (AC)) reduces the risk, but does not provide full 
protection 2,3. No parameters are available to aid in estimating thrombotic risk in individual patients. 
The mechanism of increased thrombophilia (reviewed in 6,7) is incompletely understood. 
GPI-deficient platelets become activated upon complement activation 8 and may shed 
microparticles (MP) with procoagulant properties 9-13. Additionally, free hemoglobin and 
arginase released from lysed erythrocytes activate endothelium and deplete nitric oxide (NO) 
from the circulation. NO normally inhibits platelet activation 14. Furthermore, deficiency of GPI-
anchored proteins involved in hemostasis such as urokinase plasminogen activator receptor 
(uPAR) and tissue factor pathway inhibitor (TFPI) may contribute 15-18.
Treatment with eculizumab, a monoclonal antibody to complement factor C5, has 
dramatically improved quality of life and survival in PNH patients 19. It reduces hemolysis, 
improves anemia and hemolysis-associated symptoms, and prevents secondary organ damage 
such as renal failure 20-25. Importantly, eculizumab is currently the only available treatment that 
significantly reduces thrombotic risk in PNH 26. Helley and Weitz et al. have demonstrated 
reduced markers of coagulation activation, fibrinolysis and plasma markers of endothelial 
activation at week 5 of eculizumab treatment 27,28. Case reports describe immediate abrogation 
of progressive thrombus formation upon administration of eculizumab 29,30. This suggests that 
changes in coagulation and fibrinolysis markers occur very rapidly. 
Here, we have studied coagulation and fibrinolysis in a large population of 55 untreated PNH 
patients. In addition, we have studied 20 patients before and during eculizumab treatment within 
a time window of one hour up to ≥ 12 weeks after the start of the first eculizumab infusion. We have 
assessed levels of procoagulant microparticles (MP), prothrombin fragment 1+2 (F1+2) and D-dimer 
levels as parameters of thrombin generation and fibrinolysis respectively. To study the interplay 
between coagulation and fibrinolysis, the Nijmegen Hemostasis Assay (NHA) was used, which allows 
simultaneous analysis of the plasma potential to generate both thrombin and plasmin 31. All parameters 
were correlated with clinical parameters of PNH (LDH, PNH clone size and history of thrombosis). 
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m at e r i a l s  &  m e t H o d s
c l i n i c a l  d a t a  a n d  s a m p l e s
Clinical data and venous peripheral blood samples from 55 consecutive PNH patients were 
collected after obtaining written informed consent in the period 2006-2011 in the Radboud 
University Medical Center. AC was prescribed when deemed appropriate according to the 
clinician’s judgment. Generally, patients received AC if their PNH granulocyte clone size was > 50% 
or they had already suffered thrombosis. Eculizumab was given at standard doses of 600 mg in a 30 
minute intravenous infusion once per week for 4 weeks and 900 mg per day once every two weeks 
as of week 5. Patients who commenced eculizumab treatment (n = 20) had an additional blood 
sample drawn immediately before the start of the first infusion. Follow-up samples were drawn at 
1 and 2 hours after the start of the first eculizumab infusion, and before subsequent infusions at 
1, 4 and ≥ 12 weeks. Control samples for the NHA were collected from 10 healthy controls (HC). 
All samples were collected in 3.2% citrate, theophylline, adenosine and dipyridamole (CTAD) and 
were centrifuged within 1 hour at 4oC for 15 min at 2000g. Subsequently, plasma was aliquoted and 
stored at -80 oC until use. From a subset of patients, peripheral blood mononuclear cells (PBMC) 
were isolated from whole blood by Ficoll Hypaque gradient separation. PBMCs were subsequently 
frozen in Iscove’s Modified Dulbecco’s Medium (IMDM, Invitrogen, Carlsbad, CA) containing 10% 
dimethylsulfoxide (DMSO) and stored in liquid nitrogen until use. 
m i c r o p a r t i c l e  e l i s a
Microparticle procoagulant activity in PNH patients was determined using the Zymuphen MP-Activity 
kit (Hyphen BioMed, Neuville-sur-Oise, France). Briefly, this assay measures thrombin generation, 
catalyzed by the exposure of phosphatidylserine upon binding of microparticles to a microtiter 
plate coated with streptavidine and biotinylated annexin A5.  Results were expressed as nanomolar 
phosphatidylserine equivalent by using a calibrator with a known microparticle concentration. 
t i s s u e  f a c t o r  ( t F )  a c t i v i t y  a s s a y
Functional TF activity was measured in plasma MP and lysed PBMCs of PNH patients, using a two 
stage amidolytic assay (detection limit 15 mU/ml) based on the ability of TF to accelerate the 
activation of FX by FVIIa as described previously 32. 
d - d i m e r 
D-dimer concentrations in PNH patients were determined using STA Liatest D-dimer (Stago 
Diagnostics, Asnières, France) according to the manufacturer’s instructions.
P r o t h r o m b i n  f r a g m e n t  F 1+2
Concentrations of prothrombin fragment F1+2 (F1+2) in PNH patients were determined using 
an enzyme-linked immunosorbent assay (ELISA) (Enzygnost F1+2 (monoclonal), Siemens 
Healthcare Diagnostics, Marburg, Germany) according to the manufacturer’s instructions 
(reference values 69-229 pmol/l). 
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N i j m e g e n  H e m o s t a s i s  a s s a y  ( N H a )
The NHA was performed as described previously 31. This assay simultaneously analyzes coagulation 
and fibrinolysis in plasma samples upon in vitro activation. In brief, the assay was mediated by 
~0.3 pM human recombinant tissue factor (Innovin®, Siemens Healthcare Diagnostics, Marburg, 
Germany), and 1.7% (v/v) crude cephalin (Roche, Basel, Switzerland) as a source of phospholipids. 
Fibrinolysis was mediated by 190 IU/mL tPA (Alteplase® , Boehringer Ingelheim, Ingelheim am 
Rhein, Germany). The assay is subsequently started by the addition of 17 mM CaCl
2
. Thrombin 
and plasmin generation are continuously measured using fluorogenic synthetic substrates 
(Chiralix, Nijmegen, The Netherlands) specific for thrombin (Bz-β-Ala-Gly-Arg-7-amino-4-
methylcoumarin, final concentration 833 μM) and plasmin (bis-(CBZ-L-phenylalanyl-L-arginine 
amide)-rhodamine, final concentration 33 μM).  Thrombin and plasmin-specific substrates are 
excitated at 355 nm and 485 nm and measured at emission wavelengths of 460 nm and 520 nm 
respectively. The procedure is performed in a 37 oC thermostated fluorometer (Fluostar Optima 
Fluorometer, BMG Labtechnologies, Offenburg, Germany) using Black polystyrene Fluotrac 
microtiter plates (Greiner Bio-One, Monroe, NC, USA).  Seven parameters are derived from the 
NHA: a) lag-time, the time at which thrombin formation is initiated; b) thrombin peak time, i.e. 
the time when thrombin production reaches maximal velocity; c) thrombin peak height, the 
maximum velocity of thrombin generation; d) thrombin potential (AUC), i.e. the area under 
the curve which represents the total amount of thrombin formed; e) fibrin lysis time (FLT), the 
time between the initiation of thrombin generation and the time plasmin generation reaches 
maximum velocity; f) plasmin peak height, the maximum velocity of plasmin production and g) 
plasmin potential, area under the curve representing the total amount of plasmin generated. 
s t a t i s t i c a l  a n a l y s i s
Data are expressed as medians unless otherwise indicated. Mann-Whitney-U test was used to 
compare differences between two groups. The Kruskall-Wallis test was used to compare differences 
between ≥ 2 groups. If significant differences were found, data were further evaluated by the Dunn’s 
test for multiple comparisons. The Spearman rank test was used to assess correlations with clinical 
characteristics. To determine changes before and during eculizumab treatment, Wilcoxon signed 
rank test was used. Statistical significance was accepted for p values below 0.05.
r e s u lt s
c l i n i c a l  d a t a
Clinical data of 55 PNH patients, including 20 patients who commenced eculizumab treatment, 
are shown in Table 1. LDH levels in untreated PNH patients significantly correlated with PNH 
granulocyte clone size (r 0.65, p < 0.0001, Supplementary Figure 1). Specific details on patients 
with a history of thrombosis are shown in Table 2. A total of 16 thrombotic events occurred 
in 12 patients before start of eculizumab treatment. Three patients (UPN 1, 5 and 11, Table 2) 
experienced multiple thrombotic events. Median follow-up from diagnosis to time of sampling 
was 4.8 years (range 0.1-29). 
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table 1: clinical features of PNH patients 
all patients Patients on eculizumab Healthy controls
No 55 20 10
Median age, y (range) 38 (13-82) 44 (13-82) 33 (23-49)
Male/female (%) 28/27 (51/49%) 14/6 (30/70%) 5/5
PNH granulocyte clone size (%) (range) 63% (5-100%) 83% (50-100%) NA
LDH level (IU/l) (range) (reference range < 450 IU/l) 1555 (217-1549) 2222 (550-4661) < 450 
No of thrombotic events (No of patients)
Arterial:
Central nervous system
Ischemic colitis
Myocardial infarction
Venous:
Deep venous thrombosis
Budd-Chiari/portal vein 
Pulmonary embolism
Mesenteric veins
Subclavian vein
16 (12)
2
1
1
4
4
1
2
1
13 (9)
1
1
0
3
4
1
2
1
0
Current anticoagulant treatment (No, %):
None
VKA
ASA
LMWH
30 (55%)
17 (31%)
5 (9%)
3 (5%)
6 (30%)
10 (50%)
1 (5%)
3 (15%)
0
VKA= vitamin K antagonists, LMWH = low molecular weight heparin, ASA = acetyl salicylic acid, NA= not applicable.
P h o s p h a t i d y l s e r i n e  ( P s )  e x p r e s s i n g  m i c r o p a r t i c l e s  ( m P )
MP concentrations (≥ 10 nM) were elevated in 15/50 (30%) of PNH patients. MP levels in 
eculizumab-naive PNH patients significantly correlated with LDH (r 0,61, p < 0.0001, Figure 1A) 
but not with PNH granulocyte clone size (data not shown). MP levels were similar in patients 
with and without a history of thrombosis (Figure 1B) and in those with and without AC (data not 
shown). MP levels did not change during eculizumab treatment (n = 20). In one patient we did 
observe a clear decrease in MP level already at 2 hours after the start of eculizumab treatment 
(Figure 1C). This patient (UPN10) was diagnosed with subclavian vein thrombosis 3 months 
earlier and had a very high MP level at baseline. All other patients with recent thrombosis (≤ 
3 months; UPN3, UPN4, UPN5, UPN7) had normal baseline MP levels at the start of treatment 
(maximum 8 nM).
P l a s m a  t i s s u e  f a c t o r  ( t F )  a c t i v i t y
As we and others 27 did not observe strong decreases in PS expressing MP during eculizumab 
treatment, we wondered whether expression of functional TF on MP might be an alternative 
explanation for the prothrombotic tendency in PNH patients. Therefore, we measured plasma 
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Figure 1: Procoagulant microparticle levels 
correlate with the degree of hemolysis 
and remain unchanged during eculizumab 
treatment. Figure 1A:  Correlation between the 
degree of hemolysis as determined by the level 
of LDH (IU/l, x-axis) and the level of procoagulant 
MP (nM, y-axis). Figure 1B: MP levels in PNH 
patients with (left column) and without history 
of thrombosis (right column). Bars represent 
medians. Figure 1C: Level of procoagulant 
microparticles in eculizumab treated patients 
compared to baseline. t = 0: immediately before 
start of eculizumab treatment, t = 1: 1 hour, t = 2: 
2 hours, t = 3: 1 week, t = 4: 4 weeks and t = 5: 
≥ 12 weeks after start of eculizumab treatment 
respectively. * UPN 10. 
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TF activity in 11 eculizumab-naive PNH patients and in 10 patients on eculizumab treatment 
(Table 3). TF activity in all patients was below or at the detection limit of the assay (≤ 0.15 mU/ml). 
The low plasma TF activity may be explained by rapid binding of TF containing MP by 
monocytes and/or platelets. Therefore, we have tested TF activity levels in PBMCs in 7 patients 
(Table 4). TF activity was found in patient 1 at the time she experienced a mesenterial thrombosis 
before treatment with eculizumab, and in patient 5 (UPN 10, table 2) who was treated with 
eculizumab and had experienced a subclavian vein thrombosis 8 months earlier. 
d - d i m e r
Increased D-dimer levels (> 500 ng/ml) were found in 9/49 untreated PNH patients (18 %). 
D-dimer levels did not correlate with LDH or PNH granulocyte clone size. In patients with a 
history of thrombosis D-dimer levels (median 418; range 211-32928 ng/ml) were significantly 
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table 2: clinical data of PNH patients with a history of a thrombotic event
uPN
time since 
diagnosis of 
PNH (years) Patient age
site of  
thrombosis
time since 
diagnosis of 
thrombosis at 
sampling (years)
PNH granulocyte 
clone size (%) 
at diagnosis of 
thrombosis
anticoagulant 
treatment 
at time of 
sampling
1 33 44 DVT 26 ND none
Myocardial infarction  5 ND
2 1 77 DVT 1 41 none
3 0,3 20 Mesenterial 0.1 75 LMWH
4 11 27 Budd Chiari 0.1 85 VKA
5 26 67 DVT 26 ND none
Budd Chiari 4 ND
Mesenterial 0.1 90
6 5 37 DVT 4 50 VKA
7 3 80 Ischemic colitis 0.1 95 LMWH
8 5 56 Portal vein 5 60 VKA
9 29 54 Portal vein 20 ND VKA
10 17 50 Subclavian vein 0/0,25* 100 none
11 14 45 Pulmonary embolism 1,7 100 LMWH
CVA 1 100
12 1 81 CVA 0 92 VKA
UPN = unique patient number; DVT = deep venous thrombosis; CVA = cerebrovascular accident; LMWH = 
low molecular weight heparin; VKA = vitamin K antagonist.  N.D.  = not determined, clone size at diagnosis 
unavailable. * This patient was sampled twice, at the time of diagnosis of thrombosis and at the start of 
eculizumab treatment 3 months after.
higher than in those without (264; 74-1986 ng/ml) (p 0.02, Figure 2A). However, upon exclusion 
of patients with a recent thrombosis (≤ 3 months; UPN 3, 4, 5, 7, 10 and 12, Table 2) no difference 
was found (data not shown). As expected, D-dimer levels in all patients with a history of 
thrombosis showed a significant inverse correlation to the time to thrombosis (r -0.72, p 0.02). 
During eculizumab treatment, we observed a significant decrease of D-dimer levels in 
patients with elevated baseline D-dimer levels (n = 8; median 1932; range 564-32928 ng/l) 
already as early as 1 hour after the first dose of eculizumab (median 1646; range 44-31851 ng/l, 
p 0.008). This decrease was maintained at ≥ 12 weeks (median 367; range 184-2012 ng/l, p 0.03) 
(Figure 2B). To rule out a possible D-dimer decrease as a result of thrombosis resolution, we 
performed an analysis excluding patients with a recent thrombotic event (≤ 3 months ago; UPN 
3, 4, 5, 7 and 10, Table 2). In this subgroup (n = 13) median D-dimer levels at baseline were normal 
(median 277; range 102-2077 ng/ml). Yet, compared to baseline, we observed a slight but 
significant decrease of D-dimer levels again already after 1 hour (median 264; range 130-1896 
ng/ml, p 0.05) which was sustained until at least week 12 of eculizumab treatment (median 211; 
range 102-467 ng/ml, p 0.05; data not shown). 
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table 3: tF activity levels in PNH patients with and without eculizumab treatment
No eculizumab eculizumab
n 11 9
Median PNH granulocyte clone size  (range) 94 (50-99%) 93 (63-96%)
Median LDH level (range) 3560 (2018-5068 IU/l) 423 (345-561 IU/l)
Median TF activity (range) 0.05 (0-0.1 mU/ml) 0.06 (0-0.16 mU/ml)
table 4: tissue factor activity in peripheral blood mononuclear cells
Patient age (y) clone size (%) ldH (iu/l)
History of 
thrombosis
anticoagulant 
treatment eculizumab 
tF activity 
(mu/ml)
1 * 20 62%
92%
539
427
mesenterial 
mesenterial 
LMWH
LMWH
no
yes
0.63
< 0.15 
2 26 12% 507 no none no < 0.15 
3 87 90% 360 no none yes < 0.15 
4 26 6% 402 no none no < 0.15 
5# 50 100% 602 subclavian vein VKA yes 0.2
6 77 53% 2613 no none no < 0.15 
7 35 82% 1070 no VKA no < 0.15 
* = UPN 3 in table 2; #  = UPN 10 in table 2. 
P r o t h r o m b i n  f r a g m e n t  1+2  ( F 1+2 )
Elevated levels of F1+2 were found in 8/54 (15%) untreated patients (median 131; range 
41-915 pmol/l). As expected, F1+2 levels were significantly lower in patients on AC, compared 
to those who were not (p < 0.0001, Mann-Whitney U test, data not shown). In patients not on 
AC elevated levels of F1+2 were found in 8/35 (23%) patients (median 193; range 85-915 pmol/l). 
No correlation was found between F1+2 levels and LDH or PNH granulocyte clone size, 
neither in the total group of untreated patients, nor in subgroups treated with or without AC 
(data not shown). Interestingly, in patients on AC we found significantly elevated levels of F1+2 
in those with a history of thrombosis (median 106; range 56-301 pmol/l) compared to patients 
without (median 47; range 41-131 pmol/l) (p 0.003, Figure 3A). To rule out elevated F1+2 levels as 
a consequence of a recent thrombotic event (≤ 3 months ago) we subsequently performed this 
analysis excluding 6 patients (UPN 3, 4, 5, 7, 10 and 12). In this population, F1+2 levels in patients 
with thrombosis were not significantly higher (p 0.07). 
During eculizumab treatment, we observed a significant decrease in F1+2 levels at ≥ week 
12 (median 104; range 42-392 pmol/l) compared to baseline (median 122; range 34-915 pmol/l) 
(p 0.03, Wilcoxon signed rank test, data not shown). This accounted specifically for patients 
not treated with AC (median 134 at  ≥ week 12; range 42-392 compared to median 169.5; range 
56-915 at baseline, p 0.008, Wilcoxon signed rank test, Figure 3B). Again, to rule out the possible 
effect of thrombosis resolution we performed the same analysis in all patients who commenced 
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Figure 2: d-dimer levels are increased in 
patients with a history of thrombosis and 
decrease during eculizumab treatment. 
Figure 2A: Elevated D-dimer levels in PNH 
patients not treated with eculizumab with 
a history of thrombosis compared to PNH 
patients without history of thrombosis. Bars 
represent medians. Figure 2B: D-dimer levels 
immediately before and during eculizumab 
treatment in PNH patients with elevated 
D-dimer levels (●) and normal D-dimer levels 
(■) at baseline. t = 0: immediately before start of 
eculizumab treatment, t = 1: 1 hour, t = 2: 2 hours, 
t = 3: 1 week, t = 4: 4 weeks and t = 5: ≥ 12 weeks 
after start of eculizumab treatment respectively. 
Data points and error bars represent median 
and interquartile ranges. * = p < 0.05, ** = p < 0.01 
compared to baseline in patients with elevated 
D-dimer levels at baseline. 
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eculizumab irrespective of AC treatment, however excluding those with a recent thrombosis (≤ 
3 month ago) (n = 5). In this population (n = 15), we did not observe a similar decrease in F1+2 
levels (data not shown). 
N i j m e g e n  H e m o s t a s i s  a s s a y  ( N H a )
Using the NHA, we screened for abnormalities in both coagulation and fibrinolysis and its interplay 
in patients with PNH. Unexpectedly, in PNH patients not on any anticoagulant or eculizumab, we 
found significant differences suggesting impaired thrombin generation compared to HC. The 
lag time to thrombin generation (median 4.4 vs 2.6 min, p 0.006) and time to thrombin peak 
(8.5 vs 6.3 min, p 0.02) was longer in PNH patients than in healthy controls (HC) (Figure 4A). 
The area under the thrombin generation curve (AUC), correlating to the endogenous thrombin 
potential, was lower in PNH patients (median 1230 nM/min, range 595-1868 nM/min) than in HC 
(1441 nM/min, range 1258-2366 nM/min) (p 0.003, Figure 4A). Thrombin peak level and AUC had 
a significant inverse correlation with LDH (r -0.55, p 0.0007 and r -0.47, p 0.005 respectively) and 
PNH granulocyte clone size (r -0.43, p 0.01 and r -0.38, p 0.03 respectively) in patients not on 
eculizumab and not on AC (Figure 4B). All parameters of fibrinolysis were similar to HC (Figure 
4A). During eculizumab treatment, a significant decrease in median thrombin peak height was 
observed in patients not treated with VKA at ≥ week 12 (177; range 57-272 nM) compared to 
baseline (170; range 55-224 nM, p 0.02, Figure 4C). No significant changes in any of the other 
NHA parameters were observed upon eculizumab treatment (data not shown). 
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Figure 3: F1+2 levels are increased in patients 
with a history of thrombosis and decrease 
during eculizumab treatment. Figure 3A: F1+2 
levels in PNH patients treated with VKA or LMWH 
not on eculizumab treatment with a history of 
thrombosis (●) and without (■). Bars represent 
medians. Figure 3B: F1+2 levels immediately 
before and during eculizumab treatment in PNH 
patients treated with (●) and without (■) VKA. 
Data points and error bars represent median and 
interquartile ranges. ** = p < 0.01 for patients not 
treated with VKA compared to baseline. 
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As we found a significant inverse correlation of AUC and thrombin peak level with LDH levels 
and PNH granulocyte clone size we wondered whether free hemoglobin or bilirubin may disturb 
thrombin generation in the NHA, as shown in other thrombin generation assays 33. Indeed, addition of 
free hemoglobin at 10, 25, and 75 μM decreased thrombin peak height with 6, 7 and 30% respectively 
(data not shown). This was also true for bilirubin at 32 and 128 μM which decreased thrombin peak 
height with 7 and 12% respectively (data not shown). Unfortunately, free hemoglobin levels in our 
patient cohort were not available. Bilirubin levels (median 13 μM, range 8-73 μM) were were ≥ 32 μM 
in 4/49 patients. When analyzing patients with bilirubin levels < 32 μM, the inverse correlation with 
thrombin peak height but not AUC remained significant (r -0.39, p 0.02, data not shown). 
d i s c u s s i o N
Thrombosis is a serious and unpredictable complication of PNH. Biomarkers that may predict 
thrombosis in PNH patients are unavailable. Although eculizumab reduces thrombotic risk 
in PNH, it is still unclear via which mechanism. In this study, we have determined the effect 
of eculizumab on various parameters of coagulation, particularly at time points early after 
treatment initiation, as clinical evidence suggests that eculizumab has an immediate effect 
on abrogating thrombus formation 29,30. Furthermore, we have investigated the correlation of 
different biomarkers in a large cohort of PNH patients with variable clinical features to assess 
their potential utility in estimating thrombotic risk. 
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Figure 4: NHa parameters in PNH patients before and during eculizumab treatment. Figure 4A: Comparison 
of various NHA parameters in PNH patients not treated with eculizumab or VKA (●) compared to healthy controls 
(HC; ■). Bars represent medians. Figure 4B: Correlations between LDH level and thrombin peak height (upper 
left panel), LDH level and endogenous thrombin potential (ETP) (upper right panel), PNH granulocyte clone size 
and thrombin peak height (lower left panel) and PNH granulocyte clone size and ETP (lower right panel). Figure 
4C: Thrombin peak height immediately before and during eculizumab treatment in PNH patients treated with 
(■) and without (●) VKA. Data points and error bars represent median and interquartile ranges. * = p < 0.05 for 
patients not treated with VKA compared to baseline.
In eculizumab-naïve patients, D-dimer levels were significantly increased in patients with a 
recent history of thrombosis. Most likely, this results from ongoing fibrinolysis. Alternatively, PNH 
patients with elevated D-dimer levels may represent a subgroup at higher thrombotic risk, similar 
as in patients with idiopathic deep venous thrombosis (DVT) or cancer 34,35. Only among patients 
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on AC, we found higher F1+2 levels in patients with a history of thrombosis compared to those 
without. However, the majority of patients on AC had¸ as expected, F1 + 2 levels within the normal 
range. This renders the significance of this finding unclear. Ideally, the hypothetical prognostic 
value of D-dimer and F1+2 levels in untreated PNH patients should be tested in prospective 
studies. However, these are difficult to perform due to the orphan character of the disease. 
Interestingly, we demonstrated significant decreases of D-dimer already at 1 hour after initiating 
eculizumab treatment. This observation may be linked to an abrogation of thrombus formation as 
observed in patients who have ongoing thrombosis when eculizumab treatment is initiated 29,30. 
Confirming the studies of Helley et al. and Weitz et al., this decrease was sustained for at least 12 
weeks 27,28. Median F1+2 levels, which were normal at baseline, did not significantly decrease until 
week 12 of treatment, indicating that eculizumab may decrease thrombin generation. Helley et al. 
observed such a decrease in PNH patients already at week 5 and irrespective of their use of AC. In 
our cohort, a decrease was seen only in patients not on AC. Small sample sizes and heterogeneity 
of the patient populations with respect to use of AC may explain these differences. 
In eculizumab-naïve patients, procoagulant MP significantly correlated with LDH levels. In 
agreement with Hugel et al., no correlation with PNH granulocyte clone size was found 10, suggesting 
that the degree of hemolysis or complement activation is the most important determinant of MP 
level. Several studies have shown enhanced MP generation upon in vitro complement stimulation 
of PNH erythrocytes 11,36, explaining a correlation to LDH as a measure of erythrocyte lysis. We 
confirmed the observation by Helley et al. that MP levels did not decrease significantly during 
eculizumab treatment, whereas LDH levels do 27. As eculizumab reduces thrombotic risk, this finding 
suggests that PS expressing MP do not play a major role in PNH-related thrombosis. 
Interestingly, in one patient with a recent central venous catheter related subclavian 
vein thrombosis, we did see highly increased MP levels, which decreased significantly almost 
immediately after initiation of eculizumab. In vivo MP half life is unknown, but mice studies 
suggest rapid clearance of PS exposing particles by the spleen within 2 hours, fitting a potential 
early effect of eculizumab 37. Interesting questions remaining to be answered are whether these 
high MP levels reflect the thrombotic event or play a causal role in this particular patient, and 
whether the decrease was a consequence of eculizumab treatment or of thrombosis resolution. 
Studies evaluating MP levels in patients with VTE employ various methods and results are 
ambiguous. Higher PS expressing MP levels were not predictive of venous thrombosis in cancer 
patients 38, arguing against a role for MP in provoking thrombosis. In contrast, TF containing 
MP levels were higher in cancer patients with VTE compared to those without 39,40, but not 
in patients with idiopathic DVT and pulmonary embolism 41,42. We did not observe plasma TF 
activity in eculizumab-naïve patients, even in those with high LDH levels, confirming the study 
of Weitz et al. 28. Both Liebman and Weitz et al. demonstrated elevated TF antigen in untreated 
PNH patients, however this probably concerns non-functional TF 28,43. The absent plasma TF 
activity in our study indicates that the number of TF expressing MP is probably low in PNH 
patients. Another possibility is that TF expressing MP are taken up by monocytes or platelets. 
We assessed uptake by monocytes by determining TF activity in PBMCs in a subset of patients. 
TF activity was found in PBMCs of two patients with a history of thrombosis, suggesting a 
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pathophysiological role for TF or TF containing MP in PNH-related thrombosis. These findings 
require confirmation in a larger patient group. 
The NHA showed interesting changes in parameters of thrombin generation in eculizumab-
naive PNH patients not on AC. Fibrinolysis parameters were all similar to HC, indicating that 
fibrinolysis is normal in PNH patients. Longer lag time to thrombin generation and time to 
thrombin peak, and a lower AUC and thrombin peak height compared to HC all indicate impaired 
in vitro thrombin generation in PNH patients. Free plasma hemoglobin, characteristic for PNH 
patients, reduced thrombin peak height in the NHA in a concentration-dependent manner. In 
the eculizumab trial TRIUMPH 22, median free hemoglobin level at baseline was 28.7 μM (www.
ema.europe.eu). Although plasma free hemoglobin levels were not available in our cohort, we 
expect these to be lower than in the TRIUMPH study, since the level of hemolysis was lower in 
our study (mean LDH level +/- SE at baseline 1987 +/-226 versus 2100+/-158 U/L in the TRIUMPH 
study). Yet, it cannot be excluded that the baseline NHA parameters in individual patients were 
falsely influenced by high free hemoglobin levels. During eculizumab treatment, free hemoglobin 
levels decrease as hemolysis is blocked. Therefore, if impaired thrombin generation were only 
an in vitro effect, one would expect that during eculizumab treatment, thrombin generation 
parameters increases. Since we observe the opposite, we conclude that the decrease in 
thrombin peak height at ≥ week 12 of eculizumab is not an in vitro effect. Unlike D-dimer, NHA 
parameters of thrombin generation did not show early changes upon eculizumab treatment. In 
vivo consumption of coagulation factors may explain lower thrombin generation parameters and 
the inverse correlation of thrombin generation parameters with LDH and clone size in untreated 
PNH patients. A similar finding was described by Grünewald et al., who demonstrated a reduced 
ETP which was inversely correlated with PNH reticulocyte clone size in untreated PNH patients 44.
This study is limited by the fact that we did not investigate platelet function or endothelial 
cell activation markers. Previous in vitro studies have suggested that upon stimulation by 
the membrane attack complex (MAC), GPI-deficient platelets release procoagulant MP and 
increase thrombin generation. Ex vivo studies provided some evidence for in vivo platelet 
activation 8, but were not confirmed by others 45,46. As eculizumab inhibits MAC formation, 
reduced platelet activation may be expected. Besides a reduction in P-selectin levels during 
eculizumab treatment described by Weitz et al. 28, the effect of eculizumab on other platelet 
activation markers remains to be studied. Since platelet poor plasma is used in the NHA, effects 
of platelets on thrombin generation may have been missed in our study. Helley et al. previously 
demonstrated reduced endothelial activation markers during eculizumab treatment, 
suggesting that eculizumab may reduce endothelial activation 27.
In conclusion, our studies show that the decrease of D-dimer levels upon treatment with 
eculizumab already occurs in the first hours and is sustained. In addition, upon treatment with 
eculizumab, F1+2 levels and thrombin peak height decrease. This suggests that, besides the 
previously described effect on endothelial activation, there may also be effects on thrombin 
generation. The possible prognostic value of elevated D-dimer levels in untreated PNH patients 
with a history of thrombosis is promising but requires further investigation.
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supplementary Figure 1: PNH granulocyte clone size correlates to the degree of hemolysis. Correlation 
between PNH granulocyte clone size (%, x-axis) and LDH level (IU/l, y-axis) at the time of sampling. 
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8Paroxysmal Nocturnal Hemoglobinuria (PNH) is characterized by chronic intravascular 
hemolysis and a high risk of thrombosis, on a background of variable pancytopenia. The disease 
is caused by an acquired mutation of the PIG-A gene in the hematopoietic stem cell, resulting in 
deficiency of glycosyl phosphatidyl inositol (GPI) anchors. Lack of GPI-anchored complement 
inhibitors on erythrocytes renders these susceptible to complement-mediated hemolysis. 
Thrombosis frequently complicates PNH with high morbidity and mortality 1. Thrombotic risk is 
correlated to PNH clone size 2.  Prophylaxis with coumarins does not offer full protection, particularly 
in patients with prior thrombosis 1. Proposed mechanisms include shedding of procoagulant 
microparticles by complement-damaged platelets and deficiencies of GPI-anchored urokinase 
plasminogen activator receptor (uPAR) and tissue factor pathway inhibitor (TFPI) (reviewed in 3). 
Additionally, depletion of nitric oxide by free hemoglobin may promote platelet activation 4. 
Eculizumab, a monoclonal antibody to complement factor C5, effectively blocks intravascular 
hemolysis, improves anemia and reduces thrombotic risk 5-7. Treatment must be continued 
lifelong to maintain terminal complement inhibition. During treatment, prolonged survival of 
GPI-deficient PNH erythrocytes increases their number 5. Consequently, in the first weeks after 
stopping eculizumab, significant hemolysis may be anticipated. Thrombotic risk is expected to 
return to pre-treatment levels; rebound thrombosis however has not been described. 
Here, we report on a patient with a first thrombotic event shortly after stopping eculizumab. 
While on anticoagulant prophylaxis, she suffered from a fatal arteriovenous thrombosis of the 
small bowel 3 weeks after her last eculizumab dose. This female patient was diagnosed with 
classic PNH (granulocyte clone size 70%) at the age of 32 years. Initial treatment included 
erythrocyte transfusions (1-2 units/month) and anticoagulant prophylaxis with fenprocoumon. 
She never suffered from thrombosis. Three years after diagnosis PNH clone size had increased 
to 92%.  She started eculizumab treatment, which normalized lactate dehydrogenase (LDH) 
levels, rendered her transfusion independent and improved her quality of life.  
In 2007, one year after starting eculizumab, she developed progressive pancytopenia 
and transfusion dependency. LDH levels remained normal, and PNH clone size was still 98%. 
Underdosing of eculizumab was excluded. Bone marrow histology suggested developing 
aplastic anemia. At that time, high transfusion requirements masked the clinical benefit of 
eculizumab. Though unlikely, a role for eculizumab in developing aplastic anemia could not be 
excluded and eculizumab was stopped. PNH erythrocytes were undetectable at that time and 
significant hemolysis did not occur. 
Three weeks after her last eculizumab dose, while on therapeutically dosed fenprocoumon 
and severely thrombocytopenic, she reported abdominal pain and feculent vomiting. 
Explorative surgery revealed segmental necrosis of the small bowel. Histology showed extensive 
arteriovenous thrombosis (Figure 1). Anticoagulant treatment was switched to argatroban. 
Nine weeks later, she again developed abdominal pain and hematemesis. Endoscopy revealed a 
duodenal ischemic ulcer suspect for a novel thrombosis. The patient’s condition deteriorated. 
Eculizumab treatment was restarted but unfortunately, she died one day later. 
This case suggests a possible causal relationship between stopping eculizumab and the 
development of thrombosis. No hyperhemolysis was observed after stopping eculizumab. At 
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8Figure 1: Hematoxilin and eosin staining (80x) of an ileal section of patient 1, showing numerous thrombi in the 
capillaries and veins, ischemic enteritis with transmural haemorrhage, mucosal necrosis and infiltration of the 
submucosa by plasma cells, lymphocytes and macrophages.
the time of thrombosis, PNH erythrocytes were undetectable, LDH levels were in range with 
previous levels after stopping, and there was no evidence of infection. Thus, no other factors 
that may have elicited thrombosis were identified.  
If indeed thrombosis was precipitated by stopping eculizumab, the mechanism remains 
speculative. In untreated PNH patients, Grünewald et al. reported platelet hyporeactivity possibly 
explained by compensatory downregulation in response to chronic, complement-mediated 
hyperstimulation 8. During eculizumab therapy platelet hyporeactivity may be reversed, and 
therefore, platelets might get more easily activated upon relief of complement inhibition, 
thus increasing thrombosis risk. A compensatory increase in early complement factors during 
eculizumab is unlikely, as most complement proteins are regulated by inflammatory cytokines 9.   
In conclusion, although causality is unproven, stopping eculizumab in a patient with a 
persistent large PNH clone appears to be associated with a particularly high risk of thrombosis. 
Presentation may be atypical, and as demonstrated here, thrombosis can occur in patients with 
anticoagulant prophylaxis or thrombocytopenia. Therefore, in our view, special awareness 
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8of the potentially high thrombosis risk in patients discontinuing eculizumab is necessary. 
Eculizumab at this time may be the most effective way to prevent thrombosis in PNH. 
Although anticoagulation failed to prevent thrombosis in our patient, we still recommend 
anticoagulation, if safe, in patients stopping eculizumab. 
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9Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare disease characterized by chronic 
intravascular hemolysis and a highly increased risk for thrombosis. A mutation of the 
phosphatidylinositol glycan class A (PIG-A) gene in a hematopoietic stem cell results in 
deficiency of glycosylphosphatidylinositol (GPI) anchored proteins at the cell membrane of 
all its progeny. Complement-mediated hemolysis results from deficiency of GPI-anchored 
complement inhibitor CD59 on PNH erythrocytes. 
Surgery, and particularly open heart surgery has a high risk of complications in PNH 
patients. First, major complement activation by both the surgical procedure itself and 
cardiopulmonary bypass (CPB) can elicit a hemolytic crisis 1. Second, CPB causes excessive 
thrombin generation and further increases thrombotic risk 2. Lastly, PNH patients frequently 
have associated bone marrow failure, increasing the risk of infections and bleeding. Strategies 
minimizing the risk of hemolysis include leukocyte depleted red blood cell (RBC) transfusions 
to reduce the percentage of GPI-deficient erythrocytes, and avoiding complement containing 
blood products 3-8. Nevertheless, surgery in untreated PNH patients was generally discouraged 
because of associated risks and low life expectancy. 
Eculizumab, a monoclonal antibody to complement factor C5, effectively blocks 
intravascular hemolysis and reduces the risk of PNH-related thrombosis 9;10. With the availability 
of eculizumab, quality of life and prognosis improved 10, raising new issues for PNH patients 
requiring surgery while on eculizumab. In normal circumstances, eculizumab prevents 
hemolysis at a trough level above 35 μg/ml, which is maintained with standard dosing 11. Dosages 
required to maintain adequate levels during excessive complement activation as in surgery are 
unknown and peroperative monitoring of serum levels is impossible. Moreover, complement 
activation, bleeding and hemodilution may easily render peroperative eculizumab levels 
insufficient. This implies a risk of massive lysis of the GPI-deficient erythrocyte clone, which is 
relatively large during eculizumab treatment because lysis is prevented. Therefore, strategies 
to minimize additional complement activation and to maintain adequate complement blockade 
are extremely important in eculizumab treated PNH patients requiring surgery and CPB. 
Here, we report on a seventy-year-old classic PNH patient undergoing elective aortic 
valve replacement surgery during maintenance treatment with eculizumab. PNH granulocyte 
and erythrocyte clone size at that time were 95% and 70% respectively. After suffering from 
endocarditis for which he received long-term intravenous antibiotic treatment, eventually 
aortic valve replacement surgery proved necessary.
Surgery was scheduled one day after his regular eculizumab infusion. Two units of RBC were 
given to dilute the number of GPI-deficient erythrocytes. To reduce complement activation 
by blood-air contact, a minimized Physio coated (Sorin, Italy) CPB circuit was assembled 12;13. 
Priming of the extracorporeal circuit included 2500 IU of heparin, 500 mg tranexamic acid and 
40 mg dexamethasone. 1500 mg cefuroxim antibiotic prophylaxis, 10 mg dexamethasone and 
1000 mg tranexamic acid, followed by 400 mg/h to prevent fibrinolysis, were administered. 
The coated minimized CPB circuit allowed reduction of the amount of heparin to 30% prior 
to cannulation. Thereby, we aimed to restore coagulation by metabolizaton of heparin 
without using protamin, which causes classical pathway complement activation upon complex 
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9formation with heparin 14. Four units of RBC were given peroperatively to compensate for blood 
loss. An aortic valve bioprosthesis (Perimount, Carpentier-Edwards, United States) was placed. 
Additionally, half a dose of eculizumab was infused after closure of the heart. 
Despite sufficient decrease of the activated clotting time 1 hour after closure, prolonged 
bleeding necessitated multiple RBC and thrombocyte transfusions. Bleeding finally ceased 
upon prothrombin complex (80ml) administration, which was initially avoided because of 
potential contamination with complement proteins. Subsequently, the bioprosthesis turned 
out to obstruct an aberrantly localized right coronary artery (RCA) ostium, urging RCA bypass 
grafting which was performed on a beating heart.
As expected, complement was clearly activated during surgery, evidenced by a rise in the C3/
C3d ratio. However, undetectable terminal complement complex (TCC) levels confirmed complete 
C5 blockade by eculizumab peri-operatively. Intravascular hemolysis was not significant, as LDH 
and bilirubin levels remained unchanged. To measure coagulation activation, levels of D-dimer 
and procoagulant microparticles were determined at various time points peri-operatively. 
Although microparticle concentration rose slightly after initiating CPB, low D-dimer levels peri-
operatively militated against major coagulation activation (Table I). Serum eculizumab levels 
preoperatively and two days postoperatively proved adequate (43 and 76 μg/ml respectively).
The normal dosing regimen for this patient (1200 mg biweekly) was resumed 2 days 
postoperatively. He was discharged after 12 days and had an uneventful recovery without 
hemoglobinuria or thrombosis. In conclusion, this case demonstrates that adequate 
complement blockade by peri-operative eculizumab administration and the strategies applied 
for minimizing procedure-related complement activation contributed to a successful outcome.
table 1: laboratory parameters before, during and after open heart surgery
baseline
5 minutes 
after start 
of cPb
5 minutes 
before 
ending cPb
1 hour  
post 
surgery
2 days 
postoperatively
Hemoglobin (mmol/l) 7.3 4.4 5.4 6.3 5.8
Thrombocytes ( x 109/l) 57 NA 49 80 72
LDH (U/l) (reference value < 450) 569 402 478 339 175
Bilirubin (umol/l) 
direct (reference value < 5)
Total (reference value < 20)
<5
20
6
22
NA
NA
16
30
< 5
13
Terminal complement complex (AU/ml) NA <6 <6 <6 NA
Ratio C3d(%)/C3(mg/L) NA 0.0021 0.0046 0.0079 NA
D-dimer (reference value < 500 ng/ml) 640 < 500 NA NA < 500
Microparticles (nM) (reference value < 5 nM) 6.2 26.3 11.7 NA 10.1
Laboratory parameters determined before, during and after open heart surgery. NA = not available. Microparticle 
concentration was determined by Zymuphen MP-Activity ELISA (Hyphen Biomed, Neuville-sur-Oise, France). 
TCC and C3d were determined as previously described 15;16. C3 was determined nephelometrically (Immage, 
Beckman Coulter, Fullerton, CA, USA). All other parameters were determined by standard diagnostic assays. 
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Pa rt  1 :  a u to - i m m u N i t y  a N d  b o N e  m a r r ow  Fa i l u r e  
i N  t H e  Pat H o g e N e s i s  o F  P N H 
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, chronic disease, characterized by 
hemolytic anemia, an increased risk of thrombosis and bone marrow failure. The clinical picture 
of individual patients is highly variable. The disease is caused by one or more acquired somatic 
mutations in hematopoietic stem cells (HSC) of the X-linked phosphatidylinositol glycan 
complementation class A (PIG-A) gene 1-3, which codes for an essential enzyme in the synthesis 
of glycosyl phosphatidyl inositol (GPI) anchors. Hence, this mutation results in clonal deficiency 
of GPI-anchored proteins in all mature blood cells. Deficiency of the GPI-anchored complement 
inhibitors CD59 and CD55 on erythrocytes results in hemolysis upon complement activation. 
Besides CD55 and CD59, numerous other proteins use GPI to anchor to the cell membrane. These 
include proteins with a function in the immune system, such as CD58 on lymphocytes and CD16 on 
neutrophils. In addition, proteins with a function in coagulation and fibrinolysis are affected, such 
as tissue factor pathway inhibitor (TFPI) and urokinase plasminogen activator receptor (uPAR). 
The bone marrow failure component is one of the intriguing features of PNH. It has been 
attributed to immune-mediated mechanisms similar as in most cases of aplastic anemia (AA). 
PNH and AA show considerable overlap. This is illustrated by the fact that 40% of AA patients have 
(mostly small) PNH clones at diagnosis and overt PNH often develops during the course of AA 4. 
The current working classification of PNH as proposed by the International PNH Interest Group 
(IPIG) described three different categories of PNH: 1) classical PNH, characterized by clinically 
evident hemolysis and normal or near normal marrow morphology with increased erythropoiesis 
only, 2) PNH in the setting of another specified bone marrow disorder, also characterized by 
clinically evident hemolysis and (a history of) another bone marrow disorder, and 3) subclinical 
PNH, with no evidence of hemolysis usually also occurring in the setting of another bone 
marrow disorder such as myelodysplastic syndrome (MDS) 5. However, these categories show 
considerable overlap. For example, despite normal marrow morphology, the frequent presence 
of mild cytopenias in classic PNH suggests some degree of marrow failure in classic PNH as well 6.
Immune-mediated marrow damage has been hypothesized to be responsible for both marrow 
failure and clonal expansion in PNH7. In some PNH patients, over time, PIG-A mutated HSC achieve 
mono- or oligoclonal dominance at the expense of normal hematopoiesis. The immune escape 
theory proposes that, in a setting of autoimmune mediated bone marrow damage, GPI-deficient 
HSCs escape immunological attack, whereas their normal counterparts do not. As a consequence, 
this differential susceptibility may lead to a relative growth advantage, and thus clonal expansion of 
GPI-deficient HSC. Other hypotheses explaining clonal expansion include a proliferative advantage of 
the PNH clone due to the acquisition of additional mutations or an increased resistance to apoptosis. 
Part 1 of this thesis focuses on the possible role of immune-mediated bone marrow failure 
in PNH pathogenesis, and the mechanism of clonal expansion. Previous studies have suggested 
a potential involvement of Natural Killer cell receptors (NKR) on T or NK cells in clonal expansion 
by mediating selective immunological attack to GPI-expressing cells 8-10. In Chapter 2, we have 
investigated the presence of T cells with NKR in PNH, and their capacity to mediate selective 
immune attack to normal and not GPI-deficient HSC. We demonstrated that several NKR 
175
Su
m
m
a
ry
 a
n
d
 g
en
er
a
l d
iSc
u
SSio
n
10
expressing T cell populations were present at increased frequency in PNH patients compared 
to healthy donors. These included T cells expressing CD56 (p < 0.001), and the activating NKRs 
NKG2D (p < 0.01), NKG2C (p < 0.01), and KIR2DS4 (p = 0.01). Further characterization showed 
that these populations were predominantly terminally differentiated CD8+ effector memory 
CD45RA+ T cells (T
EMRA
), which is consistent with their presumed role as autoimmune effectors. 
Isolated NKR+ cytotoxic T lymphocytes (CTLs) from blood and bone marrow of PNH patients 
were highly cytotoxic towards CD34+ hematopoietic progenitor cell lines and the MHC class I 
deficient K562 cells. In some, but not all cases, we were able to demonstrate that these NKR+CD8+ 
CTLs isolated from PNH patients differentially lysed of GPI+ and GPI- variants of these cell lines. 
Definite proof for a role for NKR expressing T cells in immune-mediated marrow failure 
and differential susceptibility for lysis of GPI-deficient HSC requires cytoxicity studies using 
CD34+ cells isolated from autologous bone marrow. Such studies are generally hampered by 
low CD34+ cell numbers in bone marrow.  In addition, at the time of sampling, the autoimmune 
insult may already have subsided, as most PNH patients do not come to clinical attention until 
significant clonal expansion has already taken place. A long-term prospective study in PNH and 
particularly AA-PNH patients in whom sequential blood and bone marrow samples are collected 
during follow-up would provide the possibility to perform such experiments in patients while 
significant clonal expansion is ongoing. 
If indeed NKR expressing T cells lyse GPI-deficient HSC less efficiently than their normal 
counterparts, which mechanism can explain differential lysis? The following mechanisms could 
be envisioned (Figure 1); a) the GPI anchor itself is the auto-antigen, b) the GPI-deficient HSCs 
lack GPI-anchored NKR ligands, c) the GPI-deficient HSCs lack other GPI-anchored costimulatory 
ligands. The first option was recently investigated by Gargiulo et al. They found an increased 
frequency of CD8+ T cells reactive towards human GPI in PNH patients. GPI was presented in the 
context of CD1d, a non-classical MHC molecule 11. It would be interesting to investigate whether 
the NKR expressing T cell populations we found display CD1d restricted cytotoxicity towards 
GPI as well. In this scenario, NKR expression on T cells may be regarded as a marker of chronic 
immune activation 12. It remains highly speculative why autoreactive GPI-specific CD1d restricted 
CTLs appear in PNH. GPI-specific CTLs have been implicated in the immune response to various 
parasite antigens 13, and this observation might explain cross-reactivity towards human GPI. 
Evidence in favor of the second possibility, postulating a lack of GPI-anchored NKR ligands 
on HSC, has been provided by the studies of Hanaoka et al, who studied the role of UL16-binding 
Figure 1: Hypothetical mechanisms for differential lysis of gPi+ and gPi-deficient cd34+ cells by cytotoxic t 
cells in the pathogenesis of PNH. Various hypotheses can be proposed for the mechanism of differential lysis of 
GPI+ and GPI-deficient CD34+ cells in PNH, potentially resulting in clonal expansion of GPI-deficient HSC. 
Figure 1A: the GPI anchor itself is the auto-antigen and is presented in the non-classical MHC class I molecule 
CD1d by a normal, GPI+ CD34+ HSC. Its GPI-deficient CD34+ counterpart cannot synthesize GPI and therefore does 
not present GPI antigens. The CD1d restricted T cell specific for GPI therefore recognizes the GPI+ and not the 
GPI-deficient CD34+ HSC. In this scenario, there are no differences in the expression of co-stimulatory and co-
inhibitory ligands between the GPI+ and GPI-deficient CD34+ HSC. 
Figure 1B: The GPI+ CD34+ HSC expresses a GPI-anchored stimulatory NKR ligand, whereas the GPI-deficient CD34+ 
HSC does not. As NKR expressing T cells have been described to be capable of MHC class I independent cytotoxicity, ▶
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GPI as auto-antigen
Other unknown auto-antigen
MHC class I
CD1d
T cell receptor
Costimulatory/
co-inhibitory molecule
Costimulatory ligand
Co-inhibitory ligand
T cell
A GPI anchor serving as an auto-antigen
B GPI-anchored ligand lacking on GPI- CD34+ cell
C Lack of GPI-anchored costimulatory ligands
in this case, auto-antigen expression by the CD34+ HSC may not be required. The balance between stimulatory and 
inhibitory signals delivered by NKR ligands on the GPI+ HSC will result in a net activating signal to the cytotoxic T cell, 
whereas the GPI-deficient HSC will deliver a net inhibitory signal, or a less potent activating signal. 
Figure 1C: Both the GPI+ and the GPI-deficient CD34+ HSC present an identical, unknown auto-antigen, which is 
recognized by a cytotoxic T cell. Therefore, although signal 1 is delivered identically by both the GPI+ and GPI-
deficient HSC, the balance between costimulatory and co-inhibitory signals delivered by the GPI+ HSC will result 
in a net activating signal to the cytotoxic T cell, whereas the GPI-deficient HSC will deliver a net inhibitory, or a less 
potent activating signal. In this scenario, costimulatory and co-inhibitory molecules may also include non-NKR 
ligands. In that case, NKR expressed by the cytotoxic T cell may represent markers of chronic inflammation, 
rather than to have a direct role in differential lysis. 
▶
177
Su
m
m
a
ry
 a
n
d
 g
en
er
a
l d
iSc
u
SSio
n
10
proteins (ULBPs)9. ULBPs are stress-inducible GPI-anchored ligands for the activating NKR NKG2D. 
They found that in PNH patients, ULBPs are expressed on normal CD34+ cells. This observation fits 
a potential role for NKG2D expressing T cells in differential lysis of normal and GPI- CD34+ cells, 
via differential expression of its GPI-anchored ligand ULBP. However, for the other NKR (CD56 
and KIR2DS4) expressed with increased frequency on T cells of PNH patients in our study, no GPI-
anchored ligands are known. KIR2DS4 binds to HLA*A1102, HLA-Cw4 and an unknown non-MHC 
ligand 14-16, whereas CD56 binds to fibroblast-growth like receptor-1 17. In preliminary experiments, 
we were not able to demonstrate GPI-anchoring of the unknown KIR2DS4 ligand (unpublished 
data). In this experiment, we treated FO-1, a melanoma cell line known to express a KIR2DS4 ligand 
15, with phospholipase C, which cleaves GPI anchors. However, it did not reduce staining with a 
KIR2DS4-Fc fusion protein, indicating that the ligand of KIR2DS4 is most likely not GPI-anchored. 
As CD56 and KIR expression on T cells were also reported as markers of chronic immune activation 
18,19, it is more likely that these markers identify a pathogenetic T cell subset, rather than mediating 
autoreactivity itself. In this case (3rd hypothesis), the lack of other GPI-anchored costimulatory 
molecules on GPI-deficient CD34+ cells may mediate differential cytotoxic lysis of NKR expressing 
T cells. Such molecules may include LFA-3 (CD58), CD48, CD52, and many others (Table 1, Chapter 
1). In conclusion, the role of specific NKR in PNH pathogenesis requires further study.
In Chapter 3, we have studied bone marrow histology in a large series of patients (n = 67) with a 
PNH clone in different presentations. This provides the first comprehensive overview of the spectrum 
of BM histology in such patients and may serve as a reference for the histopathological characteristics 
of PNH. We have compared bone marrow histology in patients with a broad range of PNH clone 
sizes (1-100%). Based on clinical characteristics, patients with PNH clones were divided in AA-PNH 
and classic PNH (cPNH). AA-PNH patients were defined as fulfilling the peripheral blood criteria for 
aplastic anemia as defined by the International Agranulocytosis and Aplastic Anemia Study Group 20, 
whereas cPNH patients did not fulfill those criteria and had evidence of intravascular hemolysis. These 
patient groups were compared to an age-matched control group of AA patients without PNH clone, 
in order to search for differences that might account for the occurrence of a PNH clone. 
Interestingly, we found that decreased marrow cellularity, which was almost universally present 
in AA-PNH patients (95%), was a frequent feature of cPNH patients as well (36%, p < 0.0001). 
In addition, myeloid hypoplasia was found in the majority of both AA-PNH (85%) and cPNH 
(86%), although usually more subtle and often masked by increased erythropoiesis in the latter. 
Inflammatory features such as lymphoid nodules and increased mast cell numbers were present 
in both cPNH and AA-PNH, but more frequently in AA-PNH (38% and 73%) than in cPNH (20% 
and 43%) (p = 0.02 and p = 0.05 respectively). Collectively, these results demonstrate that despite 
obvious differences in bone marrow histology, cPNH and AA-PNH show considerable overlap in 
histological features. These data suggest that similar to AA-PNH, marrow failure is ongoing in cPNH 
as well. Thus, they emphasize the notion that both entities need to be considered as different ends 
of a continuous spectrum of BM failure syndromes rather than separate entities, as suggested by 
the current clinical working classification of the International PNH Interest Group (IPIG) 5. 
How can we explain the differences in cellularity and inflammatory infiltrates if we assume that 
an identical pathogenetic mechanism, i.e. immune-mediated bone marrow failure, is at work both 
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in AA-PNH and in cPNH? Such differences may reflect differences in the nature and timing of HSC 
injury. cPNH patients with decreased marrow cellularity may hypothetically represent patients 
at an earlier stage of disease, currently undergoing clonal expansion. In that case, such patients 
may be characterized by smaller PNH clone sizes and lower peripheral blood counts. However, 
we could not demonstrate such differences. Another open question is why some AA patients 
develop PNH clones whereas others do not. The low frequency of lymphoid nodules in AA patients 
(13%) compared to AA-PNH patients (38%, p = 0.02) may suggest differences in the strength or 
nature of the immune response. More definitive answers to these questions would require a larger 
prospective study with longer follow-up. In addition, studies investigating in more detail the 
differences in the nature of the inflammatory infiltrates between the different patient categories 
may provide valuable information. Immunohistochemistry or flow cytometry may be helpful to 
study whether these inflammatory infiltrates contain NKR expressing or CD1d restricted T cells. 
In Chapter 4, we have investigated the increased frequency of NKR expressing T cells 
in other auto-inflammatory diseases such as rheumatoid arthritis (RA) and psoriatic arthritis 
(PsA). Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic inflammatory 
diseases characterized by synovial inflammation and progressive joint damage with a complex 
pathophysiology, including genetic, immunological and environmental factors. Although the 
type of effector cells presumably involved in RA, PsA and AA/PNH and consequently the treatment 
of these diseases is obviously different, previous studies suggest that involvement of NKR 
expressing T cells may be a common element in pathogenesis. Epidemiological associations with 
KIR genes and disease prevalence have been reported in RA and PsA. In addition, several studies 
have provided data suggesting involvement of KIR-expressing T cells in these diseases 21-26. Their 
exact role in either RA or PsA or PNH is unknown. We aimed to answer the question whether the 
increased NKR expressing T cell populations observed in PNH are specific for PNH, or represent 
a more general feature of chronic immune activation. In the latter case, we wondered whether 
there is a correlation with disease severity or other clinical features in RA or PsA. To this end, we 
have extensively characterized the NKR repertoire in both T and NK cells of RA and PsA patients 
by 10-color flow cytometry. We have found low but elevated frequencies of T cells expressing 
KIR CD158ah both in RA and in PsA (0.7%, range 0.2-6%; PsA: 0.3%, range 0.1-1.4%) compared to 
healthy controls (0.2%, range 0.1-0.5%; p <  0.05). In addition, in RA, T cells expressing CD158e1e2 
were increased (1.5%, range 0-9%) compared to healthy controls (median 0.4%, range 0-2.8%; p < 
0.05). Further analysis of these T cell subsets, including further phenotypical characterization and 
functional assessment, e.g. cytokine production and killing capacity, and their presence in the 
synovium should answer the question whether these T cells are truly involved in RA pathogenesis. 
If these receptors are activating receptors, as shown for KIR expressing CD4+ T cells in RA 22, 
such T cells may represent autoimmune effectors. Alternatively, if these KIRs are inhibitory, a 
net activating signal to the T cell may result when HLA-ligands triggering the inhibitory KIR 
are absent. The association of PsA with the KIR2DS1 gene, particularly when HLA-Cw group 2 
ligands for its inhibitory counterpart KIR2DL1 are lacking, fits this hypothesis 24-26. In RA, similar 
mechanisms for CD158ah and/or CD158e1e2 expressing T cells may apply, although associations 
with the genes encoding KIR2DS1/KIR2DL1 or KIR3DS1/KIR3DL1 have not been reported. 
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In contrast to PNH patients, we did not find increased frequencies of T cells expressing 
CD56, KIRDS4, NKG2C and NKG2D neither in RA nor in PsA patients. Since KIRs in general 
bind to HLA class I alleles, differences in KIR expression in PNH versus RA and PsA patients 
may reflect differences in KIR genotype and/or HLA background, corresponding to a different 
susceptibility to develop these diseases. Alternatively, such differences may also mirror 
differential pathogenetic mechanisms. For example, in the case of PNH, the expansion of 
NKG2D expressing T cells may be driven by increased expression of ULBP on GPI+ HSC. 
In RA, but not in PNH or PsA, we observed a different phenotype of peripheral blood NK cells 
compared to healthy controls. We have demonstrated an increased frequency of NKG2A+ NK cells, 
which were predominantly CD56dim and lacked expression of KIRs and activating NKG2C. This may 
indicate a more immature or hyporesponsive status, corresponding to previous observations of 
decreased NK cell cytotoxicity in RA patients 27. However, no functional defects of NKG2A expressing 
NK cells were observed in our study. In contrast, a study in a mouse model of RA showed that 
NKG2A expressing NK cells were less capable of killing pathogenic T
helper
 (T
h
) subsets 28. Interestingly, 
the same study showed that treatment with anti-NKG2A antibodies decreased pathogenic T
h
 cell 
numbers, and importantly, improved arthritis. Together with our results, this study suggests that 
NKG2A expressing NK cells may have a role in RA pathogenesis, and that boosting NK cells by 
blocking NKG2A might provide a novel treatment option in RA. In PNH, blocking NKG2A is most 
likely not effective, as we found no differences in NK cell phenotype with healthy controls.
Taken together, differences in NKR expression patterns in NK and T cells as described in Chapter 4 
may mirror the diverse pathogenetic mechanisms implicated in these diseases. Future should include 
further phenotypical characterization, more extensive correlation with clinical characteristics and 
further functional analysis to determine their role in the pathogenesis of these diseases. 
Pa rt  i i :  P N H  a N d  t H r o m b o s i s 
Another major unresolved topic in the field of PNH is the mechanism of thrombosis. Patients with 
PNH have a highly increased risk of thrombosis which is correlated with PNH granulocyte clone 
size 29. The estimated cumulative 10-year incidence of thrombosis is 23-31% in PNH patients not 
treated with eculizumab 6,29. Thrombosis is one of the most severe complications of PNH, seriously 
affecting quality of life and survival, and is one of the major causes of death in PNH 6. Thrombosis 
frequently occurs in vital organs such as liver, intestine or central nervous system, with the 
Budd-Chiari syndrome (portal vein thrombosis) as the most common manifestation 6,30-33. The 
occurrence of thrombosis in PNH is impossible to predict; it is a presenting symptom in 7.2% 6 of 
patients but the first clinical thrombosis may also occur many years after presentation 29. Patients 
who have suffered one thrombotic event are prone to develop other thrombotic events 6. 
Until now, the only strategy with proven efficacy to reduce thrombotic risk is complement 
inhibition via eculizumab 34; however, the mechanism is still unknown. Traditional primary 
prophylaxis using vitamin K antagonists (VKA) decreases the risk of thrombosis, but nevertheless 
serious thrombotic events still occur 6,29.  The effect of platelet inhibitors or novel oral anticoagulants 
(NOACs) is unknown. Platelet inhibitors may increase the risk of bleeding, particularly in patients with 
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thrombocytopenia. Considering the mechanism of action of NOACs, it is not expected that these 
will provide improved protection over traditional VKA. A better understanding of the mechanism 
of thrombosis and ideally, to identify markers that may aid in estimating an individual patient’s risk 
of thrombosis, is highly important to prevent thrombosis and its burdening symptoms. Part 2 of 
this thesis has focused on thrombosis in PNH, the possible mechanisms via which the complement 
C5 inhibitor eculizumab reduces thrombotic risk, and some potential complicating factors in the 
management of PNH patients treated with eculizumab in relation to thrombosis. 
In Chapter 5, the current knowledge on epidemiology, mechanisms and treatment of 
thrombosis was reviewed. Mechanisms postulated to explain thrombotic risk in PNH include 
endothelial damage due to the toxic effects of free hemoglobin, nitric oxide depletion by free 
hemoglobin, platelet activation and the release of microparticles (MP), small membrane-derived 
vesicles with procoagulant properties. In addition, deficiencies of GPI-anchored proteins involved 
in coagulation and fibrinolysis may play a role. The studies showing that eculizumab significantly 
reduces thrombotic risk in PNH are summarized.
In Chapter 6, we have studied the role of neutrophil activation and formation of neutrophil 
extracellular traps (NETs) in PNH patients before and during treatment with eculizumab. NETs 
are extracellular meshworks of DNA fibers comprising histones and neutrophil proteases which 
are extruded from the nucleus of neutrophils and other myeloid cells upon activation35. This 
may or may not result in cell death. Similar to MP, they are highly procoagulant as they form a 
platform for platelet adhesion, activation and aggregation. Although both NET and MP may serve 
as markers of cellular damage, they are generated via different mechanisms. Stimuli that induce 
NET formation include cytokines, bacterial or fungal products, endothelial damage, complement 
factor C5, and free heme. Hypothetically, the lack of GPI-anchored complement inhibitors CD55 
and CD59 may render PNH neutrophils more prone to release NETs upon C5 induced activation, as 
occurs during infection, and thus, increase thrombotic risk via a novel mechanism. 
In this study, we have determined in 51 PNH patients before and during eculizumab treatment 
the levels of elastase-α1-antitrypsin (EA) complexes and circulating nucleosomes as markers of 
neutrophil activation and NET formation respectively. Interestingly, we demonstrated increased 
nucleosome levels in untreated PNH patients with a history of thrombosis compared to those without 
(p < 0.001). No correlation with MP concentrations was found, suggesting that MP and nucleosome 
release are not merely two different manifestations of complement-mediated cellular damage. Our 
data may suggest circulating nucleosomes to reflect ongoing subclinical thrombosis, which is known 
to be a frequent complication in PNH 36, and hence may indicate an even more thrombosis prone 
phenotype. Ideally, a prospective study would be required to validate this finding; however, due to 
the orphan character and the heterogeneity of the disease, these are extremely difficult to perform. 
Upon eculizumab treatment, we observed a prompt and persistent decrease in EA complex 
levels. As C5 is one of the stimuli which induces neutrophil activation and subsequent NET formation, 
this finding indicates a decreased level of neutrophil activation and thus, possibly a decreased ability 
of neutrophils to form NET during eculizumab treatment. Apart from reducing hemolysis, this may 
be another mechanism via which eculizumab reduces thrombotic risk, particularly in a setting of 
concurrent infection. A decrease in nucleosome levels was observed only in patients with a history 
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of thrombosis as early as 1 hour after initiation of eculizumab treatment but not at later time points. 
Future studies are required to confirm these findings in larger patient cohorts, and should ideally 
include in vitro studies to compare the ability of GPI-deficient and normal neutrophils and other 
myeloid cells to generate NET, in the presence and absence of eculizumab. 
In chapter 7, we have studied coagulation and fibrinolysis in a large population of PNH patients 
by measuring procoagulant microparticles (MP), prothrombin fragment 1+2 (F1+2), tissue factor 
and D dimer levels. In addition, we have simultaneously analyzed coagulation and fibrinolysis and 
their interplay using the Nijmegen Hemostasis Assay (NHA). In PNH patients we unexpectedly 
found a decreased thrombin peak height and thrombin potential compared to healthy controls, 
which inversely correlated to LDH and clone size. These parameters derived from the NHA 
represent the maximum velocity and the total amount of thrombin generation respectively. In 
vivo consumption of coagulation factors due to a continuously ongoing low degree of coagulation 
activation may explain these data. No tissue factor activity in PNH patient plasma or peripheral 
blood mononuclear cells was demonstrated. Microparticle levels correlated with LDH levels in 
PNH patients, but were increased in only a minority of patients.  When comparing PNH patients 
with and without a history of thrombosis in order to identify potential biomarkers that may aid in 
predicting thrombotic risk, those with a history of thrombosis had higher F1+2 and D dimer levels. 
However, the latter accounted only for patients with a recent thrombotic event, suggesting that 
the D dimer elevation is merely a consequence of the thrombotic event. The prognostic value of 
F1+2, D dimer and NHA parameters in assessing thrombosis risk requires further study. 
In this study, we have also evaluated the effect of eculizumab on these parameters in order to 
gain more insight on the mechanism by which eculizumab reduces thrombotic risk. Confirming and 
extending the results of Helley et al. 37, we found that during eculizumab treatment, D dimer already 
significantly decreased after 1 hour (p = 0.008) and remained decreased at ≥ 12 weeks (p = 0.03) in 
patients with elevated baseline levels. Apparently, eculizumab inhibits coagulation very rapidly as 
was already previously suggested by clinical observations 38,39. F1+2 in patients not on VKA (p = 0.03) 
significantly decreased at ≥ week 12. Although in untreated PNH patients, MP levels significantly 
correlated to LDH levels, their levels remained unchanged during eculizumab treatment despite 
a reduction in hemolysis and thrombotic risk. A possible explanation may be that C3a alone is 
sufficient to stimulate the MP generation by PNH blood cells, due to the lack of CD55 which blocks 
C3 convertase at the cell surface. Alternatively, the sensitivity of the assay may be too low to detect 
a significant decrease in MP levels, which were only slightly increased in most patients. Finally, we 
found that thrombin peak height was significantly reduced at ≥ 12 weeks of treatment. 
The introduction of eculizumab has significantly improved the symptoms, quality of life and 
survival of patients with PNH 40. However, particularly in rare diseases like PNH, it is essential that 
potential complications of this treatment are investigated and reported in individual case studies. 
Chapter 8 reports on a PNH patient who developed thrombosis shortly after withdrawal of 
eculizumab treatment, raising the question whether there is a causal relationship between these 
two events. In this patient with classical PNH we discontinued eculizumab treatment after she 
developed aplastic anemia. Unfortunately, she developed a mesenterial thrombosis 3 weeks after 
her last dose of eculizumab which finally led to her death. Hillmen et al. reported two additional 
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patients who developed a thrombotic event within 8 weeks after stopping eculizumab in a total of 
19 patients (15.8%) 41. If the discontinuation of eculizumab precipitated thrombosis in these patients, 
the mechanism remains speculative. As our patient did not have any PNH erythrocytes due to the 
aplastic anemia and frequent transfusions, hyperhemolysis did not occur and therefore cannot be 
a cause of thrombosis in this patient. Our observation warrants special awareness of the potentially 
high thrombotic risk in patients discontinuing eculizumab treatment when there is a persistent 
population of PNH cells.
Clinical events that enhance complement activation such as surgery and pregnancy have 
a high rate of morbidity and mortality in PNH. With the availability of eculizumab, effective 
complement inhibition can be achieved during such events. However, knowledge on adequate 
eculizumab dosing is lacking. Chapter 9 discusses the management of one of the first PNH 
patients undergoing cardiopulmonary bypass (CPB) for aortic valve replacement surgery and 
coronary artery bypass grafting (CABG) during eculizumab treatment. Surgery in general 
and particularly CPB, induces complement activation and thrombin generation, which in 
PNH patients may aggravate hemolysis and induce thrombosis. In this chapter, a successful 
peri-operative dosing regimen for eculizumab was described, which resulted in undetectable 
terminal complement proteins and low parameters of coagulation activation during and 
after surgery. Future research should further optimize dosing regimens during complement 
enhancing events by assessing levels of complement and eculizumab in individual patients. 
c o N c l u d i N g  r e m a r k s  a N d  F u t u r e  P e r s P e c t i v e s
Major progress in the treatment of PNH has been made in the last decade with the introduction 
of eculizumab. Eculizumab, a monoclonal antibody to complement factor C5, effectively reduces 
hemolysis, associated symptoms and thrombotic risk. Although eculizumab has markedly 
improved PNH patients’ quality of life and survival, it is not a curative therapy which needs to be 
administered lifelong at high costs and has no influence on concomitant bone marrow failure. 
Other disadvantages include increased susceptibility for infection and in some cases continued 
transfusion requirement. Until now, infectious risk was only apparent for meningococcal and 
gonococcal infections, but our finding of reduced neutrophil activation during eculizumab 
treatment may indicate that susceptibility for other infections is also increased. Continued 
transfusion requirement during eculizumab treatment may be caused by bone marrow failure and/
or by opsonization of C3 coated PNH erythrocytes due to deficient CD55 expression. The latter 
results in persistent extravascular hemolysis during eculizumab treatment. Novel complement 
inhibitors, which block the complement system earlier in the cascade or also at the level of C5, 
are currently under preclinical and clinical investigation42-48. Although the earlier blocking agents 
are expected to reduce extravascular hemolysis, they will not provide a curative therapy either. 
Whether these agents increase susceptibility for infections even more should be investigated in 
future clinical trials. In addition, the factors that determine the degree of extravascular hemolysis, 
such as complement polymorphisms, should be a topic of future research. Knowledge of such 
factors may eventually result in individualized complement inhibiting strategies in PNH.
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When aiming to design a curative therapy for PNH, a better understanding of the mechanism of 
expansion of a PNH clone is crucial. Clonal expansion in PNH is generally believed to involve immune-
mediated bone marrow failure. In this thesis, we have shown that NK cell receptor expressing T cells 
may mediate this process via differential cytotoxic lysis of normal and GPI-deficient hematopoietic 
stem cells. Alterations in NK cell receptor repertoire on T and NK cells are also present in other 
immune-mediated diseases such as rheumatoid arthritis, indicating that these changes are not 
specific for PNH but probably represent a more general phenomenon in autoimmune and auto-
inflammatory diseases. Additional research is necessary to interpret these findings both in PNH 
and other autoimmune diseases. In PNH, such studies should answer the question whether NKR 
expressing T cells are indeed autoimmune effectors reactive towards HSC, whether they mediate 
differential susceptibility of normal and GPI-deficient HSC, at what time during disease course these 
processes take place, and lastly, what is the role of specific NKR in these processes. 
The recent discovery by Shen et al. of a variety of additional mutations in a large proportion 
of PNH patients, some of which have also been implicated in other myeloid neoplasms, raises 
several interesting questions that need to be addressed in future research49. Shen et al. showed 
that some of these mutations predate the PIG-A mutation, whereas in other patients, they occur 
within the PNH clone. Future studies should focus on correlating the diverse clinical picture and 
particularly the pattern of PNH clone expansion, regression or stabilization over time, to the 
mutational landscape of individual PNH patients. In addition, it would be very interesting to 
investigate the presence of these mutations in AA patients without PNH clone. Finally, how 
does this finding relate to the immune escape theory? Is immune escape of GPI-deficient cells 
related to the presence or absence of specific mutations? Does immune escape occur only in 
some patients, whereas in other patients GPI-deficient cells have an intrinsic growth advantage 
due to the presence of specific mutations? Answers to these questions may eventually provide 
a target for a rational strategy to prevent the development of PNH. 
Besides the mechanism of clonal expansion, other important questions to be answered 
in the field of PNH are the pathogenesis of thrombosis in PNH and how eculizumab or other 
complement inhibitors reduce thrombotic risk. Is it possible to predict which patients will 
develop thrombosis when, and are there other ways to prevent the development of thrombosis 
than complement inhibition? Finally, why does thrombosis in PNH have a predilection for the 
abdomen and the central nervous system? 
The hemostatic balance is maintained by a delicate equilibrium between coagulation and 
fibrinolysis, and is influenced by various blood cells and the vessel wall. In PNH several factors may 
direct this balance towards a prothrombotic state, and the relative contribution of each factor 
is still unknown. In this thesis, we did not show apparent defects in fibrinolysis. Coagulation 
parameters were paradoxically decreased in patients with the highest level of hemolysis and 
the largest clone size, presumably at the highest thrombotic risk. This phenomenon may 
indicate consumption of coagulation factors. Other factors that may influence the balance 
towards a prothrombotic state in PNH include neutrophils, platelets and other blood cells, and 
importantly, the endothelium. In this thesis, we have investigated in clinical studies whether 
the formation of neutrophil extracellular traps (NETs) may be one of these factors. Since NETs 
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are released upon infection, it may provide another mechanistic link, next to complement-
induced hemolysis, between infection and the occurrence of thrombosis. Experimental studies 
should delineate the possible role of NETs in PNH. The role of platelet activation, other blood 
cells such as monocytes, and complement-mediated endothelial damage in PNH-related 
thrombosis, was not investigated in this thesis and should be the subject of future studies. 
The complement inhibitor eculizumab significantly reduces thrombosis risk, highlighting 
the major role of complement itself or complement-mediated cellular damage in PNH-related 
thrombosis. Clinical evidence suggests that eculizumab may abrogate thrombus formation within 
hours. The exact mechanisms and timing of action of reducing thrombotic risk are unknown. In this 
thesis, we have shown rapid decreases in D dimer levels and neutrophil activation markers upon 
eculizumab treatment. The latter may indicate that during eculizumab treatment, neutrophils are 
less susceptible to form thrombogenic NETs. This may pose a novel mechanism via which eculizumab 
reduces thrombotic risk, but may also have, yet unrecognized, negative consequences for innate 
immunity. Importantly, platelet function during eculizumab treatment has not been investigated yet. 
Ideally, one would like to use biomarkers that identify patients at the highest risk of 
thrombosis. Whether this will ever be possible remains to be determined. In this thesis, we 
have shown that in retrospect, PNH patients with a history of thrombosis have higher levels of 
nucleosomes, a marker of NET formation, fragment 1+2 and D dimer. It is unclear whether such 
changes are the consequence or cause of thrombosis, or indicate the presence of subclinical 
thrombosis. In the latter case, these markers indicate a more thrombosis prone phenotype in 
PNH patients. Prospective national or international studies are required to determine whether 
these markers have predictive value for thrombosis in patients with PNH. This could provide the 
opportunity to develop more patient-tailored strategies to prevent thrombosis in PNH patients. 
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d e e l  1 :  r o l  v a n  a u t o - i m m u n i t e i t  e n  b e e n m e r g f a l e n  
i n  d e  p a t h o g e n e s e  v a n  P N H
Paroxysmale Nachtelijke Hemoglobinurie (PNH) is een extreem zeldzame chronische ziekte die 
gekenmerkt wordt door bloedarmoede ten gevolge van afbraak van rode bloedcellen (hemolyse). 
Daarnaast is er een verhoogd risico op trombose en is er soms een verminderde werking van het 
beenmerg (beenmergfalen). Hierdoor ontstaat een tekort aan witte bloedcellen, bloedplaatjes en 
rode bloedcellen. De mate waarin deze verschillende kenmerken van het ziektebeeld aanwezig 
zijn varieert sterk. De ziekte wordt veroorzaakt door een verworven mutatie in het X-gebonden 
fosfatidylinositol glycaan complementatie klasse A (PIG-A) gen in de bloedcelvormende stamcel in 
het beenmerg (de hematopoietische stamcel, HSC). Dit gen is noodzakelijk is voor de vorming van 
glycosyl-fosfatidyl-inositol (GPI) ankers. GPI ankers verbinden diverse eiwitten met het celmembraan. 
De mutatie in het PIG-A gen in de HSC leidt tot het ontstaan van een kloon van bloedcellen. Op het 
membraan van deze bloedcellen ontbreken alle GPI-verankerde eiwitten. Diverse eiwitten zijn door 
middel van een GPI anker met het celmembraan verbonden, waaronder de complementremmers 
CD55 en CD59. Complement is een onderdeel van ons afweersysteem dat wordt geactiveerd tijdens 
onder andere infecties. Normaliter worden lichaamseigen cellen beschermd door de aanwezigheid 
van complementremmers. Het ontbreken van deze remmers op de rode bloedcellen van PNH 
patiënten leidt tot hemolyse welke verder versterkt wordt tijdens infecties. 
Het beenmergfalen is een intrigerend kenmerk van PNH. Vermoedelijk wordt dit 
veroorzaakt door een afweerreactie gericht tegen de HSC, zoals dat ook meestal het geval 
is bij aplastische anemie (AA), waarmee PNH nauw verwant is. Deze auto-immuun reactie is 
mogelijk ook verantwoordelijk voor de toename in grootte van de PNH kloon (zogenaamde 
klonale expansie), die bij veel patiënten gedurende het ziektebeloop wordt waargenomen. Een 
of meerdere PIG-A gemuteerde HSC nemen de bloedcelvorming (hematopoiese) grotendeels 
over ten koste van de normale HSC. Een veel genoemde hypothese die deze klonale expansie 
verklaart stelt dat, wanneer er sprake is van een afweerreactie gericht tegen de HSC, de 
GPI-deficiënte HSC mogelijk beter hiertegen bestand is dan zijn normale tegenhanger (de 
zogenaamde “immune escape” theorie). Deze verschillen in gevoeligheid voor immunologische 
schade (cytotoxische lysis) tussen GPI-deficiënte en normale HSC zou kunnen leiden tot een 
selectief groeivoordeel voor GPI-deficiënte HSC, en dus klonale expansie van deze cellen. 
Deel 1 van dit proefschrift richt zich op de rol van auto-immuniteit en beenmergfalen in de 
pathogenese van PNH. Uit eerdere studies is gebleken dat Natural Killer cel receptoren (NKR), 
aanwezig op het oppervlak van T en Natural Killer (NK) cellen, mogelijk een rol spelen in dit 
proces. In Hoofdstuk 2 hebben wij bij PNH patiënten de aanwezigheid van T cellen met expressie 
van NKR onderzocht, en daarnaast hun mogelijke rol in de expansie van een PNH kloon. PNH 
patiënten hadden, vaker dan gezonden, T cel populaties met expressie van NKR. Dit betrof de NKR 
CD56, en de activerende NKR NKG2D, NKG2C en KIR2DS4. Bij verdere karakterisering bleek dat 
deze T cellen voornamelijk terminaal gedifferentieerde CD8+ effector memory CD45RA+ T cellen 
(T
EMRA
) waren. Dit zou kunnen passen bij hun veronderstelde rol als auto-immuun effector cellen. 
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Vervolgens hebben wij in vitro aangetoond dat deze T cellen in staat zijn CD34+ hematopoietische 
progenitor cellijnen en de K562 cellijn te lyseren. In sommige gevallen bleek dat de GPI-deficiënte 
varianten van deze cellijnen hiervoor minder gevoelig waren dan hun normale tegenhangers.
Om definitief te kunnen bewijzen dat T cellen met NKR een rol hebben in auto-immuun 
gemedieerd beenmergfalen, en dat GPI-deficiënte HSC inderdaad verminderd gevoelig zijn voor 
lysis door deze T cellen, zijn experimenten nodig waarbij gebruik gemaakt wordt van CD34+ cellen 
geïsoleerd uit autoloog beenmerg. Dergelijke studies worden vaak beperkt door lage aantallen 
CD34+ cellen in het beenmerg, en mogelijk ook door een verkeerde timing van monsterafname. Bij de 
meeste patiënten komt PNH namelijk pas aan het licht als klonale expansie al heeft plaatsgevonden. 
De oorspronkelijke auto-immuunreactie gericht tegen het beenmerg is dan mogelijk al uitgedoofd. 
Een prospectieve studie met lange follow-up bij PNH patiënten, en belangrijker nog, ook bij patiënten 
met het PNH-AA overlapsyndroom, waarbij op gezette tijden bloed- en beenmergmonsters worden 
afgenomen, biedt de mogelijkheid om dergelijke experimenten uit te voeren met monsters van 
patiënten die op dat moment klonale expansie ondergaan. 
Een tweede vraag is waarom GPI-deficiënte HSC minder gevoelig zijn dan normale HSC 
voor lysis door NKR+ T cellen, en wat is de rol van NKR hierin? Er zijn meerdere hypothesen 
mogelijk: a) het GPI anker is een auto-antigen, m.a.w. het lokt een afweerreactie uit waarvoor 
vanzelfsprekend de GPI-deficiënte HSC verminderd gevoelig is, b) op de GPI-deficiënte HSC 
ontbreken GPI-verankerde liganden van NKR, c) andere GPI-verankerde costimulatoire 
moleculen ontbreken op de GPI-deficiënte HSC. De eerste mogelijkheid is recent onderzocht. 
Men toonde aan dat PNH patiënten een verhoogd aantal CD8+ T cellen hebben gericht tegen 
humaan GPI. Het zou interessant zijn om te onderzoeken of de NKR+ T celpopulaties uit onze 
studie eveneens reactief zijn tegen GPI. De tweede hypothese, te weten een deficiëntie van 
GPI-verankerde NKR liganden op GPI-deficiënte HSC, wordt ondersteund door eerdere 
onderzoeken. Deze toonden aan dat UL-16 binding proteins (ULBPs), GPI-gebonden liganden 
voor de NKR NKG2D, aanwezig zijn op normale CD34+ HSC van PNH patiënten. Dit zou een 
mogelijke rol voor NKG2D+ T cellen, welke in onze studie verhoogd aanwezig waren, in het 
verschil in gevoeligheid voor lysis tussen normale en GPI-deficiënte CD34+ cellen kunnen 
ondersteunen. Echter, voor CD56 en KIR2DS4, de andere 2 NKR met verhoogde frequentie op T 
cellen van PNH patiënten in onze studie, zijn geen GPI-verankerde liganden bekend. Het is dan 
ook waarschijnlijker dat CD56 en KIRs op deze T cellen slechts markers zijn voor een pathogene 
T cel subset dan dat deze receptoren daadwerkelijk betrokken zijn bij de auto-immuunreactie. 
In het eerste geval zou het ontbreken van GPI-verankerde co-stimulatoire moleculen op 
GPI-deficiënte CD34+ HSC verantwoordelijk kunnen zijn voor een verschil in cytotoxische 
lysis tussen normale en GPI-deficiënte CD34+ HSC door NKR+ T cellen (3e hypothese). Diverse 
eiwitten zouden een dergelijke rol kunnen vervullen waaronder LFA-3 (CD58), CD48, CD52 en 
nog vele andere (Tabel 1, hoofdstuk 1). Concluderend kunnen we stellen dat verder onderzoek 
noodzakelijk is naar de rol van specifieke NKR in de pathogenese van PNH. 
In Hoofdstuk 3 hebben we de histologie van het beenmerg in een grote serie van 67 patiënten 
met een PNH kloon met verschillende klinische presentaties onderzocht. Deze studie vormt een 
eerste overzicht van het spectrum van beenmerghistologie in PNH patiënten. PNH kloongrootte 
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varieerde van 1 tot 100%. Op basis van klinische kenmerken werden patiënten onderverdeeld in 
patiënten met een AA-PNH overlap syndroom en klassieke PNH. Patiënten werden als AA-PNH 
geclassificeerd op basis van criteria voor hun perifere bloedwaarden. Klassieke PNH patiënten 
voldeden niet aan deze criteria en hadden daarnaast intravasculaire hemolyse. AA-PNH en 
klassieke PNH patiënten werden vergeleken met een qua leeftijd vergelijkbare controlegroep 
van AA patiënten zonder PNH kloon, met als doel mogelijke verschillen in beenmerghistologie 
te detecteren die het ontstaan van een PNH kloon zouden kunnen verklaren. 
Een interessante bevinding was dat niet alleen bij het merendeel van de AA-PNH patiënten 
(95%) er sprake was van een verminderde beenmergcellulariteit, maar ook bij een belangrijk deel 
van de klassieke PNH patiënten (36%, p < 0.0001). Daarnaast had een vergelijkbaar deel van de 
klassieke PNH patiënten en AA-PNH patiënten myeloїde hypoplasie. Bij patiënten met klassieke 
PNH was dit echter meestal meer subtiel aanwezig dan bij AA-PNH en werd dit vaak gemaskeerd 
door een versterkte erythropoiese. Kenmerken van ontsteking, zoals lymfoїde noduli en een 
verhoogd aantal mestcellen, waren bij beide categorieën patiënten aanwezig maar significant 
vaker bij AA-PNH (38% en 73%) dan bij klassieke PNH (20% en 43%) (respectievelijk p = 0.02 en p 
= 0.05). Samenvattend laten deze resultaten zien dat er een aanzienlijke overlap bestaat tussen 
de histologische kenmerken van AA-PNH en klassieke PNH. Dit versterkt het concept dat beide 
entiteiten beschouwd dienen te worden als twee uiteinden van een continu spectrum van ziekte 
gepaard gaande met immuungemedieerd beenmergfalen, in plaats van twee aparte entiteiten. 
Als men aanneemt dat zowel bij AA-PNH als klassieke PNH immuun-gemedieerd 
beenmergfalen een rol speelt in de pathogenese, hoe kan men dan verschillen in cellulariteit 
en ontstekingscellen verklaren? Dit is mogelijk een weerspiegeling van verschillen in aard en 
timing van auto-immuun gemedieerde schade aan de HSC. Klassieke PNH patiënten met een 
verminderde beenmergcellulariteit zijn mogelijk patiënten in een eerder stadium van ziekte die 
op dat moment klonale expansie ondergaan. In dat geval zou men verwachten dat dergelijke 
patiënten kleinere PNH klonen hebben en lagere perifere bloedwaarden. Een dergelijk verschil 
konden wij echter niet aantonen. Een andere onbeantwoorde vraag is waarom sommige AA 
patiënten een PNH kloon ontwikkelen en anderen niet. Onze bevinding dat AA patiënten 
minder vaak lymfoїde noduli in het beenmerg hebben (13%) dan AA-PNH patiënten (38%, p = 
0.02) zou kunnen duiden op verschillen in intensiteit of aard van de immuunrespons. 
Om deze vragen te beantwoorden moeten deze bevindingen bevestigd worden in een grotere 
prospectieve studie met langere follow-up. Waardevolle informatie zou verkregen kunnen worden 
door aard van het ontstekingsinfiltraat in het beenmerg van de verschillende patiëntencategorieën 
in meer detail te onderzoeken, bijvoorbeeld door middel van immunohistochemie. Een interessante 
vraag is of deze ontstekingsinfiltraten NKR+ of GPI specifieke T cellen bevatten. 
Hoofdstuk 4 van dit proefschrift borduurt voort op de bevindingen uit Hoofdstuk 1, waarin 
we een verhoogde frequentie van T cellen met expressie van NKR beschreven in patiënten met 
PNH. We vroegen ons af of deze bevinding specifiek is voor PNH, of dat het een meer algemeen 
kenmerk van auto-immuun- of auto-inflammatoire ziekten betreft. Reumatoide artritis (RA) en 
artritis psoriatica (PsA) zijn chronisch inflammatoire ziekten gekenmerkt door ontsteking van 
het synovium en progressieve gewrichtsschade. De pathogenese van deze ziekten is complex 
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en omvat genetische, immunologische en omgevingsfactoren. Uit eerdere studies is gebleken 
dat betrokkenheid van T cellen met expressie van NKR mogelijk een gemeenschappelijke factor 
is in de pathogenese van deze ziekten. Hun precieze rol is echter nog onduidelijk. 
We hebben bij patiënten met RA en PsA het NKR repertoire op T en NK cellen 
gekarakteriseerd door middel van 10-kleuren flow cytometrie. Bij zowel RA als PsA patiënten 
vonden we lage, maar ten opzichte van gezonde controles (0.2%, range 0.1-0.5%; p < 0.05) 
verhoogde frequenties van T cellen met expressie van de KIR CD158ah (RA: 0.7%, range 0.2-6%; 
PsA: 0.3%, range 0.1-1.4%). RA patiënten hadden daarnaast een hogere frequentie van T cellen 
met expressie van CD158e1e2 (1.5%, range 0-9%) dan gezonde controles (mediaan 0.4%, range 
0-2.8%; p < 0.05). Het onderscheid tussen activerende en inhiberende varianten van deze KIRs 
kon in deze studie niet gemaakt worden. Aannemende dat het de activerende varianten van 
deze KIRs betreft, zoals reeds aangetoond is voor CD4+ T cellen met expressie van KIRs bij RA 
patiënten, dan zouden deze T cellen inderdaad betrokken kunnen zijn bij een auto-immuun 
reactie. Echter, zelfs wanneer het inhiberende KIRs betreft, kan dit mogelijk toch resulteren in 
een netto activerend signaal aan de T cel als de HLA liganden van deze KIRs ontbreken.
In tegenstelling tot patiënten met PNH, vonden we bij RA en PsA patiënten geen verhoogde 
frequentie van T cellen met expressie van CD56, KIR2DS4, NKG2C of NKG2D. Aangezien KIRs 
binden aan HLA klasse I moleculen zouden verschillen in KIR expressie tussen patiënten met 
PNH, RA en PsA kunnen duiden op verschillen in HLA genetische achtergrond, en dus op een 
verschil in vatbaarheid voor deze ziekten. Een andere mogelijkheid is dat deze verschillen in 
receptor expressie een verschillende pathogenese weerspiegelen. Zo zou bijvoorbeeld bij PNH 
de expressie van UL-16 binding proteins (ULBPs) op GPI+ HSC kunnen leiden tot het ontstaan 
van een T cel populatie met expressie van NKG2D. 
Een andere interessante bevinding in deze studie was een verschil in fenotype van NK cellen 
tussen RA patiënten enerzijds, en PsA patiënten en gezonde controles anderzijds. In RA patiënten 
bleek de frequentie van NK cellen met expressie van de inhiberende receptor NKG2A verhoogd. 
Deze NK cellen waren voornamelijk van het CD56dim subtype, en hadden geen expressie van 
KIRs of de activerende receptor NKG2C. Een dergelijk fenotype kan passen bij een meer onrijp 
subtype NK cellen met een verminderde cytotoxische capaciteit. Onze experimenten lieten 
echter geen verminderde functionaliteit zien. NK cellen met expressie van NKG2A zijn mogelijk 
minder goed in staat om pathogene T
helper
 (T
h
) subsets te doden, zoals recent in een muismodel 
van RA werd aangetoond. Deze studie liet daarnaast zien dat behandeling van muizen met een 
antistof tegen NKG2A leidde tot een afname van pathogene Th cellen en gewrichtsontsteking. 
Deze en onze resultaten suggereren dat NK cellen met expressie van NKG2A een rol spelen in 
de pathogenese van RA en dat het stimuleren van de functie van NK cellen door middel van 
antistofblokkade van NKG2A een nieuwe behandelingsmogelijkheid zou kunnen zijn. 
Samenvattend laat de studie beschreven in Hoofdstuk 4 zien dat het expressiepatroon van 
NK cel receptoren in T en NK cellen verschilt tussen RA en PsA patiënten en gezonde controles. 
In toekomstige studies zal verdere karakterisering, functionele analyse en uitgebreidere 
correlatie met klinische kenmerken moeten plaatsvinden om de rol van deze T en NK cel 
populaties in de pathogenese van deze ziekten beter te definiëren. 
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d e e l  i i :  P N H  e n  t r o m b o s e
PNH patiënten hebben een sterk verhoogd risico op trombose, dat gerelateerd is aan de 
grootte van de PNH granulocyten kloon. De cumulatieve 10-jaars incidentie van trombose bij 
onbehandelde PNH patiënten wordt geschat op 23-31%. Het optreden van trombose heeft een 
belangrijke invloed op overleving en kwaliteit van leven, en is vaak de doodsoorzaak van PNH 
patiënten. Trombose kan ontstaan in belangrijke organen zoals de lever, de darmen of het 
centraal zenuwstelsel. Het optreden van trombose bij PNH patiënten is onvoorspelbaar; het kan 
een eerste manifestatie van de ziekte zijn maar ook vele jaren na diagnose optreden. Patiënten 
die eenmaal trombose hebben gehad hebben een sterk verhoogd risico op meerdere tromboses. 
Tot op heden is de enige bewezen effectieve preventie van trombose bij PNH patiënten 
complementremming met eculizumab. De manier waarop eculizumab trombose voorkomt is 
echter nog onbekend. Traditionele primaire profylaxe met vitamine K antagonisten verlaagt 
weliswaar het risico maar voorkomt ernstige tromboses niet. Het effect van plaatjesremmers 
of de nieuwe orale anticoagulantia (NOACs) is niet bekend. Een beter begrip van de manier 
waarop trombose ontstaat bij PNH, en idealiter het identificeren van biomarkers die het risico 
op trombose kunnen voorspellen, zijn noodzakelijk om trombose te voorkomen. Deel 2 van dit 
proefschrift behandelt trombose bij PNH en de manier waarop eculizumab het tromboserisico 
vermindert. Daarnaast worden enkele problemen die kunnen optreden tijdens behandeling 
met eculizumab in relatie tot trombose besproken. 
In hoofdstuk 5 wordt de huidige stand van zaken op het gebied van epidemiologie, 
ontstaanswijze en behandeling van trombose bij PNH patiënten weergegeven. Mechanismen 
die een rol zouden kunnen spelen in het ontstaan van trombose bij PNH zijn onder andere het 
vrijkomen van hemoglobine, dat endotheel beschadigt en stikstofoxide wegvangt, activering 
van bloedplaatjes en het vrijkomen van zogenaamde micropartikels met stollingsbevorderende 
eigenschappen. Daarnaast speelt de afwezigheid van GPI-verankerde eiwitten met een functie 
in stolling of fibrinolyse op aangedane bloedcellen een mogelijke rol. Dit hoofdstuk geeft tevens 
een samenvatting van de studies die laten zien dat eculizumab het tromboserisico verlaagt. 
In hoofdstuk 6 bestuderen we de rol van neutrofiel activatie en de vorming van neutrofiel 
extracellular traps (NETs) in 51 PNH patiënten voor en tijdens behandeling met eculizumab. 
NETs zijn extracellulaire netwerken bestaande uit DNA vezels, histonen en proteases afkomstig 
van neutrofielen en andere myeloїde cellen na activatie. NETs zijn sterk stollingsbevorderend 
en vormen een platform waarop plaatjesadhesie, activatie en aggregatie kan plaatsvinden. 
Cytokines, bestanddelen van bacteriën en schimmels, complement factor C5 en vrij 
hemoglobine bevorderen alle het vrijkomen van NETs. Mogelijk vormen PNH neutrofielen 
gemakkelijker NETs dan hun normale tegenhangers door het ontbreken van GPI-verankerde 
complementremmers CD55 en CD59. Wij bepaalden elastase-α1-antitrypsin (EA) complexen 
en circulerende nucleosomen als markers van neutrofiel activatie en NET vorming. Er was 
weliswaar geen verschil in neutrofiel activatie tussen PNH patiënten en gezonden, maar PNH 
patiënten die ooit trombose doormaakten hadden hogere concentraties nucleosomen dan 
patiënten die nooit trombose hadden. Dit zou kunnen betekenen dat patiënten met verhoogde 
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nucleosomen een nog hogere stollingsneiging hebben. Of dat inderdaad zo is zou idealiter 
onderzocht moeten worden in een prospectieve studie. 
Tijdens behandeling met eculizumab zagen we een snelle en langdurige daling van EA 
complexen. Dit betekent dat neutrofielen tijdens behandeling met eculizumab minder geactiveerd 
zijn en mogelijk minder goed in staat zijn tot vorming van NETs. Naast het remmen van hemolyse is 
dit mogelijk een andere manier waarop eculizumab het tromboserisico verlaagt, met name wanneer 
ook een infectie in het spel is. Een daadwerkelijke verlaging van de concentratie nucleosomen als 
marker voor de vorming van NETs werd alleen gezien 1 uur na het starten van de behandeling met 
eculizumab, echter niet op latere tijdspunten en alleen bij patiënten met een voorgeschiedenis van 
trombose. Toekomstig onderzoek is noodzakelijk om deze bevindingen te bevestigen in een groter 
patiëntencohort. Door middel van in vitro onderzoek kan de vorming van NET door normale en 
PNH neutrofielen en andere myeloide cellen met elkaar vergeleken worden. 
In hoofdstuk 7 hebben we diverse parameters van stolling en fibrinolyse, waaronder 
micropartikels, protrombine fragment 1+2 (F1+2), tissue factor en D-dimeer, bepaald in 
een populatie van 55 PNH patiënten. Met behulp van de Nijmegen Hemostase assay (NHA) 
konden we gelijktijdig stolling en fibrinolyse en hun interactie bestuderen. Ten opzichte van 
gezonden vonden we bij PNH patiënten een onverwachte daling van de trombine piekhoogte 
en trombine potentiaal welke omgekeerd evenredig was met LDH en kloongrootte. Deze 
parameters geven respectievelijk de maximale snelheid waarmee en de totale hoeveelheid 
trombine die gevormd wordt weer. Deze bevinding kan duiden op een verhoogd verbruik 
van stollingsfactoren in vivo door een continue stollingsactivatie. Geactiveerd tissue factor 
werd niet aangetoond. Ook microparticles waren slechts in een minderheid van de patiënten 
verhoogd. Tijdens behandeling met eculizumab trad er geen daling van microparticles op. Dit 
suggereert dat de rol van microparticles in de pathogenese van PNH-gerelateerde trombose 
beperkt is. Wanneer we PNH patiënten met en zonder trombose met elkaar vergeleken om 
potentiële biomarkers te identificeren die het tromboserisico helpen te voorspellen, vonden 
we hogere concentraties van F1+2 en D dimeren bij patiënten met een voorgeschiedenis van 
trombose. Echter, een verhoogde D-dimeer werd alleen gezien bij patiënten met een recente 
trombose. Waarschijnlijk betekent dit dat de verhoogde D-dimeer geen oorzaak maar gevolg 
is van trombose. Evenals in eerdere onderzoeken vonden wij een daling van de D-dimeer 
concentratie na ≥ 12 weken behandeling met eculizumab. Opvallend was dat deze daling al na 
1 uur zichtbaar was. Klaarblijkelijk heeft eculizumab een zeer snel effect op de stolling, zoals 
klinische observaties ook suggereren. De concentratie van F1+2 en de maximale snelheid 
waarmee trombine gevormd wordt daalt eveneens na ≥ 12 weken behandeling met eculizumab. 
De introductie van eculizumab heeft geleid tot een enorme verbetering van symptomen en 
kwaliteit van leven voor PNH patiënten. In het bijzonder bij een zeldzame ziekte als PNH is het uiterst 
belangrijk dat mogelijke problemen tijdens behandeling van individuele patiënten onderzocht en 
gemeld worden. In hoofdstuk 8 beschrijven wij een patiënte met klassieke PNH die kort na het 
staken van de behandeling met eculizumab een trombose ontwikkelde. Dit riep de vraag op of dit 
een direct gevolg was van het staken van eculizumab. Helaas kreeg zij een mesenteriaaltrombose 
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3 weken na het staken van eculizumab waaraan zij uiteindelijk overleed. Hoe het staken van 
eculizumab het optreden van trombose tot gevolg kan hebben is onbekend. Er bestaat een 
theoretisch risico op hyperhemolyse door een relatieve toename van PNH erytrocyten tijdens 
behandeling met eculizumab doordat zij langer overleven. Na staken van eculizumab kunnen deze 
PNH erythrocyten ineens massaal afgebroken worden. Bij onze patiënte was dit echter niet het 
geval. Hoewel een causaal verband dus zeker niet bewezen is, is het belangrijk dat men zich bewust 
is van een uitzonderlijk verhoogd risico op trombose na het staken van eculizumab. 
Tot slot beschrijven wij in hoofdstuk 9 de eventuele problemen van een PNH patiënt die een 
aortaklepvervanging, cardiopulmonale bypass, en coronaire bypasschirurgie onderging tijdens 
behandeling met eculizumab. Chirurgie in het algemeen, en cardiopulmonale bypass in het 
bijzonder leidt tot complement activatie en vorming van trombine. Bij patiënten met PNH kan 
hemolyse hierdoor toenemen en het tromboserisico verhogen. Wij beschrijven in dit hoofdstuk 
en peri-operatief doseringsschema voor eculizumab. Dit leidde tot niet-detectecteerbare 
concentraties van terminaal complement en lage stollingsparameters peri- en postoperatief. 
c o n c l u s i e s  e n  t o e k o m s t p e r s p e c t i e f
De introductie van eculizumab heeft geleid tot een grote vooruitgang in de behandeling van PNH 
in de afgelopen 10 jaar. Eculizumab is een monoklonale antistof gericht tegen complementfactor 
C5. Behandeling met eculizumab remt hemolyse, en vermindert het risico op trombose. Hoewel 
het de kwaliteit van leven van patiënten met PNH sterk verbetert is het geen curatieve therapie 
en is levenslange behandeling noodzakelijk met hoge kosten. Daarnaast heeft het geen effect 
op bijkomend beenmergfalen en blijven sommige patiënten transfusie-afhankelijk. Een ander 
nadeel is een verhoogde gevoeligheid voor infecties zoals meningokokken en gonokokken. 
Onze bevinding dat neutrofielen tijdens behandeling met eculizumab minder geactiveerd zijn 
zou kunnen betekenen dat PNH patiënten ook vatbaarder zijn voor andere infecties. 
Persisterende transfusie-afhankelijkheid tijdens behandeling met eculizumab is mogelijk het 
gevolg van beenmergfalen, dan wel van extravasculaire hemolyse. Extravasculaire hemolyse ontstaat 
door opsonisatie van PNH erythrocyten die door gebrek aan CD55 complementfactor C3 op hun 
oppervlak binden. Nieuwe complementremmers die momenteel onderzocht worden beogen de 
extravasculaire hemolyse te remmen maar hebben dezelfde overige nadelen als eculizumab. Zij 
genezen PNH evenmin, en verhogen waarschijnlijk ook de vatbaarheid voor infecties. Dit dient 
verder onderzocht te worden in klinische studies. Daarnaast is het belangrijk de rol van factoren die 
de mate van extravasculaire hemolyse bepalen, zoals complement polymorfismen, te onderzoeken. 
Idealiter leidt dit in de toekomst tot geïndividualiseerde behandelstrategieën voor PNH patiënten. 
Een eerste en cruciale stap naar een curatieve therapie voor PNH is een beter begrip van het 
mechanisme van klonale expansie. Men veronderstelt dat immuungemedieerd beenmergfalen 
hierin een belangrijke rol speelt. In dit proefschrift hebben wij laten zien dat T cellen met expressie 
van NK cel receptoren mogelijk betrokken zijn bij de pathogenese van PNH doordat zij mogelijk 
minder goed in staat zijn om GPI-deficiënte hematopoietische stamcellen te lyseren. In andere 
immuungemedieerde ziekten zoals reumatoïde artritis vonden wij eveneens veranderingen in het 
NK cel receptor repertoire op T en NK cellen ten opzichte van gezonden. Dit betekent dat een 
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veranderd NK cel receptor repertoire waarschijnlijk niet specifiek is voor PNH maar een fenomeen 
betreft dat meer algemeen in verschillende auto-immuun en auto-inflammatoire ziekten aanwezig 
is. Toekomstig onderzoek zal moeten uitwijzen of T cellen met NK celreceptoren inderdaad 
hematopoietische stamcellen van PNH patiënten kunnen lyseren, en zoja, wanneer tijdens het 
beloop van de ziekte dit proces plaatsvindt en wat precies de rol van NK cel receptoren daarin is. 
Recent is aangetoond dat een groot deel van de PNH patiënten naast de PIG-A mutatie 
verschillende andere mutaties hebben in het beenmerg. Sommige van deze mutaties zijn ook 
gevonden bij andere hematologische maligniteiten. In de toekomst zal onderzocht moeten 
worden hoe het patroon van expansie van de PNH kloon gerelateerd is aan het optreden van 
additionele mutaties. Ook is het interessant om na te gaan hoe deze bevinding zich verhoudt 
tot de zogenaamde “immune escape” theorie. Is het een het gevolg van het ander, of kan er 
onderscheid gemaakt worden tussen patiëntengroepen bij wie verschillende mechanismen 
verantwoordelijk zijn voor klonale expansie? 
Naast het mechanisme van klonale expansie is het sterk verhoogde tromboserisico een 
ander belangrijk onderwerp in het PNH onderzoeksveld. Belangrijke vragen zijn onder andere: 
hoe onstaat trombose bij PNH, op welke manier vermindert eculizumab het tromboserisico, is 
het mogelijk om te voorspellen wie trombose krijgt, en hoe kunnen we trombose voorkomen? 
De hemostatische balans is een delicaat evenwicht tussen stolling en fibrinolyse dat wordt 
beïnvloed door de bloedcellen en de vaatwand. Bij PNH patiënten wordt deze balans verstoord 
door verschillende factoren. Dit betreft onder andere complement-gemedieerde schade aan 
bloedplaatjes, neutrofielen en andere bloedcellen, en de vaatwand. In dit proefschrift hebben 
wij laten zien dat daarnaast de vorming van neutrofiel extracellular traps (NETs) mogelijk een 
van deze factoren is. Verder onderzoek naar deze en andere factoren is echter noodzakelijk. 
Aangezien eculizumab zowel hemolyse als het tromboserisico duidelijk vermindert, lijkt 
complement dan wel complement-gemedieerde hemolyse een belangrijke rol te spelen in het 
optreden van trombose bij PNH. Casuïstiek suggereert dat eculizumab de ontwikkeling van trombose 
binnen enkele uren kan afremmen. Het mechanisme hiervan is echter onbekend. In dit proefschrift 
hebben wij laten zien dat D-dimeer en neutrofiel activatie markers snel dalen tijdens behandeling 
met eculizumab. Dit zou bijvoorbeeld kunnen betekenen dat neutrofielen tijdens behandeling met 
eculizumab minder gemakkelijk NETs vormen. Dit zal in de toekomst verder onderzocht moeten 
worden, evenals de functie van bloedplaatjes tijdens behandeling met eculizumab. 
Idealiter zou men door middel van een bloedtest kunnen bepalen welke PNH patiënten 
het hoogste risico op trombose hebben en wie dus profylactisch behandeld dient te worden. 
In dit proefschrift hebben wij laten zien dat retrospectief PNH patiënten met een trombose in 
de voorgeschiedenis verhoogde concentraties van nucleosomen, fragment 1+2 en D-dimeer 
hebben. Of deze veranderingen het gevolg zijn van trombose, duiden op de aanwezigheid 
van subklinische trombose, of voorspellend zijn voor het optreden van nieuwe tromboses is 
onbekend. Dit zou idealiter onderzocht moeten worden in een prospectieve studie. Dergelijke 
studies zijn echter moeilijk uitvoerbaar gezien de zeldzaamheid van de ziekte. Als dergelijke 
markers geïdentificeerd zouden kunnen worden biedt dat de mogelijkheid tot patiëntspecifieke 
behandelingen om het tromboserisico te verminderen. 
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Het kost wat maar dan heb je ook wat. Een doctorstitel. Dit zou echter nooit mogelijk geweest zijn 
zonder de bijdrage van velen. De laatste woorden van dit proefschrift wil ik graag aan jullie wijden. 
Allereerst de PNH patiënten. Jullie waren zonder uitzondering belangeloos bereid vele buisjes 
bloed of zelfs beenmerg af te staan. Het onderzoek beschreven in dit proefschrift geneest 
PNH niet, maar hopelijk is dat doel een stapje dichterbij gekomen. Dankzij jullie leren we PNH 
telkens weer iets beter begrijpen. 
Beste Petra, ik bewonder de wijze waarop jij je met hart en ziel, dag en nacht, voor al je patiënten 
hebt ingezet. Je hebt de afgelopen jaren hard gewerkt om de zorg voor PNH patiënten te 
organiseren in een Nijmeegs expertisecentrum. Ook heb je een zeer belangrijke bijdrage 
geleverd aan de eerste eculizumab trials en de registratie van eculizumab in Nederland. Hiervan 
profiteerden uiteraard de patiënten en kreeg ik de mogelijkheid mijn onderzoek uit te voeren. 
Je bent ontzettend kritisch en perfectionistisch. Ik was hier misschien niet altijd blij mee maar 
uiteindelijk heeft het geleid tot dit mooie resultaat, waarvoor dank. Ik hoop dat je in de komende 
jaren weer mooie nieuwe uitdagingen zult vinden en we nog eens vaker zullen bijpraten. 
Harry, als 2e copromotor kreeg jij de taak om mede mijn project in goede banen te leiden. Dit 
was een hele uitdaging want we hadden  aanvankelijk plannen voor drie totaal verschillende 
onderzoekslijnen. Daarnaast heb je mij, een dokter met weinig laboratoriumervaring, ingewijd 
in het basaal immunologisch onderzoek. Ik heb veel van je geleerd; jouw nuchtere kijk heeft 
me vaak weer vooruit geholpen. Ook al was in de laatste fase het onderzoek op jouw terrein al 
afgerond, toch bleef je persoonlijk betrokken.  
Waander, ook jij speelde vanaf de start een rol in mijn promotie. Dank voor je prettige 
begeleiding en belangrijke bijdrage aan het stollingsgedeelte van mijn onderzoek. 
Theo, als mijn promotor bewaakte jij de grote lijnen. Je bent altijd optimistisch en hebt de gave 
overal een positieve draai aan te geven. Jij gaf me de mogelijkheid om nog enkele zijpaden op het 
gebied van MDS te bewandelen, welke helaas niet in dit proefschrift terecht zijn gekomen. Nicole, 
in een later stadium werd jij professor in de hematologie en raakte je betrokken bij mijn promotie. 
Dank voor je steun in het afronden van het proefschrift en je kritische en verfrissende blik. 
Maartje en Willemijn, ik ben blij dat jullie mij als paranimfen gaan ondersteunen en gesteund 
hebben. Maartje, chica, we leerden elkaar kennen tijdens onze studie en werden echt goede 
vriendinnen tijdens onze stage in Mexico. Door onze nagenoeg gelijke carrières en op elkaar 
lijkende karakters begrijp jij als geen ander de dagelijkse hoogtepunten en frustraties van een 
promovendus en AIOS. Dank voor alle keren dat ik even heb mogen spuien en hopelijk kunnen 
we nog vele hoogtepunten samen vieren. Willemijn, we waren lange tijd buren op de AIO 
kamer. Je hebt me vaak geholpen bij de opzet van experimenten of een niet lopende zin in een 
artikel. Je fietst door je carrière zoals je een berg af skiet: razendsnel van de zwarte piste zonder 
concessies aan techniek of après-ski. Deze zomer ga je op de fiets de Alpe d’Hu(z)es een of 
meerdere bedwingen, sterkte! Ik bewonder de wijze waarop jij je zaakjes georganiseerd hebt 
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en ben ervan overtuigd dat je een glansrijke onderzoekscarrière te wachten staat. Hopelijk 
houd je ook in de toekomst tijd om nog eens samen te gaan skiën! 
Wieger, Kelly, Anniek, we hebben in dezelfde periode ons promotie-onderzoek in de CTI unit 
uitgevoerd. We hebben vele ups en downs samen kunnen delen. Wieger en Kelly, jullie leerde 
ik pas echt goed kennen tijdens ons tripje naar Sardinië. Wieger, het is fijn te weten dat andere 
mensen ook wel eens iets kwijt raken, en Kelly, dankzij jouw scouting vaardigheden (en een fles 
Mirto) overleefden we het kamperen in de stromende regen zonder haringen. Dank jullie voor 
het wegwijs maken van een dokter op het lab en voor de vele leuke momenten zowel op als 
buiten het werk. Veel succes in jullie verdere carrières en het ten uitvoer brengen van overige 
“future plans”. Ik hoop dat we ook in de toekomst contact zullen blijven houden. 
Het grootste gedeelte van mijn laboratoriumwerk heb ik verricht te midden van een 
fijne groep collega’s van de CTI unit. Marian, jij hebt ruim een jaar mijn project ondersteund. 
Qua werkwijze zijn we soms totaal verschillend maar volgens mij hebben we daar beiden van 
geprofiteerd. We vonden steeds gemakkelijker een gulden middenweg tussen mijn soms 
“quick & dirty” en jouw soms wel heel nauwkeurige benadering. Zonder jouw enorme inzet was 
hoofdstuk 2 er niet geweest. Dank voor de fijne samenwerking!
 Hanny en Frans, de stabiele factoren binnen de CTI unit. Jullie kennis is van onschatbare 
waarde. Dank voor de vele praktische adviezen en de morele ondersteuning als een proef 
weer eens niet wilde lukken. Robbert, Marleen, Annelies, Vivienne, Thomas, Marij, Jan, Basav, 
Jeanette, Karishma en Niken: allen bedankt voor de gezellige en productieve sfeer op en buiten 
het lab. Rob, en Jeroen, dank voor alle celsorteringen en je hulp bij het analyseren van flow 
cytometrie data. Rob, je hebt me zo gek gekregen om de Zevenheuvelenloop te lopen en je 
hebt een goede poging gedaan me op de racefiets te krijgen. Dat laatste is helaas niet helemaal 
gelukt maar dat lag niet aan jou. Students Maria and Astrid, your work on MDS did not make it 
into my thesis unfortunately. You both worked hard and it was fun to supervise your projects, 
good luck in finishing your own PhD’s. 
Marta, although you are officially not a member of the CTI Group, considering the amount of 
time you spent there, you could be one for sure. Thanks for your tough work on finishing our paper; 
hopefully by the time this thesis is printed it is finally published. Good luck in finishing your own thesis 
and finding the right career path. Hopelijk ooit als Nederlandse dokter en collega reumatoloog of 
immunoloog! Mieke, ook dank voor jouw bijdrage aan de experimenten in hoofdstuk 4. 
In mijn project heb ik met vrijwel alle units van het Laboratorium Hematologie mogen samenwerken. 
Ten eerste wil ik alle huidige en oud-medewerkers van de Trombose & Hemostase en morfologie 
unit bedanken, en in het bijzonder Paul, Nancy, Wideke, Kitty en Mia. Dan de collega’s van de 
immunofenotypering, bij wie ik vele malen de Navios mocht bezetten om mijn data te analyseren, 
en die mij vaak van antistoffen voorzagen. De collega’s van de BMT unit hielpen mij met de opslag 
van patiëntenmonsters en met colony-forming assays. Tot slot de collega’s van de moleculaire 
hematologie, die mij hebben ingewijd in de wondere wereld van kloneren en PCR’s.
Essentieel voor translationeel onderzoek is een goede samenwerking tussen kliniek en 
laboratorium; daarom wil ik graag alle hematologen bedanken voor hun medewerking in 
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het verzamelen van patiëntenmateriaal. Dan een woord van dank aan de trialcoördinatoren, 
researchverpleegkundigen en datamanagers van het datacentrum hematologie. Olga, Margo, 
Manita en Jackie, het was fijn een kamer met jullie te delen; allen dank voor mijn inwijding in de 
wereld van de klinische trials, good clinical practice en data management. 
Veel van het onderzoek beschreven in dit proefschrift is verricht in samenwerking met andere 
afdelingen zowel binnen als buiten het RadboudUMC. Konnie, dank voor het reviseren van alle 
beenmergbiopten en je input bij het schrijven van ons artikel. Sacha, je nam het initiatief voor opzet 
en uitvoer van het onderzoek beschreven in hoofdstuk 6. Hopelijk wordt deze mooie samenwerking 
in de toekomst voortgezet. Arnold van der Meer en Bram van Cranenbroek van het laboratorium 
Medische Immunologie wil ik bedanken voor hun hulp bij het onderzoek naar NK cel receptoren. 
I would like to thank Professor Peter Hillmen, Anita Hill and Richard Kelly of the Leeds PNH team 
for their collaboration, numerous fruitful discussions and helpful advice on complicated PNH patients. 
Professor Hillmen, it is a great honour for me to defend my PhD thesis in front of one of the world’s 
leading PNH experts. Professor Østerud, thanks for your help on the tissue factor experiments. 
Velen waren weliswaar niet direct betrokken bij mijn onderzoek maar verdienen toch een 
speciaal woord van dank. De vriendinnetjes van middelbare school en universiteit voor hun 
fijne vriendschap in de afgelopen tien tot twintig jaar waarvan ik hoop dat deze nog minstens 
zo lang mag voortduren. Goede adviezen kreeg ik regelmatig op vrijdagavond in de kantine van 
mijn badmintonmaatjes en wannabe paranimfen. Als ik er meer dan 2 had gemogen waren jullie 
erbij. Aniet, een spelletje op zijn tijd was vaak een goede afleiding, bedankt voor je luisterend 
oor. Miranda, ook al groeide Kasper te snel voor zijn PhD thesis romper, het was een goede 
stimulans! Floor, het is altijd leuk met je te filosoferen over van alles en nog wat, en te luisteren 
naar je avonturen als klinisch informaticus in de ziekenhuiswereld. Ik wacht met spanning op 
het boek dat je gaat schrijven. Marjolein, wij zijn samen groot geworden en volgens mij vieren 
wij dit jaar ons 30-jarig jubileum. Het klikt nog altijd uitstekend, op naar ons gouden jubileum! 
Jos & Nicole, Sandrine, Stephan & Babs, ik voel me thuis in jullie familie. Jos en Nicole, Kasper 
heeft het getroffen met jullie als opa en oma. Mede dankzij jullie goede zorgen kan ik met 
een gerust hart aan het werk. Sandrine, ik vind het erg bijzonder een collega-reumatoloog 
en promovendus als schoonzusje getroffen te hebben, terwijl ik je broer gewoon in een café 
ontmoet heb. Ik kijk uit naar jouw promotie die vast niet lang meer op zich laat wachten. 
Pa, je moest erg je best doen te onthouden waar de afkorting PNH voor staat. Begrijpelijk, maar het 
lukte al vrij vlot. Jij steunt mij onvoorwaardelijk, niet alleen tijdens mijn promotie maar mijn hele 
leven al. Je hebt mij en Rick ondanks moeilijke omstandigheden een stabiele basis meegegeven. 
Nu spring je vaak bij om ons gezin draaiende te houden. Mam, ik had graag gewild dat je erbij had 
kunnen zijn. Mede dankzij jouw genen en hetgeen je me in te korte tijd hebt meegegeven is het 
dan toch gelukt. Rick, broertje, er is er maar een de echte hard core scientist bij ons thuis en dat 
ben jij. Met ons pa kunnen we altijd goed discussiëren over allerhande zaken, en op zijn tijd met 
jou een shuttletje slaan in de zaal, in de tuin of in de huiskamer is ook altijd fijn. Ik hoop dat jij en 
Gerrie in de komende jaren jullie plannen voor de toekomst verder vorm kunnen geven. 
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Tot slot nog enkele woorden voor de twee mij meest dierbare mannen in mijn leven. Kasper, als 
je later groot bent legt mama je nog wel eens uit wat PNH precies is. Ik ben blij dat je ons leven 
verrijkt hebt en dat je me zo nu en dan laat weten dat het promoveren leuk en aardig is maar 
andere zaken toch echt belangrijker zijn. Sébastien, je hebt hard je best gedaan om met steps 
to milestones en andere projectmanagement vaardigheden mijn promotie te bespoedigen. 
Maar veel belangrijker is dat jij mij gelukkig maakt en ik heel veel van je hou. Ik hoop dat er nog 
vele gelukkige jaren samen zullen volgen!
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Sandra van Bijnen werd geboren op 29 juli 1980 te ’s-Hertogenbosch. In 1998 behaalde zij haar 
VWO-diploma aan het Stedelijk Gymnasium te ’s-Hertogenbosch. Datzelfde jaar begon zij 
haar studie geneeskunde aan de Universiteit Maastricht. Tijdens haar studie verrichte zij onder 
begeleiding van dr. A. Duivestijn en prof dr. Cohen Tervaert wetenschappelijk onderzoek 
binnen de afdeling immunologie aan de universiteit Maastricht. In het kader van een student-
assistentschap en een wetenschappelijke stage onderzocht zij de interactie tussen T cellen en 
endotheelcellen. Keuzestages chirurgie en primary health care vonden plaats in het Academisch 
Ziekenhuis te Paramaribo, Suriname, en de aan de Universidad Autónoma Metropolitana te Mexico 
City, Mexico. In 2002 behaalde zij haar doctoraalexamen en in 2004 het artsexamen, beide met 
het predicaat cum laude.  In 2005 werkte zij als ANIOS interne geneeskunde in het St. Elisabeth 
te Tilburg. Vanaf 2006 was zij als arts-onderzoeker werkzaam op de afdeling hematologie van 
het RadboudUMC. Zij was betrokken bij de uitvoer en opzet van diverse klinische trials op het 
gebied van paroxysmale nachtelijke hemoglobinurie (PNH) en myelodysplastisch syndroom 
(MDS). Daarnaast was zij mede verantwoordelijk voor de klinische en poliklinische begeleiding 
van patiënten met PNH. Hierop volgend startte zij in 2007 met het promotie-onderzoek zoals 
beschreven in dit proefschrift. Dit vond plaats onder begeleiding van copromotores dr. Petra 
Muus, dr. Harry Dolstra, en promotores prof. dr. Theo de Witte en prof. dr. Nicole Blijlevens. 
In 2011 startte zij met haar vooropleiding interne geneeskunde in het kader van de opleiding 
tot reumatoloog in het Jeroen Bosch Ziekenhuis (opleiders dr. P. Netten en dr. W. Smit). Na 
afronding van de vooropleiding startte zij in 2014 met de vervolgopleiding tot reumatoloog in 
de Sint Maartenskliniek  te Nijmegen (opleiders dr. K. Bevers en dr. A. van Ede). 
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